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It has been suggested that coffee drinking may confer a beneficial effect on health by 
reducing the risk of developing Type 2 Diabetes Mellitus (T2DM) and indeed there is 
much epidemiological evidence for a reduced incidence of T2DM in habitual coffee 
drinkers. However, many acute studies have reported a temporary worsening in 
postprandial glycaemia following caffeinated coffee (CC) consumption. Varied 
methodologies have been employed by these studies with many giving their 
participants large doses of coffee.  
In the acute studies conducted for this thesis, a single serving of CC increased the 
postprandial glycaemic response more than control (p=0.008), with no apparent dose-
response effect. Furthermore, a single serving of decaffeinated coffee (DC) consumed 
in the morning, produced no effect on postprandial glycaemia, although a trend was 
observed for a reduction in the postprandial glucose peak (p=0.060) when DC was 
consumed at lunchtime. 
The majority of longer-term investigations have recruited habitual coffee drinkers who 
are likely to have already obtained any potential benefits of coffee consumption. The 
longer-term intervention reported in this thesis found no overall effects of twelve weeks 
of CC drinking on glucose and lipid metabolism in coffee-naïve individuals. However, 
differences were observed between fast and slow caffeine metabolisers when the 
analysis was split by phenotype. The fast caffeine metabolisers displayed a lower 
postprandial glucose response (p=0.019) and greater NEFA suppression (p=0.001) at 
baseline. Furthermore, significant interaction effects were observed between visit and 
phenotype for postprandial glucose (p=0.048) and NEFA (p=0.019), with the 
intervention producing an apparent increase in postprandial glycaemia in fast 
metabolisers and reduced NEFA suppression in slow metabolisers. 
In conclusion, no evidence was found for a beneficial effect of coffee drinking on 
glucose and lipid metabolism in the general population, however, individual differences 
in response to longer-term coffee drinking were observed which warrant further 
investigation. 
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1.1 Overview 
Diabetes is a global health problem, with the World Health Organisation (WHO) 
estimating the prevalence to be 9% of the adult population in 2014 (1). It affects almost 
350 million people worldwide, the majority of which (90%) have T2DM. If poorly 
controlled, it can result in serious complications, including cardiovascular disease, 
nephropathy and retinopathy, and it is estimated to have caused 1.5 million deaths in 
2012 (1).  
There is much epidemiological evidence demonstrating a reduced risk of T2DM in 
coffee drinkers, particularly in those who drink large amounts of coffee, with a reduced 
risk being reported for both caffeinated and decaffeinated coffee drinkers (2–6). 
However, it is not known precisely how coffee may exert this protective effect. 
Furthermore, studies into the acute effects of CC have generally reported a detrimental 
effect on the postprandial glycaemic response compared to a control (7–9). Caffeine in 
isolation has been demonstrated to produce a greater increase in the postprandial 
glycaemic excursion than that observed following CC ingestion (10), giving rise to the 
hypothesis that components in coffee, other than caffeine, may be attenuating the 
acute detrimental effects of caffeine. There have been few longer-term interventions 
into the effects of coffee on glucose metabolism, the majority of which have examined 
the effects in habitual coffee drinkers (11–13). 
This chapter will begin with an overview of glucose and lipid metabolism and how it is 
affected by T2DM. It will then discuss coffee production and the various components 
of coffee and will end with a review of the literature on coffee’s effects on glucose and 
lipid metabolism. 
1.2 Glucose homeostasis 
Glucose is the main fuel for the brain due to its ability to cross the blood-brain barrier. 
Blood glucose is typically about 5 mmol/L after an overnight fast, dropping further to 
approximately 3.0 mmol/L under conditions of prolonged fasting (14). In the postprandial 
state, in healthy individuals, it rarely exceeds 7.8 mmol/L (15). High blood glucose over 
a prolonged period, such as can be found in poorly controlled T2DM, can lead to 
serious macro- and microvascular problems (16). It is therefore very important for the 
body to maintain blood glucose levels within a relatively narrow range, both to prevent 
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the complications associated with high levels and to ensure sufficient fuel for the brain. 
For healthy individuals, it is also important to minimise the postprandial glucose 
excursion as elevated postprandial glycaemia is associated with development of 
T2DM (17). 
In the fasted state, plasma glucose levels are maintained by glycogenolysis 
(breakdown of glycogen to glucose in the liver) and gluconeogenesis (formation of 
glucose in the liver and kidney from other compounds such as lactate and 
pyruvate) (18). In the postprandial state, plasma glucose originates mainly from the 
digestion and absorption of dietary carbohydrate (CHO), although hepatic glucose 
production is never completely switched off and continues to make a small 
contribution (19). Glucose is taken up from the blood into the various organs by two 
families of transporters: the GLUT family (by passive diffusion) and the SGLT family 
(by active transport), by both insulin-mediated and independent processes (20,21). The 
rates of appearance and clearance of glucose determine plasma glucose 
concentrations at any given time (22). These are regulated either directly or indirectly 
by a number of hormones such as insulin, glucagon, cortisol, adrenalin, glucose-
dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and 
growth hormone, the relative importance of which depends on whether the body is in 
the fasted or postprandial state. These regulatory mechanisms will be covered in more 
detail later. 
1.2.1 Postprandial glucose metabolism 
 Carbohydrate digestion 
Dietary CHO consists of simple sugars such as the disaccharides, sucrose and 
lactose, and complex CHOs such as rapidly digestible starch (RDS), resistant starch 
(RS) and dietary fibre (DF). RS and DF pass through the small intestine undigested to 
the colon and will not be discussed further here. RDS consists of the polysaccharides 
amylose and amylopectin: long, unbranched (amylose) and branched (amylopectin) 
chains of glucosyl units (23) which are digested in a multi-stage process by enzymes in 
the mouth and gut.  
Starch digestion begins in the mouth (24), where the -amylase enzyme, secreted in 
saliva, hydrolyses -1,4 bonds anywhere in the chain, breaking the starch down into 
smaller units (25). This continues in the upper stomach for some time, before the acidic 
environment of the stomach inhibits the process. The process is finished in the lumen 
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of the small intestine by -amylase secreted in pancreatic juices, resulting in small 
oligosaccharides and di- and trisaccharides, maltotriose and maltose. 
These smaller molecules, along with the simple sugars, are hydrolysed by brush 
border enzymes, -glucosidase, sucrase, maltase and lactase, to the 
monosaccharides glucose, fructose and galactose, ready for absorption (26). The 
absorption and disposal of fructose and galactose will not be covered in this thesis. 
 Glucose absorption 
Glucose is absorbed into the enterocyte via two different transporters on the apical 
membrane. When glucose concentrations in the lumen are high, GLUT2 transporters 
translocate to the apical membrane and glucose diffuses across them (27). When 
glucose levels are lower, the GLUT2 transporters are recycled and glucose is co-
transported with Na+, against the concentration gradient, by the SGLT1 transporter via 
an active transport mechanism. Glucose then enters the circulation via GLUT2 
transporters in the basolateral membrane.  
 Glucose disposal 
Absorbed glucose is taken by the portal vein to the liver where it enters via GLUT2 
transporters. Approximately 30% of absorbed glucose is retained by the liver and 
stored as glycogen; the remainder passes into the systemic circulation. Of the glucose 
entering the circulation, about 20% is taken up into the brain via GLUT1 transporters,  
about 40% is taken up by skeletal muscle via GLUT4 transporters and the remainder 
is either taken up by the kidneys (GLUT2) and adipose tissue (GLUT4) or returned to 
the liver (28). 
1.2.2 Glucose production: gluconeogenesis and glycogenolysis 
Glucose can be produced by the liver from various substrates, the main ones being 
alanine, lactate and glycerol, in a process called gluconeogenesis. It is a multi-step 
process involving the formation of several intermediaries, with the terminal step being 
the conversion of glucose 6-phosphate (G6P) to glucose, catalysed by the glucose 
6-phosphatase enzyme (G6Pase). Glucose can also be produced by the breakdown 
of glycogen stores in the liver, in a process called glycogenolysis. In this process 
glycogen is broken down to glucose 1-phosphate (G1P), which converts to G6P and 
thereafter to glucose as in gluconeogenesis. Whilst these processes occur mainly in 
the fasted state, they are not entirely inhibited in the postprandial period. 
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1.2.3 Lipid metabolism 
Lipids are the body’s main source of energy in the fasted state. They are stored in 
adipose tissue as triacylglycerol (TAG). When required, they are hydrolysed to free 
fatty acids (FFA) and glycerol by the actions of adipose triacylglycerol lipase (ATGL), 
hormone-sensitive lipase (HSL) and monoacylglycerol lipase (MAGL) in a process 
called lipolysis (29).  They are then released into the circulation along with the liberated 
glycerol. The FFAs which are released are non-esterified fatty acids (NEFAs) and are 
transported in the blood bound to albumin. NEFA levels tend to be highest in the 
morning and decrease after a meal. 
After a meal, digestion of dietary lipid begins in the stomach through the actions of 
gastric lipase. When the partially hydrolysed lipid arrives in the small intestine it is 
emulsified by bile salts released from the gall bladder. Pancreatic lipase further 
hydrolyses the lipids resulting in fatty acids (FAs) and monoacylglycerols (MAGs) 
which are packaged into micelles, along with bile salts, for transportation through the 
intestine. FAs and MAGs are absorbed into the enterocyte via transporter proteins. 
Once inside the cell they are re-esterified to TAG and are packaged, along with 
proteins and phospholipids, into chylomicrons in which they are transported, via the 
lymphatic system, into the blood (30). Absorption of lipid is a lengthy process with peak 
TAG levels occurring about 3 - 5 h after a meal. 
As the chylomicrons travel through the blood they interact with other particles such as 
high density lipoproteins (HDL), transferring apolipoproteins between them. As they 
pass tissues such as muscle and adipose tissue they come into contact with lipoprotein 
lipase (LPL) on the endothelial surface of these tissues. LPL hydrolyses TAG, 
releasing NEFAs which are taken up into the cells and either used immediately for 
energy or repackaged into TAGs for storage (31). LPL requires the presence of 
apolipoprotein CII, which the chylomicron acquires from HDL, in order to release TAG 
from it. As the chylomicrons travel around the body they reduce in size as more and 
more TAGs are liberated from them, eventually becoming chylomicron remnants which 
are taken up by the liver (29). 
TAGs are also released into the blood from the liver in very low density lipoproteins 
(VLDL). These VLDL also interact and exchange contents with other particles, such as 
HDL, and deliver TAG to the tissues via the actions of LPL, much like chylomicrons. 
They also reduce in size, becoming cholesterol-ester-rich low density lipoproteins 
(LDL), which deliver cholesterol to the tissues. Some LDL remains in the circulation 
and some is taken up by the liver. HDL is also released by the liver; its main function 
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is to accept cholesterol from the tissues and transport it back to the liver where it is 
converted to bile salts or excreted in bile. 
1.2.4 Regulation of glucose and lipid metabolism 
 Insulin 
When food is seen, smelled or tasted the parasympathetic nervous system (PNS) 
stimulates the release of saliva; it also triggers first-phase release of insulin. In the fed 
state, when blood glucose concentrations are raised, glucose binds to receptors on 
the pancreas and signals the  cells of the pancreas to increase insulin release. Insulin 
secretion is further stimulated by the insulin potentiators, GIP and GLP-1. GIP is 
secreted by the K cells of the proximal intestine in response to nutrients in the gut; its 
concentration is strongly correlated with the rate of glucose absorption (32). GIP also 
stimulates the L cells of the intestine to release glucagon-like peptide-2 (GLP-2), which 
has been demonstrated to promote the translocation of GLUT2 receptors to the apical 
membrane thereby increasing glucose absorption (27). GLP-1 is secreted by the L cells 
of the distal intestine in response to glucose presence in the gut. It has been estimated 
that the actions of incretins contribute between 20 and 70% of the total insulin response 
after oral glucose administration (33,34). 
Insulin acts in a variety of ways, both directly and indirectly, to reduce plasma glucose 
concentration. It binds to receptors on muscle and adipose tissue, activating signalling 
pathways, leading to translocation of glucose transporters to the cell surface and thus 
enhancing glucose uptake into these tissues. It suppresses the action of HSL, reducing 
the amount of NEFA released into the circulation, which in turn reduces the amount of 
gluconeogenesis. It also promotes glycolysis (the storage of glucose as glycogen) by 
inhibition of some of the key enzymes involved in the breakdown of glycogen, such as 
G6Pase, and by stimulating glycogen synthase, an enzyme involved in glycogen 
synthesis (35). 
 Glucagon 
Glucagon is a counter-regulatory hormone to insulin and is released from the  cells 
of the pancreas when glucose levels are low. It is mainly inhibited by high blood 
glucose and insulin, but also by GIP and GLP-1 (33). Its main action is to increase blood 
glucose. It binds to G-protein coupled receptors (GPCRs) on its target cells activating 
a signalling cascade involving formation of cyclic adenosine monophosphate (cAMP) 
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and activation of protein kinase A (PKA). In hepatic tissue this leads to release of 
glucose by glycogenolysis.  
 Adrenalin 
Adrenalin is a catecholamine secreted by the adrenal medulla in times of stress. It 
binds to adrenoreceptors (GPCRs), of which there are two groups: - and -receptors. 
Adrenalin has different effects on glucose metabolism, depending on which receptor it 
binds to. The receptors are present in varying proportions on different tissues and it is 
the relative proportion of each that determines the overall effect of adrenalin on that 
tissue. 
Binding to -receptors results in stimulation of cAMP and activation of PKA, resulting 
in increased glycogenolysis and gluconeogenesis, thus raising blood glucose in the 
same way as glucagon. In vitro work has demonstrated that cAMP also stimulates 
glucose transport across both the brush border and basolateral membranes (36). 
Stimulation of cAMP in adipose tissue leads to activation of HSL by phosphorylation 
which causes the release of NEFA and glycerol, which can be utilised in 
gluconeogenesis. Binding to 2-receptors inhibits cAMP, thereby counteracting the 
effects of the -receptors, particularly with respect to the mobilisation of fatty acids in 
adipose tissue.  Binding to 1-receptors activates a process which increases cytosolic 
Ca2+, which in turn activates PKA leading to increased blood glucose. Adrenalin also 
inhibits glucose uptake in skeletal muscle via the β2-receptor (37). Although - and 
receptors can have opposing actions, the overall net effect of adrenalin binding to 
them is to raise blood glucose. 
 Cortisol 
Cortisol is a glucocorticoid secreted by the adrenal cortex, which is increased in times 
of stress. Its levels change throughout the day and are highest in the morning. It has 
a similar effect to adrenalin on glucose metabolism but its effects are not immediate 
as it works mainly by affecting protein synthesis rates of key enzymes (38). The net 
result of increased cortisol is an increase in HSL activity, leading to release of NEFA 
and glycerol from adipose tissue and increased gluconeogenesis in the liver. It has 
also been demonstrated to reduce glucose uptake in skeletal muscle and impair insulin 
release from the pancreas. 
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 Inflammatory markers 
Tumour necrosis factor alpha (TNF-) and interleukin-6 (IL-6) are adipocytokines, 
released by adipose tissue as part of the inflammatory response. They also play a role 
in glucose regulation. TNF- inhibits insulin receptor tyrosine kinase activity thus 
inhibiting glucose uptake and increasing insulin resistance in adipose and muscle 
tissue (39). TNF- and IL-6 both inhibit LPL thus increasing circulating NEFA, raised 
levels of which are associated with insulin resistance and obesity (40). 
 Adiponectin 
Adiponectin is a hormone which is mainly secreted by adipose tissue. It circulates in 
the blood in several forms: as dimers, trimers or as protein complexes of high 
molecular weight (HMW) and low molecular weight (LMW) hexamers. Although it is 
secreted by adipose tissue, circulating levels are inversely associated with adipose 
tissue mass, with lean people generally having higher levels than the obese (41). 
Adiponectin increases insulin sensitivity by several methods. It binds to receptors on 
skeletal muscle, activating 5' adenosine monophosphate-activated protein kinase 
(AMPK), increasing translocation of GLUT4 to the cell surface and resulting in greater 
glucose uptake (42).  It also inhibits gluconeogenesis via inhibition of one of the key 
enzymes in the pathway, phosphoenolpyruvate carboxylase (43). 
1.2.5 Alterations to glucose homeostasis in T2DM 
T2DM is a disease characterised by high fasted blood glucose and impaired insulin 
sensitivity; obesity and Metabolic Syndrome (MS) are strong risk factors.  According 
to the WHO (44), a person has MS if they have insulin resistance, determined by one 
of: 
 T2DM (fasted glucose ≥ 7.0 or 2 h glucose ≥ 11.1 mmol/L) 
 Impaired fasted glucose (fasted glucose 6.1 – 6.9 mmol/L) 
 Impaired glucose tolerance (2 h glucose 7.8 – 11.0 mmol/L) 
Plus any two of: 
 High blood pressure (systolic ≥ 140 mm Hg or diastolic ≥ 90 mm Hg) 
 Plasma TAG ≥ 1.7 mmol/L 
 HDL cholesterol < 0.9 mmol/L in men or < 1.0 mmol/L in women 
 Body mass index (BMI) > 30 kg/m2 and/or waist:hip ratio >0.90 in men and 
>0.85 in women 
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High fasted NEFA levels are associated with development of T2DM (45,46), however a 
re-analysis of data from three cohort studies concluded that this association 
disappears when 2 h glucose is included in the analysis (47). Furthermore another 
prospective cohort study found no association between baseline fasted NEFA and 
development of glucose intolerance, but did find an association between fasted NEFA 
and glucose intolerance when they performed a cross-sectional analysis on their data, 
leading them to conclude that NEFA levels change alongside development of MS, 
rather than MS developing as a consequence of this lipotoxicity (48). Many people with 
poorly controlled T2DM also have elevated NEFA (49), although a meta-analysis of 
studies, examining the relationship between NEFA and obesity, failed to find an 
association between fat mass and NEFA levels (50). High intra-individual variation in 
NEFA has been found with day-to-day variation being as high as 45% (51), with NEFA 
levels being particularly sensitive to stress states. This daily variation is likely to 
confound results of studies examining associations between NEFA and T2DM and 
obesity. Chronically high NEFA leads to impaired insulin sensitivity and reduced insulin 
secretion from the pancreas (52). Acutely elevated NEFA reduces insulin sensitivity via 
reduced glucose transport in muscle (53). Reduced insulin sensitivity results in failed 
suppression of NEFA release and reduced uptake of TAG into cells, causing greater 
circulating NEFA. As insulin resistance increases, the pancreas initially produces more 
insulin in order to regulate blood glucose. This can lead to failure of pancreatic  cells 
to respond to glucose and reduced insulin secretion resulting from both loss of  cell 
mass and amyloid deposition. 
Various studies have reported associations between inflammatory markers and T2DM. 
A recent meta-analysis found a dose-response association between IL-6 levels and 
risk of T2DM (54). Furthermore, an analysis of data from the Nurses’ Health Study found 
significant associations between baseline levels of TNF- receptor 2, IL-6 and 
C-reactive protein (CRP) and T2DM risk. However, when all three markers were 
analysed together, only the association with CRP remained (55). Increased levels of the 
pro-inflammatory cytokines, TNF- and IL-6 are also evident in obesity. 
Adiponectin levels tend to be lower in T2DM and MS (56), although this may not be a 
consequence of the disease as there appears to be a genetic predisposition to lower 
adiponectin levels with associations having been found between various 
polymorphisms in the adiponectin gene and lower circulating adiponectin levels and 
T2DM risk (57).  
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1.3 Coffee 
1.3.1 Coffee consumption in the UK 
Coffee consumption in the UK is growing rapidly with coffee imports to the UK 
increasing by 45% between 2004 and 2014 (58). Most of the coffee imported to the UK 
in 2013 was in the form of green coffee beans (2.5 million x 60 kg bags), followed by 
instant coffee (1.2 million x 60 kg bags) and roasted coffee (0.5 million x 60 kg bags). 
The UK population, as a whole, consumed 174 million kg of coffee in 2014, equivalent 
to 2.8 kg per capita (59). Instant coffee is the most popular form of coffee in the UK and 
accounted for almost 75% of retail value sales in 2015 (60). However its popularity has 
been in decline in recent years, as sales of pod-type coffee increases, with the overall 
percentage of people drinking instant coffee dropping from 70% in 2014 to 64% in 
2015 and only 35% drinking it at least once a day. Nevertheless, this is still 
substantially higher than the 15% of people who drink ground coffee at least once per 
day (60).  
1.3.2 Coffee production 
More than 80 species of coffee have been identified (61), including several which are 
naturally caffeine-free, such as Coffea bengalensis (62), however the majority are not 
commercially important. Only two species, C. arabica and C. camphora, account for 
the majority of global sales. Arabica coffee accounts for over 65% of coffee exports 
with C. camphora, also known as Robusta coffee, comprising the remainder (63). 
Arabica beans are generally considered to produce a better quality coffee and are most 
commonly used in the preparation of filter and espresso-type coffees, whereas 
Robusta beans are favoured in the production of instant coffee. 
After harvesting, the outer pulp is removed from the ripe coffee berries to produce the 
green coffee beans. The pulp is removed in one of two ways, either by soaking in water 
or by air drying followed by mechanical abrasion of the dried outer shell. The wet 
method is considered to produce a superior product. After the green beans have been 
dried they are ready for decaffeination or roasting. 
There are several methods which can be employed in the decaffeination process. The 
least expensive is to use an organic solvent, such as dichloromethane, along with 
water to wash the beans, however there have been health concerns about residual 
levels of solvent in the coffee bean with this method and so it is no longer used in 
certain parts of the world, such as Europe and the United States (61). Certain 
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water-soluble flavour molecules and chlorogenic acids (CGAs) are also lost in this 
process which can impact on the coffee flavour. Other methods use water or 
supercritical carbon dioxide (carbon dioxide held at high pressure and temperature 
>31 oC). The supercritical carbon dioxide method is more costly but has the advantage 
of being caffeine specific, thus retaining the flavour of the coffee. After decaffeination 
the beans are dried again, prior to roasting. 
The temperature and duration of the roasting process can vary considerably 
depending on the type of roaster (drum or fluid bed) and the desired degree of roasting 
in the end product. Temperatures typically range from 180 – 250 oC, with roasting times 
as short as two minutes at higher temperatures, increasing up to 25 minutes for lower 
temperatures (64). These extreme processes result in major changes to the chemical 
composition of the coffee beans. 
1.3.3 Composition of green coffee beans 
Of the many compounds present in green coffee beans, CHOs comprise the largest 
proportion, providing almost 60% of dry weight. Other components include lipids, 
proteins, polyphenols, caffeine and trigonelline, quantities of which vary between bean 
varieties, with Arabica beans containing smaller amounts of CHO, caffeine and 
polyphenols and larger amounts of sucrose, free amino acids and diterpenes than 
Robusta beans. The main components of green coffee are listed in Table 1.3.3-1.   
 
 
Table 1.3.3-1  Composition of green coffee beans. 
Compound
Proportion 
(% dry weight) Examples
carbohydrates 60 soluble and insoluble polysaccharides: cellulose, arabinogalactan, galactomannan
oligosaccharides: stachyose, raffinose
disaccharides: sucrose
monosaccharides: glucose, galactose, arabinose, fructose, mannose, manitol, 
xylose, ribose
lipids 8 - 18 triglyceride (75%), sterols, fatty acids (e.g. linoleic, linolenic, stearic, oleic, palmitic), 
diterpenes (cafestol, kahweol)
proteins, peptides 
and amino acids
9 - 16 asparagine, glutamic acid, alanine
polyphenols 6 - 10 CGAs (CQAs, FQAs, diCQAs), cinnamoylquinic acids, cinnamoyl-amino acid 
conjugates, cinnamoyl-glycosides
caffeine 0.9 - 2.5 0.9 - 1.3 % in Arabica, 1.5 - 2.5 % in Robusta beans
trigonelline 1
other compounds theobromine, theophylline
Data from Ludwig et al., 2014 (64). CGA: chlorogenic acid; CQA: caffeoylquinic acid; FQA: feruloylquinic 
acid.
29 
 
1.3.4 Composition of roasted coffee beans 
Coffee roasting, whilst being a relatively straightforward procedure, results in major 
changes to the chemical composition of the coffee beans. In the early stages of the 
roasting process free water evaporates then, as the coffee bean temperature 
increases, chemical reactions begin to take place. Sucrose begins to caramelise at 
about 130 oC, at which point the beans also begin to swell and turn brown. At higher 
temperatures, over 180 oC, pressures of up to 7 atm build up inside the coffee bean 
and many chemical transformations take place. One of the key reactions taking place 
during the roasting process is the Maillard reaction, which produces a variety of end 
products, including melanoidins which make up approximately 25% by weight of 
roasted coffee. Almost a thousand volatiles are produced during roasting, many of 
which are key to the aroma and taste of roast coffee. 
Roasting results in a reduction in the amount of CHO, proteins, lipids and CGAs in the 
coffee bean, the extent of which is determined by roasting temperature and duration. 
Caffeine content, however, remains virtually unchanged. Most of the CGAs present in 
green coffee are lost during roasting, with up to 10% loss per 1% loss of dry matter. 
When one considers that 9 – 10% dry matter may be lost in a very dark roast (65), then 
this reduction in CGA content can be considerable, although such very severe roasts 
are not the norm. Nevertheless coffee is still the major source of CGAs in many 
people’s diets (66), with the main CGAs in coffee being caffeoylquinic acids (CQAs), 
feruloylquinic acids (FQAs), dicaffeoylquinic acids (diCQAs), p-coumaroylquinic acids 
(pCoQAs) and caffeoylferuloylquinic acids (CFQAs) (67). Many transformations also 
occur to the CGAs during roasting, resulting in a multitude of end-products including 
cinnamic acids, quinic acid, quinides, caffeoylquinic lactones (CQL), alkyl esters and 
caffeic acid derivatives. Roasting also results in degradation of trigonelline to a variety 
of compounds including niacin (vitamin B3) and several volatiles. In addition to niacin, 
roast coffee also contains several other micronutrients including magnesium, 
potassium and vitamin E. 
An analysis of six commercial roast ground coffees reported a caffeine range of 843 – 
1456 mg / 100 g (lowest: medium roast, 100% Arabica; highest: light-medium roast 
Arabica/Robusta blend); and a trigonelline range of 280 – 956 mg / 100 g (lowest: dark 
roast, 100% Arabica; highest: light-medium roast, 100% Arabica) (68).  
The main components of roasted coffee and their relative proportions are detailed in 
Table 1.3.4-1. 
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1.3.5 Effects of the decaffeination process on coffee composition 
Decaffeination does not remove all caffeine from the coffee bean, but instead reduces 
the amount from 1 – 2 g / 100 g to 0.02 – 0.30 g / 100 g (69). UK legislation permits a 
maximum caffeine content of 0.1% dry weight for decaffeinated coffee beans and 0.3% 
dry weight for decaffeinated instant coffee (70).  
As stated previously, the decaffeination process can alter the proportions of other key 
coffee components dependent on the decaffeination method. Decaffeination using 
organic solvents has been reported to produce CGA losses of 16% in Arabica beans 
and 11% in Robusta beans (71), with CGA losses also reported for water decaffeination 
methods (61).  
1.3.6 Instant coffee composition 
The composition of instant coffee is largely determined by the blend of beans used 
and roasting methods, as discussed previously. However the methods used to extract 
and concentrate the coffee also have an effect, with increased losses of thermolabile 
compounds, such as CGAs, occurring when extreme heat is used.  
An analysis of four decaffeinated and five caffeinated instant coffees, reported total 
CGA content ranging from 43 – 55 mg for decaffeinated coffee (DC) and 37 – 77 mg 
for caffeinated coffee (CC) in a single serving (1.8 g instant granules made up in 200 
ml water), with 5-CQA being the most abundant CGA in all coffees tested (72). Lipid 
content of instant coffee tends to be low and has been reported to range from 1.8 – 
6.6 mg per 150 ml cup (73). 
The caffeine content of instant CC has been reported to range from 2.5 – 5.0 g 
per 100 g (61), equivalent to 45 – 90 mg per 1.8 g serving. However, this “standard” 
Table 1.3.4-1  Composition of roasted coffee beans. 
Compound
Proportion 
(% dry weight)
carbohydrates 40 - 44
lipids 11 - 18
proteins 7.5 - 10
CGAs 1.9 - 3.8
caffeine 1.1 - 2.5
trigonelline 0.2 - 1.2
melanoidins 25
Data from Farah, 2012 (61); CGA: chlorogenic acid. 
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serving size of 1.8 g does not take into account individual preferences. Indeed, a 
Canadian study  which analysed the caffeine content of various instant CCs prepared 
to participants’ personal taste preferences, found a median caffeine concentration in 
the prepared coffees of 328 µg/mL (range 102 – 559 µg/ml) (74). This median value 
would provide 66 mg caffeine in a 200 ml serving, which falls within the range reported 
for the standard serving size, but the extremes reported in the Canadian study (20 – 
112 mg per 200 ml) do not, highlighting the dangers of relying on data from so-called 
“standard” measures when reporting on coffee intake. This is even more relevant when 
variation in serving size is also considered.  
Nevertheless, as instant coffee is prepared simply by the addition of hot water to the 
instant coffee granules, variability between drinks for a particular batch of instant coffee 
is very low and determined only by the accuracy of measurement of the coffee granules 
and water volume. This makes instant coffee a good choice for intervention-type 
studies where standardisation and reproducibility of the test coffee is of high 
importance. 
1.3.7 Composition of brewed coffees 
Brewing method can have a significant impact on the composition of the end product. 
Factors such as particle size of the coffee grind, length of time in contact with water, 
water volume and temperature, filter material and, in the case of espresso coffees, 
water pressure, all have an impact on the final brew.   
Use of a paper filter tends to remove most of the lipid fraction, resulting in brews 
containing less than 7 mg total lipid, compared to boiled coffees, which can contain up 
to 160 mg lipid per cup; those prepared with a metal filter, such as a mocha/stove-top 
pot, have been reported to contain intermediate amounts of up to 50 mg per cup (73). 
Reductions in chlorogenic lactones and 5-CQA along with an increase in 3-CQA and 
4-CQA have been observed when coffee is kept hot for a prolonged period, such as 
commonly occurs with filter coffee kept on a hot plate (75). 
An analysis of eight commercial ground roast coffees, brewed in a cafetiere for 4 min, 
reported total CGA content to range from ~27 mg (French blend; medium-dark roast; 
40:60 Arabica:Robusta ratio) to ~94 mg (Breakfast blend; light roast; 100% Arabica) 
for a standardised serving (11 g roast coffee) (72).  
Amounts of the key coffee components vary considerably for espresso coffees, partly 
due to the complexity of the preparation method and partly due to variation in serving 
size. One analysis of espresso coffee, from 20 different commercial establishments in 
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Glasgow, reported a variation in serving size of 23 – 70 ml, with total CQA ranging 
from 24 – 422 mg and caffeine ranging from 51 – 322 mg per serving (76). Another study 
purchased espresso from 26 coffee shops, in Scotland, Italy and Spain, and reported 
variations in mean serving size (15 – 83 ml), caffeine (48 – 317 mg) and total CQA (6 
– 188 mg) (77). They also observed noticeable differences between countries, with Italy 
favouring smaller servings of darker roasts, resulting in lower total CQA and Spain 
preferring larger servings of lighter roast coffees, with higher CQA content; the greatest 
variation was observed in the Scottish samples. 
Illustrating the scale of the effect that the barista can have on the final coffee 
composition is one study which analysed six samples of Starbucks® Breakfast Blend 
coffee, purchased on consecutive days from the same coffee shop in Florida, and 
found a variation in caffeine content of 300 – 498 mg in a 16 oz. serving (78).  
Taking the above points into consideration, it is clear that, even following a 
standardised brewing method, there is greater opportunity for variation in the 
composition of the end product when brewed coffee is used in comparison to instant. 
This should be considered when choosing a coffee preparation method for trials 
investigating coffee’s effects, particularly if participants will be required to brew their 
own coffee. Furthermore, this variability should also be considered when interpreting 
epidemiological data. 
1.3.8 Bioavailability of coffee components 
Caffeine is absorbed rapidly in the small intestine, reaching peak plasma 
concentrations (Cmax) within 30 – 60 min and with a half-life of around 5 h (79), although 
this can vary considerably, with smokers exhibiting faster caffeine metabolism and 
pregnancy, oral contraceptives and liver disease all resulting in slower caffeine 
metabolism. Caffeine is metabolised in the liver, by the cytochrome P450 enzyme, 
CYP1A2, with the primary metabolites being paraxanthine, theobromine and 
theophylline. The plasma or salivary paraxanthine (17X) to caffeine (137X) ratio is 
frequently used as a marker of CYP1A2 activity (80).  
Coffee CGAs are extensively metabolised, with one study finding only trace amounts 
of 5-CQA and slightly higher amounts of FQAs appearing in the circulation following 
coffee consumption (67). In contrast Monteiro et al. observed 3-, 4- and 5-CQA in the 
plasma of all of their participants with 4- and 5-FQA only present in one participant, 
leading them to conclude that there is large inter-individual variation in absorption and 
metabolism of CGAs in humans (81). Some of the CQAs and FQAs are broken down in 
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the small intestine, releasing caffeic and ferulic acids which are then sulphated before 
absorption, however most of the ingested CGAs pass intact to the colon where they 
are extensively metabolised by bacterial enzymes prior to absorption (67). Analysis of 
ileal fluid from ileostomy patients indicates that almost 70% of ingested CGAs will pass 
from the small intestine to the colon (82). The main metabolites absorbed in the small 
intestine, and appearing in the circulation after approximately 1 h, are caffeic acid-3’-
O-sulphate and ferulic acid-4’-O-sulphate, with DHCA, dihydroferulic acid (DHFA) and 
their sulphates being absorbed predominately in the colon and appearing in the 
circulation 4 - 6 h after ingestion (64). In vitro work has demonstrated gastric metabolism 
of several CGAs, resulting in the release of isoferulic acid, dimethoxycinnamic acid 
and ferulic acid with subsequent absorption across the gastric membrane (83). This may 
explain the rapid appearance of some metabolites, such as dimethoxycinnamic acid, 
which has been observed to reach peak levels in plasma after 30 min (84). 
Trigonelline and N-methylpyridinium, a degradation product of trigonelline formed 
during the roasting process, are both absorbed intact, reaching Cmax within 3 and 2 h 
respectively; they are not extensively metabolised, with 46 - 57% of trigonelline and 
69% of N-methylpyridinium being excreted in urine within 8 h (85). Studies in ileostomy 
patients found that approximately 70% of ingested cafestol and kahweol is absorbed 
in the small intestine, with less than 10% reaching the colon and a very small amount 
being excreted in urine, indicating extensive metabolism of these compounds (86).  
1.4 Coffee and glucose metabolism 
1.4.1 Epidemiology 
Epidemiological evidence for an inverse relationship between coffee consumption and 
T2DM risk is strong. It was first suggested in 2002 by van Dam et al., who carried out 
a prospective cohort study in over 17,000 Dutch men and women between 1987 and 
2000, and found that people who drank more than six cups of coffee per day were half 
as likely to develop T2DM as people who drank less than three cups per day (87). Many 
more papers were published in subsequent years, encompassing populations from the 
United States (5,88), Asia (2) and Europe (89,90). One study concluded that coffee and tea 
only conferred a benefit in those under 60 years old who had previously lost weight (88). 
Another, which examined data from nearly 70,000 French women who were part of the 
EPIC cohort, found that the association between coffee drinking and reduced T2DM 
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risk only applied when coffee was consumed at the lunchtime meal (91); they found no 
association between tea drinking and T2DM risk in this cohort. 
A systematic review and meta-analysis in 2009 included 18 studies with a total of over 
450,000 participants (92). They found a 7% reduction in relative risk (RR) of T2DM for 
every additional cup of CC consumed, with people drinking 3 - 4 cups/day having a 
25% lower risk than those who drank 2 or fewer. Six of their included studies examined 
the effects of DC and when these were combined they found a 33% reduction in T2DM 
risk for those who drank 3 - 4 cups/day compared to those who drank none. Similarly, 
when the results of 7 studies investigating the effects of tea were combined, they found 
those who drank 3 – 4 cups/day had a 20% lower risk than those who drank none. 
They had insufficient data to determine a dose-response relationship in either tea or 
DC. 
Two later meta-analyses (93,94), performed on 28 and 26 prospective studies 
respectively, found a dose-response reduction in RR of T2DM for CC, DC and caffeine; 
RR for 4 cups/day of any type of coffee was reported as 0.75 – 0.84 and for 6 cups/day 
was 0.67 – 0.78. Jiang et al. extended their analysis to 10 cups per day and reported 
a RR of 0.61 in this category (94). A recent analysis of data from the Nurses’ Health 
Study found a 17% increased risk of T2DM in people who had reduced their coffee 
intake by more than 1 cup/day over a four year period along with an 11% reduction in 
risk for those who had increased consumption by more than 1 cup/day (95). 
Other cohort studies have investigated links between coffee drinking and other 
markers associated with T2DM risk. Five or more cups of coffee per day was 
associated with lower incidence of impaired glucose tolerance (IGT) (96) and lower 
fasted insulin, but not fasted glucose (97). One study examined various components of 
MS and found that coffee consumption was associated with lower HDL cholesterol in 
women but not men; however they found no associations between coffee and fasted 
glucose, TAG, waist circumference or blood pressure (BP) in either men or women (98). 
A recent cross-sectional study in a Korean population found an increased risk of 
abdominal obesity, low HDL cholesterol and MS in those who drank more than three 
coffees per day (99). The authors hypothesised that this may be due to the type of coffee 
consumed by the participants, as most of them drank an instant coffee mix containing 
sugar and creamer, and this additional sugar and fat in the diet may have been 
contributing to the apparent effect of coffee. Conversely, a Japanese study found 
significant inverse associations between coffee drinking and all components of MS 
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apart from HDL cholesterol (100). Another recent study found no association between 
either Turkish coffee or instant coffee and fasted lipids (101). 
Coffee consumption has been associated with higher adiponectin levels in both 
women (102) and men (103), but others have found no such association (104). Conflicting 
results have also been found with respect to coffee drinking and inflammatory markers; 
the ATTICA study found coffee drinking to be associated with increased levels of IL-6 
and TNF- (105), whereas others have found no association with IL-6 (102) and lower 
levels of TNF- in coffee drinkers (106). 
Whilst the epidemiology puts a strong case for coffee drinking having a protective 
effect in terms of reduced risk of development of T2DM, caution is advisable in 
interpretation of the evidence relating to a dose-response relationship. As discussed 
previously, variation in coffee beans, degree of roasting, preparation method and 
serving sizes mean that there is no such thing as a typical cup of coffee. Indeed, an 
individual consuming 10 cups/day might conceivably receive less CGAs and caffeine 
than an individual consuming only one cup per day.  While this extreme scenario is 
unlikely to occur very often, a four- to five-fold variation is potentially commonplace. 
When one also considers that much epidemiological data is gathered retrospectively, 
relying on an individual’s recall of their intake over several years, then the accuracy of 
any RR for a particular number of cups of coffee is questionable.    
1.4.2 Acute effects of coffee on glucose metabolism 
In contrast to the epidemiology, many, but not all, acute studies have demonstrated a 
detrimental effect of coffee on glucose metabolism. 
An early study by Acheson et al. compared the effects of CC, containing 4 mg 
caffeine/kg bodyweight (BW), with DC on fasted glucose and insulin in an obese group 
(n=6) over a 3 h period and found no effect of CC or DC on either glucose or insulin 
over that time period (107).  
Another early study by Feinberg et al. examined the acute effects of CC on glucose 
tolerance in 23 healthy participants and found that CC reduced blood glucose at 30 
and 60 min after consumption compared to placebo (108). They also demonstrated 
higher serum NEFA at 180 min following CC consumption and no effect on serum 
insulin at any time-point. They hypothesised that the effect on NEFA at the 3 h mark 
was solely due to caffeine as the suppressive effect of insulin on NEFA would have 
dissipated by then. Unlike later studies, they varied the glucose dose administered to 
their participants by bodyweight (giving 1 g glucose / kg BW), whilst keeping the CC 
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dose constant (5 g instant CC, containing 220 mg caffeine). They also did not calculate 
area under curve (AUC) or incremental area under curve (IAUC), making comparisons 
with later studies difficult. 
In contrast to Feinberg et al., many subsequent studies have observed an increase in 
postprandial glucose following CC ingestion compared to a control (7,109,110).  Battram 
et al. compared caffeine with CC, DC and control (10). Their caffeine and CC both 
provided 4.45 mg /kg caffeine. They administered their test drinks 60 min prior to a 
standard oral glucose tolerance test (OGTT) and found caffeine increased glucose and 
insulin AUC more than CC compared to both control and DC. They also observed less 
of an increase in glucose following DC than following the control. They also found 
caffeine increased NEFA and glycerol in the 60 min prior to the OGTT, whereas CC 
did not, despite CC and caffeine producing similar levels of adrenalin in the same time 
period. This led them to hypothesise that other components in coffee were attenuating 
the effects of caffeine on both glucose disposal and lipolysis. The effects of individual 
coffee components will be discussed further, later in this chapter. 
A systematic review of all studies to date which have investigated the acute effects of 
coffee on postprandial glucose metabolism can be found in Chapter 3 of this thesis. 
1.4.3 Longer-term effects 
There have been few longer-term intervention studies into the effects of coffee on 
glucose metabolism, the majority of which have examined the effects in regular coffee 
drinkers (11–13).  
Van Dam, Pasman and Verhoef carried out two trials in coffee drinkers (12). In the first, 
they got participants to drink a litre of filtered CC (made from 70 g of coffee grounds) 
per day for 4 weeks and compared this to 4 weeks of coffee abstention in a cross-over 
design. Despite their participants regularly consuming more than 5 cups/day prior to 
the trial, they still had a large number of dropouts (10/40) due to side effects from the 
coffee. This is probably due to the very high dose administered or the strength of the 
drink. The authors reported their dose to be the equivalent of 13 cups of coffee in one 
litre of liquid. Despite this very high dose they found only a transient effect on fasted 
glucose: CC tended to increase glucose at 2 weeks (p=0.08) but not after 4 weeks, 
perhaps indicating a degree of acclimatisation. They did however find CC increased 
fasted insulin after 4 weeks. Their second study, reported in the same paper, also 
utilised a crossover design and compared 2 weeks each of filtered CC (52 g in 0.9 l), 
caffeine (870 mg in six capsules) and placebo (6 cellulose capsules). This study had 
37 
 
fewer dropouts for coffee-related issues (3/54). The caffeine content of the filter CC 
was not reported so it is unknown whether the CC and caffeine treatments were 
comparable for caffeine, although 870 mg caffeine in 52 g CC, equating to 1.7% 
caffeine, would not be unreasonable. In this study they found no effect of either caffeine 
or CC on fasted glucose, but reported a tendency for higher insulin after both CC and 
caffeine (p=0.15). They did not report any washout period for either study, either before 
the studies began or between treatment phases. 
In a non-crossover design, Kempf et al. recruited regular coffee drinkers who had an 
elevated risk of T2DM (11). They were asked to drink no coffee for four weeks, followed 
by 4 cups of CC/day for another four weeks then 8 cups of CC/day for a final four 
weeks. Most of their participants were female and obese and had a mean coffee 
consumption pre-trial of 4 cups/day. They found no effect of CC on either fasted 
glucose or insulin, nor did they find an effect on 30 min and 2 h glucose and insulin 
after an OGTT. They did however report that their lower dose of 4 cups/day increased 
HDL cholesterol and their higher dose of 8 cups/day increased both total and HDL 
cholesterol with no effect on LDL cholesterol or TAG versus coffee abstention. They 
also observed a decrease in IL-18, with no effect on IL-6 or CRP. Their lower dose of 
4 cups/day was the same as the mean pre-intervention intake of the participants, so it 
is perhaps surprising that they observed an effect on HDL cholesterol from that dose. 
However, their participants underwent a four week caffeine washout prior to the trial, 
which may be a sufficiently long period of time to reverse any effects of habitual coffee 
consumption on HDL cholesterol. Unfortunately they did not take any baseline 
measures before the washout period, so it is not possible to determine whether there 
was any effect from the washout period. 
In a parallel-arm trial, Wedick et al. gave their participants (n=45, across three groups) 
either 5 cups/day instant CC, 5 cups/day instant DC or control (no coffee) for 8 
weeks (13). Their participants were overweight (mean BMI = 29.5 kg/m2) regular coffee 
drinkers (2 or more cups/day). All groups had a 2 week caffeine-free washout period 
prior to their first visit. Coffees were provided in 2 g portions and participants were 
instructed to make it up with 177 ml boiling water. This resulted in a reported daily dose 
of 345 mg caffeine, 302 mg CGA and 78 mg trigonelline in the CC and 216 mg CGA 
and 65 mg trigonelline in the DC. There were no differences between control and either 
CC or DC for glucose AUC, 2 h glucose or insulin, nor was there any effect on HDL, 
LDL or TAG. CC increased adiponectin versus control.  
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Kempf et al. carried out another longer-term intervention in coffee drinkers, where they 
compared the effects of a medium roast (MR) and a dark roast (DR) CC in 114 
overweight individuals (111). In a parallel-arm study, with no control group, their 
participants were asked to drink at least 3 cups per day of their allotted CC over 12 
weeks, after an initial 4 week washout period. They observed a small increase of 0.1% 
in HbA1c values for both groups. In the MR group they saw an increase in HDL 
cholesterol and adiponectin, whereas they saw an increase in TAG and a decrease in 
systolic blood pressure (SBP) in the DR group. These changes did not remain 
significant after correction for multiple tests. They found no effect of either coffee on 
weight, BMI, waist circumference, diastolic blood pressure (DBP), fasted glucose, 
fasted insulin, HOMA-IR, total and LDL cholesterol. 
One study recruited people who were not heavy coffee drinkers (mean consumption: 
2 cups/week of coffee and 5 cups/week of tea) and found a reduction in the 
postprandial glycaemic response following a 16 week coffee intervention (112). It was a 
parallel-arm design with a total of 43 participants randomised to one of three 
treatments: 5 cups/day of instant CC, instant DC or water for 16 weeks. Their 
participants were overweight Japanese men, aged 40 - 64 y, with elevated fasted 
glucose. They observed a decrease in AUC glucose and 2 h glucose in both CC and 
DC groups compared to control, however the results were only statistically significant 
for the DC group after adjustment for change in waist circumference. They observed 
no change in insulin in any group. 
Effects on blood lipids 
In a randomised cross-over study, 20 healthy, habitual coffee drinkers drank 3 - 4 cups 
of medium roast (MR) or medium light roast (MLR) filtered CC per day for four weeks 
(113). Total and LDL cholesterol increased significantly in each group with no difference 
between groups. HDL cholesterol increased significantly more with MR than with MLR. 
They observed no effect on TAG, IL-6 or TNF-. The authors noted that their coffees 
had higher amounts of cafestol and kahweol than is usually found in paper filtered 
coffee and hypothesised that this may be the reason for the increase in lipids in their 
study as these two compounds have been previously identified as lipid-raising (114,115). 
Another randomised parallel-arm trial, over 8 weeks, also found filtered CC raised total, 
LDL and HDL cholesterol compared to a control (116), although they found the effect 
only in their highest dose group (720 ml/day), with no effect in a lower dose (360 
ml/day) nor in a DC group (720 ml/day). 
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This is in contrast to an earlier parallel-arm study which found boiled CC raised total 
and LDL cholesterol compared to filter CC, with no effect of filter CC compared to a 
control (117). However, their participants were instructed to drink 3 cups/day of filter CC 
in the run-in phase, with the active phases being 4-6 cups/day of either boiled CC, filter 
CC or no coffee for 9 weeks. It is possible that the increase from 3 to 4 - 6 cups/day in 
the filter CC group was insufficient to produce a noticeable difference in results over 
this time-frame. 
Two meta-analyses have been performed on the effects of coffee on serum lipids, with 
both finding a dose-response effect of coffee on total and LDL cholesterol and 
TAG  (118,119). Both found the effect to be stronger in dyslipidaemic patients and in trials 
using caffeinated and boiled coffees.  
1.4.4 Potential mechanisms 
Several mechanisms have been postulated to explain the apparent protective effects 
of coffee on T2DM risk suggested by the epidemiology. These include aiding weight 
loss by increasing energy expenditure and fat oxidation (120,121) and reducing energy 
intake (122). Caffeinated coffee has been demonstrated to reduce energy intake at a 
subsequent meal and over the course of a whole day in overweight but not in normal-
weight individuals, without any noticeable difference in feelings of hunger or 
satiety (122). However, the CC used in this study provided a high dose of caffeine 
(6 mg/kg BW) and it is unclear whether normal coffee drinking would produce the same 
effect or whether these acute effects would persist over a longer time frame. One study 
compared the effects of a DR with a light roast (LR) CC and found that the DR 
significantly reduced bodyweight in overweight participants by 2.5 kg over four weeks, 
but not in normal-weight, whereas the LR resulted in a slight increase of 0.2 kg (123). 
The weight loss can be ascribed to the observed reduced energy intake in the DR 
group. It is unlikely that this rate of weight loss would be sustainable over several 
months and indeed, another trial comparing DR and medium roast (MR) CCs did not 
see any difference in bodyweight for either CC over a three month period (111).  
Some studies have demonstrated an increase in circulating adiponectin levels 
following coffee consumption (13,112). Adiponectin levels have been reported to be 
inversely associated with insulin resistance (124), so an increase in levels  may result in 
improved insulin sensitivity, although this has not been observed previously perhaps 
due to short study durations.  
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Some of the effects of specific coffee components are discussed further in the following 
subsections. 
 Effects of caffeine 
Greater glucose and insulin AUCs have been demonstrated following caffeine 
ingestion compared to both control (125) and DC (126), with the effect being stronger than 
that produced by CC (10). Caffeine has been observed to raise plasma adrenalin and 
to act as an antagonist to both adrenergic and adenosine receptors, all of which may 
contribute to its observed glucose raising effects. However it has been suggested that 
the acute adrenalin-raising effects of caffeine are temporary, as chronic caffeine 
exposure of just seven days has resulted in acclimatisation to its effects (127). 
Acute caffeine ingestion is known to decrease glucose disposal in both sedentary and 
exercise trained individuals (128,129). It has been suggested that this inhibition of glucose 
disposal is solely a result of increased adrenalin as the effects were negated when 
propanalol, a beta-adrenergic antagonist was administered along with caffeine (69). A 
later study, however, found a difference in the reduction in glucose infusion rate (GIR) 
during an euglycaemic-hyperinsulinaemic clamp between a low dose adrenalin 
infusion and an oral caffeine dose, with the caffeine showing a significant reduction in 
GIR compared to adrenalin infusion, despite the oral caffeine producing a similar, but 
lower, adrenalin concentration as the infusion (130). This led them to conclude that 
increased adrenalin following caffeine consumption was not the only mechanism for 
the subsequent reduction in glucose disposal. They did not find any difference between 
treatments in endogenous glucose production or NEFA, leading them to postulate that 
their effects may be due to adenosine receptor antagonism. Adenosine is an 
endogenous nucleoside which binds to a variety of receptors and regulates insulin 
secretion, glucose uptake and release, and is involved in adipose tissue lipolysis. It 
can have both stimulatory and inhibitory effects on glucose metabolism depending on 
which receptors it binds to (131). As caffeine is a non-specific adenosine receptor 
antagonist (132), this is a plausible contributory mechanism to the observed reduction in 
glucose disposal following caffeine ingestion.  
Caffeine has also been demonstrated to inhibit cyclic nucleotide phosphodiesterase 
which is involved in the breakdown of cAMP (133) and appears to increase cAMP 
concentrations above levels observed with adrenalin administration alone (134). As 
increased concentrations of cAMP lead to increased blood glucose, as discussed in 
Section 1.2.4, this is another possible mechanism by which caffeine may increase the 
postprandial glucose response.   
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Acheson et al. compared caffeine (8 mg/kg BW) with placebo (0.5 g glucose) and took 
blood samples at regular intervals for 3 h after ingestion of the respective treatments. 
They found that caffeine increased metabolic rate by 16%, but with high inter-individual 
variation (107). They observed no effect on glucose or insulin but did report an increase 
in NEFA in both treatments, with caffeine increasing NEFA more than placebo. The 
increase in NEFA following caffeine ingestion is in direct contrast to another study 
reported in the same paper, where they gave CC or DC to an obese group of 
participants and observed no effect on NEFA over the same time period, however this 
lack of an effect of coffee on NEFA in obese participants has been reported by 
others (135) and has been suggested to be a result of reduced responsiveness to 
lipolytic stimuli in the obese.  
Caffeine may have a beneficial effect as an antioxidant. In vitro work using 
physiological concentrations demonstrated no effect of caffeine or its primary 
metabolites, theophylline, paraxanthine and theobromine, on LDL peroxidation, but did 
observe a protective effect from the theophylline and paraxanthine derivatives, 
1-methylxanthine and 1-methyluric acid (136). 
 Effects of chlorogenic acids 
Glucose metabolism 
It has been suggested that bioactive components in coffee, other than caffeine, may 
be attenuating the documented acute negative effects of caffeine on glycaemia, with 
CGAs and their metabolites attracting attention as possible candidates. Some 
suggested mechanisms include delayed digestion of starches, delayed glucose 
absorption and increased glucose uptake from the circulation. 
Chlorogenic acids may delay starch digestion, as in vitro work has demonstrated 
partial inhibition of pancreatic -amylase by both 5-CQA and caffeic acid (137) and 
inhibition of -glucosidase by 3,5-diCQA (138).  
Increased disposal of glucose in non-skeletal muscle has been demonstrated in animal 
models following a gastric infusion of a synthetic quinide, however the concentration 
administered was higher than would be achieved through normal coffee drinking (139). 
In vitro work has demonstrated an 80% reduction in glucose uptake by the enterocyte 
when treated with 5-CQA and 30 – 40% reduction when treated with ferulic and caffeic 
acids, with dissipation of the sodium gradient and consequent inhibition of the SGLT1 
glucose transporter being suggested as a potential mechanism (140). Under normal 
physiological conditions however, if glucose concentrations in the gut became high, 
42 
 
the facilitative transporter, GLUT2, would translocate to the brush border membrane 
and take over glucose transport, thus minimising any effect of SGLT1 blockade. 
Reduced glucose transport via GLUT2 has been observed following incubation with a 
herbal supplement containing a mixture of polyphenols some of which were derived 
from coffee beans, however the supplement contained a range of herbs and spices 
and it is unknown which particular components were responsible for the observed 
effect (141). 
Chlorogenic acids may also reduce hepatic glucose output, as in vitro (142) and 
animal (143) models have demonstrated inhibition of G6Pase by CGAs.  
It would appear from the above that there is potential for a beneficial effect of CGAs in 
terms of reducing the postprandial glycaemic response. Giving weight to this 
hypothesis, studies involving CGA on its own (144), as green coffee extract (GCE) (145) 
and coffee enriched with CGA (146) have demonstrated a reduction in glucose response 
versus control. It should be remembered, however, that these studies have used high 
doses of CGA, certainly higher than that delivered by a typical beverage; the majority 
of studies using regular coffee, both CC and DC, have failed to find any beneficial 
effect on the acute glucose response.  
Johnston et al. controlled the amount of total CQA in their coffees when comparing the 
effects of CC and DC on the postprandial response; both their CC and DC provided a 
CQA concentration of 2.5 mmol/L (147). The authors observed lower plasma GIP 
concentrations following consumption of both coffees compared to control, particularly 
with DC in the first 30 min. They also reported higher plasma GLP-1 concentrations 
following DC than control over the first 120 min. This led them to conclude that the 
altered patterns of GIP and GLP-1 were a result of delayed glucose absorption in the 
small intestine as a result of the actions of coffee components, possibly CGAs. It 
should be noted however that they found no overall effect of either CC or DC on 3 h 
glucose and insulin response, raising the question of whether the observed delay in 
glucose absorption is physiologically relevant. Furthermore, the doses of coffee given 
(12 g DC and 8.7 g CC) are not typical of normal coffee consumption, as a typical 
serving of instant coffee is 2 g. It is not known whether they would have observed the 
same effects at a lower dose. 
Weight loss 
A meta-analysis of studies investigating the effects of GCE on weight loss was carried 
out in 2011, with three trials selected for inclusion (148). The authors reported that GCE 
significantly reduced bodyweight, with a mean reduction of 2.5 kg, but noted that the 
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included trials were very heterogeneous, poorly carried out, included low numbers of 
participants (n = 30–62) and were of short duration (4–12 weeks). Doses of GCE given 
ranged from 180 to 200 mg. Longer and more rigorously controlled trials are required 
before any conclusions can be drawn regarding the efficacy of GCE as a weight loss 
treatment. 
Antioxidant capacity 
Whilst CGAs may exhibit antioxidant activity in vitro, the concentrations attained in vivo 
are low, as discussed in Section 1.3.8, and their ability to make a significant 
contribution to overall antioxidant activity has now been called into question (149). 
 Effects of trigonelline and niacin 
Trigonelline may have some beneficial effect on the glycaemic response. One study 
observed lower glucose and insulin at the 15 min time-point during an OGTT following 
trigonelline ingestion in comparison to a placebo (144). However, the dose given 
(500 mg) was substantially higher than would normally be present in coffee and they 
did not find an overall effect, so any beneficial effect from trigonelline in the 
concentrations found in coffee is likely to be small. 
The effects of caffeine on NEFA may be partially offset by niacin, which has been 
demonstrated to reduce NEFA and is prescribed as a drug to treat hyperlipidaemia, 
although in the long term it has a rebound effect and leads to elevated plasma 
NEFA (150). 
 Effects of cafestol and kahweol  
The diterpenes cafestol and kahweol are generally thought to have a detrimental effect 
on health as they have been demonstrated to increase serum cholesterol and 
TAG (114,115), although it has been suggested that cafestol is responsible for most of the 
effect (151). Recently however, an in vitro study has demonstrated increased insulin 
secretion from pancreatic beta cells and increased glucose disposal into skeletal 
muscle cells following incubation with cafestol, suggesting a potential beneficial effect 
of this compound (152). 
1.4.5 Effect of genotype 
A gene is a segment of DNA which encodes a specific genetic function. A single 
nucleotide polymorphism (SNP) is a variation in one nucleotide at a particular position 
on the genome, which is present in at least 1% of the population (153). If the SNP occurs 
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within a gene it results in different versions of that gene, known as alleles. An individual 
has two copies of each gene, which together form that person’s genotype. The 
phenotype is the physical manifestation of the genotype. If only one copy of a particular 
allele is required to produce a specific phenotype, that allele is classified as the 
dominant allele, whereas if two copies are required, the allele is classified as 
recessive (154).  
The CYP1A2 gene encodes the P450-1A2 enzyme, the primary enzyme responsible 
for caffeine metabolism by the liver. A particular SNP in this gene, rs762551, affects 
caffeine metabolism, with carriers of the dominant, C allele considered to be slow 
caffeine metabolisers and those homozygous for the recessive, A allele considered 
fast metabolisers (155). For some genes, specific environmental conditions are required 
before expression of a particular phenotype. It is thought that the fast metaboliser 
phenotype requires induction by, for example, smoking (156,157) or heavy coffee 
consumption (158). However, for convenience in this thesis and in order to easily 
distinguish between the groups, those with the A/A genotype will be referred to as 
being of a fast metaboliser phenotype and those with the A/C and C/C genotypes as 
being of a slow metaboliser phenotype. 
An association has been observed between phenotype and T2DM risk, with the slow 
phenotype appearing to confer an increased risk of T2DM irrespective of coffee 
consumption (159). Others have reported an association between coffee drinking and 
impaired fasted glucose (IFG) in those with the slow phenotype only (160). It is possible 
that the different phenotypes will respond differently to a coffee intervention, however 
to our knowledge this has not previously been explored. 
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1.5 Aims of current work 
There are several gaps in the literature relating to coffee and glucose metabolism. The 
contradictory results from previous acute coffee studies may be partially explained by 
variation in coffee composition and the different effects of the individual coffee 
components as discussed previously, however this cannot be verified as the majority 
of these studies did not report a full coffee analysis. A further limitation to previously 
published work is the relatively high dose of caffeine found in the coffees, typically 3 - 
6 mg caffeine/kg BW (126,161), which equates to 210 - 420 mg for a 70 kg person, or the 
equivalent of approximately 3 – 6 servings of instant coffee taken as a single dose. 
Additionally, there have been few longer-term interventions, the majority of which have 
been carried out in habitual coffee drinkers. It is likely that regular coffee drinkers will 
already have gained any potential longer-term benefits of coffee drinking and may 
therefore not be the most appropriate population to study. 
The aims of the current work were, therefore, to attempt to fill some of the gaps in the 
knowledge base. Namely: 
 To perform a full review of the literature relating to the acute effects of coffee 
on postprandial glycaemia (Chapter 3).  
 To investigate the effects of “normal” doses of coffee, both CC and DC, on 
postprandial glycaemia (Chapters 4 and 5).  
 To carry out a longer-term intervention in coffee-naïve individuals and to further 
examine any differences in response between slow and fast caffeine 
metaboliser phenotypes (Chapters 6 and 7). 
1.6 Hypotheses 
 A “normal” dose of CC will acutely increase the postprandial glycaemic 
response more than a control. 
 A “normal” dose of DC will have no acute effect on postprandial glycaemia. 
 Longer-term CC drinking will reduce the postprandial glycaemic response. 
 Slow and fast caffeine metaboliser phenotypes will respond differently to 
longer-term CC drinking. 
 
Chapter 2. 
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This section describes in detail the methods followed for each of the studies in chapters 
4 through 7 of this thesis. Specific study design will be included in each chapter. 
2.1 Recruitment 
All participants were recruited from the University of Surrey staff and students by email 
and poster advertisements and from the general public by word of mouth. All studies 
received a favourable ethical opinion from the University of Surrey Ethics Committee, 
details of which are provided in each chapter. 
2.2 Screening 
Respondents who expressed an interest in taking part in each study were invited to 
attend a screening session at the Clinical Investigation Unit (CIU) at the University of 
Surrey. During these sessions potential participants were given a full explanation of 
the study and had the opportunity to ask questions. If they then wished to proceed they 
were asked to sign study consent forms (sample forms can be found in Appendix 1). 
Following this they completed a brief health and lifestyle questionnaire (Appendix 2) 
and a habitual coffee and caffeine intake questionnaire (Appendix 3) to assess their 
suitability for inclusion in the study. Height and weight were measured and BMI 
calculated. Bioimpedance was used to measure body composition. A small amount of 
blood was collected by finger prick, from which fasted blood glucose and haemoglobin 
levels were measured. Those with fasted glucose ≥ 7.0 mmol/L (1) and/or haemoglobin 
< 13 g/dl (men) / < 12 g/dl (women) (162) were excluded from the studies. 
2.2.1 Anthropometry 
Height was measured to the nearest half centimetre using a Harpenden stadiometer. 
All measurements were taken in bare feet with the participants standing with their 
backs to the stadiometer and looking straight forward. 
Body composition was measured after an overnight fast and immediately after the 
participants had emptied their bladders. Different Tanita body composition analysers 
were used for each study. The studies which were carried out at the CIU (detailed in 
Chapters 4 and 5) used a Tanita MC-180MA whereas the final study (Chapters 6 and 
7) carried out at the Surrey Clinical Research Centre (SCRC) used a Tanita BC 
Chapter 2. 
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418MA. Both analysers work by passing a small electrical current through the body 
and measuring the resistance to that current. Bioimpedance analysis underestimates 
fat mass compared to the gold standard dual-energy X-ray absorptiometry (DXA) 
method (163), however it is a cheap and non-invasive method which demonstrates a 
good correlation with DXA when measuring changes in body composition (164). This 
underestimation of fat mass was not an issue for our studies as we were interested in 
relative change. 
Blood pressure was measured using an Omron portable electronic BP monitor (Omron 
Healthcare UK Ltd, Milton Keynes, UK). It was measured in the seated position after 
the participants had been resting for five minutes. Two measures were taken, one 
minute apart, and the mean value calculated. 
2.2.2 Screening blood samples 
Fasted capillary blood samples were taken at the screening session to check that 
potential participants had fasted glucose and haemoglobin within the normal healthy 
ranges. A single-use safety lancet (Owen Mumford, Oxford, UK) was used to create a 
small puncture wound in the fingertip and the finger gently squeezed to produce a drop 
of blood. This blood was collected into HemoCue Glucose 201 and Hb 201 
microcuvettes which were immediately inserted into the appropriate analyser 
(HemoCue Glucose 201 Plus analyser for measurement of glucose and HemoCue Hb 
201 Plus analyser for measurement of haemoglobin (HemoCue Ltd, Sheffield, UK)).  
2.2.3 Normal caffeine intake 
Participants’ normal coffee and caffeine intake prior to taking part in the studies was 
assessed by questionnaire (Appendix 3). Estimates of their normal caffeine intake 
were made based on the following assumptions: 
 single espresso: 140 mg caffeine (76) 
 cup of instant coffee: 54 mg caffeine (165) 
 cup of tea: 40 mg caffeine (165) 
 cola: 9.7 mg caffeine per 100 g (166) 
 small hot chocolate: 20 mg caffeine (167) 
All caffeine estimates should however be treated with caution, due to the large 
variation in caffeine content depending on source, preparation method and portion size 
as described previously in Chapter 1. 
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2.3 Blood sampling during postprandial tests 
2.3.1 Capillary blood 
Capillary blood samples were collected for the studies detailed in Chapters 4 and 5. 
After washing their hands, participants created a small puncture wound in their fingertip 
with a Unistik 3 Extra single-use safety lancet (Owen Mumford, Oxford, UK) and 
squeezed approximately 300 µl blood from the fingertip into a heparin fluoride 
microvette tube (Sarstedt, Leicester, UK). The tubes were immediately refrigerated at 
4 oC until the end of the study session when they were centrifuged for 10 min at 1370 
x g, 4 oC (Sigma 3-16PK) following which the plasma was transferred to serum 
microvette tubes (Sarstedt, Leicester, UK). These plasma samples were then frozen 
at -20 oC for batch analysis at the end of the study. 
2.3.2 Venous blood 
Venous blood samples were collected for the twelve week intervention detailed in 
Chapter 6. A cannula was inserted into the antecubital vein of each participant and 
remained in situ until the end of each study session. Cannulae were kept patent with 
saline solution. Blood samples were drawn from the cannula by a trained phlebotomist 
at regular time points throughout the session.  At each time point a small amount of 
blood (approx. 1 ml) was drawn into a syringe and discarded to clear the cannula of 
any residual saline solution, then a further 2 ml was drawn into a syringe and 
transferred to a 2 ml fluoride oxalate tube (Teklab, UK) which was stored on ice until 
the end of the session. A further 4 / 8 ml was drawn into Vacuette® Z serum clot 
activator tubes (Greiner Bio-One, UK) which were kept at room temperature for 30 min 
to encourage clotting before being stored on ice until the end of the session. At the 
end of the study session the tubes were centrifuged for 10 min at 1912 x g, 4 oC 
(LegendTM T/RT Quikset centrifuge, Thermo Scientific, UK) following which the plasma 
and serum were transferred to 0.5 ml Apex plus microtubes (Alpha Laboratories, UK) 
and frozen at -20 oC until the end of the study. 
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2.4 Plasma and serum analysis 
2.4.1 Analysis of plasma glucose 
Plasma glucose was measured in two different ways, due to availability of equipment, 
on either the YSI 2300 Stat Plus analyser or the ILab 650 analyser. The method was 
however consistent for each study. 
YSI 2300 Stat Plus 
Plasma glucose for the dose-response (Chapter 4) and repeated-dose (Chapter 5) 
studies were measured on the YSI 2300 STAT PlusTM (YSI Life Sciences, UK). 
Samples were measured at the end of each study day. The YSI 2300 utilises a 
turntable that can hold 24 samples per run; this allows for a maximum of 18 participant 
samples plus two quality controls (QCs) and one standard to be measured at the start 
and end of each run. In addition, the YSI was set to auto-calibrate after every five 
samples. All samples for an individual participant for that day were measured on the 
same run to minimise inter-assay variation; this meant that a maximum of 2-3 
participants were measured per run. Inter-assay CVs were ≤3% and intra-assay CVs 
were <2%. After being measured, samples were frozen and stored at -20 oC for future 
insulin analysis.  
The YSI uses the glucose oxidase method to determine glucose concentrations. The 
glucose oxidase enzyme is immobilised in a membrane between layers of 
polycarbonate and cellulose acetate. When the blood sample passes through the 
membrane the glucose in it is oxidised by the enzyme, producing hydrogen peroxide 
(H2O2), which is then oxidised at a platinum electrode. The current produced is 
proportional to the glucose concentration of the sample. The chemical reactions are 
as follows. 
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ILab 650 
Plasma glucose for the twelve week intervention (Chapters 6 and 7) was measured on 
the ILab 650 analyser (Instrumentation Laboratory, UK), using an IL Test Glucose 
(Oxidase) kit (Instrumentation Laboratory, UK). Two QCs were used, Human Control 
Assay 2 and 3 (Randox, UK) and the calibrant was IL Test ReferrIL G (Instrumentation 
Laboratory, UK). Up to 56 samples were placed on the carousel and analysed in batch. 
QCs were measured in triplicate at the start and end of each run. All plasma samples 
were measured in duplicate and the mean value calculated. All samples for one 
participant were analysed within the same batch. Inter-assay CVs were 2% for both 
low and high QCs and intra-assay CVs were ≤ 4% for both. 
The ILab uses an enzymatic colorimetric method to measure glucose. Glucose in the 
sample is oxidised to gluconic acid and hydrogen peroxide. The hydrogen peroxide 
reacts with phenol and 4-aminoantipyrine to produce a red quinoneimine dye. The 
concentration of the dye is determined by measuring the absorbance at 510 nm and 
is directly proportional to the concentration of glucose in the sample. The chemical 
reactions are as follows: 
 
2.4.2 Analysis of serum total cholesterol 
Serum cholesterol was measured on the ILab 650 analyser (Instrumentation 
Laboratory, UK), using an IL Test Cholesterol kit (Instrumentation Laboratory, UK). 
Two QCs were used, Human Control Assay 2 and 3 (Randox, UK) and the calibrant 
was IL Test ReferrIL G (Instrumentation Laboratory, UK). Up to 56 samples were 
placed on the carousel and analysed in batch. QCs were measured in triplicate at the 
start and end of each run. All plasma samples were measured in duplicate and the 
mean value calculated. All samples for one participant were analysed within the same 
batch. Inter-assay CVs were 4% for both low and high QCs and intra-assay CVs were 
≤ 9% and ≤ 3% respectively. 
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The ILab uses an enzymatic colorimetric method to measure total cholesterol. 
Cholesterol ester is hydrolysed to free cholesterol, which is subsequently oxidised to 
produce H2O2. The H2O2 generated reacts with phenol and 4-aminoantipyrine to 
produce a red quinoneimine dye. The concentration of the dye is determined by 
measuring the absorbance at 510 nm and is directly proportional to the concentration 
of cholesterol in the sample. The chemical reactions are as follows: 
            
2.4.3 Analysis of serum HDL-cholesterol 
Serum HDL cholesterol was measured on the ILab 650 analyser (Instrumentation 
Laboratory, UK), using an IL Test HDL-Cholesterol kit (Instrumentation Laboratory, 
UK). Two QCs were used, SeraChem Control Level 1 and 2 (Instrumentation 
Laboratory, UK) and the calibrant was IL Test ReferrIL G (Instrumentation Laboratory, 
UK). QCs were measured in triplicate at the start and end of each run. All plasma 
samples were measured in duplicate and the mean value calculated. All samples for 
one participant were analysed within the same batch. Inter-assay CVs were 9% and 
12% for the low and high QCs, respectively and intra-assay CVs were ≤2% and ≤ 9% 
respectively. 
The ILab uses a two-step enzymatic colorimetric method to measure HDL cholesterol. 
Anti-human ß-lipoprotein antibody binds to lipoproteins (LDL, VLDL and chylomicrons) 
other than HDL, blocking reaction of these lipoproteins with cholesterol esterase and 
cholesterol oxidase, which then react only with HDL cholesterol. Thereafter the method 
and reactions involved are the same as for total cholesterol, with a blue coloured dye 
formed from the final reaction with hydrogen peroxide. The concentration of the dye is 
determined by measuring the absorbance at 600 nm and is directly proportional to the 
concentration of HDL cholesterol in the sample.  
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2.4.4 Analysis of serum TAG 
Serum TAG was measured on the ILab 650 analyser (Instrumentation Laboratory, UK), 
using an IL Test Cholesterol kit (Instrumentation Laboratory, UK). Two QCs were used, 
Human Control Assay 2 and 3 (Randox, UK) and the calibrant was IL Test ReferrIL G 
(Instrumentation Laboratory, UK). QCs were measured in triplicate at the start and end 
of each run. All plasma samples were measured in duplicate and the mean value 
calculated. All samples for one participant were analysed within the same batch. 
Inter-assay CVs were 9% and 3% for low and high QCs respectively and intra-assay 
CVs were ≤ 8% and ≤ 4% respectively. 
The ILab uses an enzymatic colorimetric method to measure TAG. First the TAGs are 
hydrolysed to glycerol and FFA. The glycerol is then phosphorylated to form glycerol-
3-phosphate (G3P) which is then oxidised. Hydrogen peroxide is released in this 
oxidation step. The H2O2 generated reacts with 4-chlorophenol and 4-aminoantipyrine 
to produce a red quinoneimine dye. The concentration of the dye is determined by 
measuring the absorbance at 510 nm and is directly proportional to the concentration 
of TAG in the sample. The chemical reactions are as follows: 
 
2.4.5 Analysis of serum NEFA 
Serum NEFA was measured on the ILab 650 analyser (Instrumentation Laboratory, 
UK), using a Randox Laboratories NEFA ILab 600 kit (Randox, UK). Two QCs were 
used, Human Control Assay 2 and 3 (Randox, UK) and the calibrant was IL Test 
ReferrIL G (Instrumentation Laboratory, UK). QCs were measured in triplicate at the 
start and end of each run. All plasma samples were measured in duplicate and the 
mean value calculated. All samples for one participant were analysed within the same 
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batch. Inter-assay CVs were 8% and 6% for low and high QCs respectively and 
intra-assay CVs were ≤ 7% and ≤ 4% respectively. 
The ILab uses an enzymatic colorimetric method to measure NEFA. Firstly NEFA 
reacts with coenzyme A to form acyl CoA, which is then oxidised and H2O2 released. 
The H2O2 generated reacts with N-ethyl-N-(2-hydroxy-3-sulphopropyl)-m-toluidine 
(TOOS) and 4-aminoantipyrine to produce a purple quinoneimine dye. The 
concentration of the dye is determined by measuring the absorbance at 550 nm and 
is directly proportional to the concentration of NEFA in the sample. The chemical 
reactions are as follows: 
 
2.4.6 Analysis of plasma insulin 
Plasma insulin was measured in two different ways, either by enzyme-linked 
immunosorbent assay (ELISA) or radioimmunoassay (RIA). The method was however 
consistent for each study. 
Enzyme-linked immunosorbent assay (ELISA) 
Plasma insulin for the dose-response (Chapter 4) and repeated-dose (Chapter 5) 
studies was measured by ELISA using a Human Insulin ELISA kit (Millipore, UK). The 
kit utilises the sandwich ELISA methodology and has no cross-reactivity with intact 
human pro-insulin or c-peptide.  
Unknown samples along with known standards are added to individual wells in a 
microtitre plate which has been coated with monoclonal mouse anti-human insulin 
antibodies. The insulin in the samples binds to the antibodies coating the plate.  A 
detection antibody (biotinylated monoclonal mouse anti-human antibody) is added and 
the plate is incubated for an hour. During this time the detection antibody binds to the 
captured insulin. The plate is washed to remove any unbound materials and an 
enzyme solution (horseradish peroxidase) is added, which conjugates with the bound 
biotinylated detection antibodies. After further incubation the plate is again washed and 
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substrate solution (3,3’,5,5’-tetramethylbenzidine) is added. The substrate reacts with 
the bound enzyme and a blue colour develops, proportional to the amount of insulin in 
the sample. The plate is incubated until a strong colour gradient develops in the 
standard wells. At this point, stop solution (HCl) is added and the samples in the wells 
change to a yellow colour. The plate is immediately placed in a microplate reader 
(Opsys MR, Dynex Technologies, US) and the absorbance at 450 nm 
spectrophotometrically read. The insulin concentration in the unknown samples is 
derived by plotting the absorbance against the standard curve. 
High and low QCs were included at the beginning and end of each run. All samples for 
one participant were analysed on the same plate. Inter-assay CVs were 3% and 11% 
for low and high QCs respectively and intra-assay CVs were ≤ 10% and ≤ 6% 
respectively for the dose-response study (Chapter 3). Inter-assay CVs were 5% and 
7% for low and high QCs respectively and intra-assay CVs were ≤ 11% for the 
repeated-dose study (Chapter 4). 
Radioimmunoassay (RIA) 
Plasma insulin for the twelve week intervention (Chapters 6 and 7) was measured by 
radioimmunoassay (RIA) using a Human Insulin Specific RIA kit (Millipore, UK). The 
kit has very little cross-reactivity with human pro-insulin (< 0.2%). A fixed amount of 
labelled antigen (125I-insulin) is incubated with a fixed amount of antibody and the 
unknown sample. Insulin in the unknown sample competes with the labelled antigen 
for binding sites; the greater the insulin concentration in the sample, the less labelled 
antigen that will bind to the antibody. After overnight incubation, precipitating reagent 
is added and the supernate is aspirated leaving a radioactive pellet in the bottom of 
the tube. The tubes are then put into a gamma counter and the resultant readings are 
plotted against a standard curve to determine the insulin concentration of the unknown 
samples. All samples were measured in duplicate and high and low QCs were included 
at the beginning, middle and end of each run. All samples for one participant were 
analysed within the same batch. Inter-assay CVs were 11% for both low and high QCs 
and intra-assay CVs were ≤ 9% and ≤ 7% for low and high QCs respectively. 
2.4.7 Analysis of serum IL-6 and TNF- 
The inflammatory markers, IL-6 and TNF- were analysed by an external laboratory 
(Clinical Immunology Service, University of Birmingham), using a bead-based 
multiplex assay (Bio-Plex Precision Pro Human Cytokine Assay kit, Bio-Rad, UK). The 
plate was analysed on a Luminex-100 plate reader (Bio-Plex Systems, BioRad 
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Laboratories, California, USA) using a low 'RP1' (low PMT - photomultiplier tube) target 
setting. Data analysis was performed using Bio-Plex Manager 4.1.1 software (Bio-Rad, 
UK). Intra-assay CVs were < 10%. Limits of detection were reported as 0.46 pg/ml and 
0.59 pg/ml for IL-6 and TNF- respectively. Samples were analysed in duplicate and 
mean values calculated.  
2.5 Salivary caffeine analysis 
2.5.1 Saliva collection 
Saliva was collected from participants taking part in the 12 week coffee intervention, 
detailed in Chapter 6. Participants were first asked to thoroughly rinse their mouth with 
water, to reduce impurities in the sample, before producing more saliva and depositing 
it into a 20 ml Sterilin Universal container (Fisher Scientific, Loughborough, UK); 
approximately 1 ml of saliva was collected each time. Samples were frozen at -20 oC 
for later analysis. 
2.5.2 Caffeine analysis  
Salivary caffeine analysis was carried out by Dr J. M. Frank at the University of Surrey. 
The saliva samples collected previously were defrosted and 0.5 ml of saliva was 
aliquoted into a 2 ml Eppendorf tube, to which 0.5 ml methanol was added. The tubes 
were vortexed for approximately 30 s and then centrifuged for 10 min at 19071 x g, 
4 oC (Eppendorf 5430 R microcentrifuge, Eppendorf UK Ltd) and decanted into sample 
vials. 
Caffeine concentration in the samples was measured in batch by reversed-phase high 
performance liquid chromatography (HPLC), using a Synergi Hydro ODS (C18) 4.6 x 
250 mm column, with 35% methanol in water, run in isocratic mode at 0.75 ml/min; 
column temperature was 30 oC, injection volume was 20 µl and run time was 10 min. 
Caffeine content was determined by measuring the absorbance at 260 nm and 280 nm 
and plotting against a standard curve. 
2.6 DNA analysis 
DNA was collected from participants in the twelve week intervention (Chapter 6 and 7) 
to determine whether they were fast or slow caffeine metabolisers as determined by 
the rs762551 SNP in the CYP1A2 gene. 
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2.6.1 DNA collection 
On the first study day, buccal cells were collected from each participant by wiping a 
sterile neutral transport swab (Sarstedt, UK) around the inside of both of the 
participant’s cheeks. The swab was left to air-dry for 10 minutes, then frozen at -20 oC 
for batch analysis at the end of the study. 
2.6.2 DNA extraction 
MasterAmp DNA extraction solution (Epicentre Biotechnologies, US) was pipetted into 
1.5 ml boil-proof microtubes. The tip of each buccal swab was inserted into the 
extraction solution and swirled and rubbed against the side of the tubes to detach the 
buccal cells from the swab. The extraction solution acts as a lysing agent to free up 
the DNA from the cells into the solution. To activate this process, the tubes were 
vortexed then incubated at 65 oC for 5 min, then vortexed again and incubated at 98 oC 
for a further 5 min. After a final vortex, the tubes were frozen at -20 oC until they were 
required.  
2.6.3 DNA analysis 
The DNA extracted by the method described above was analysed for the rs762551 
SNP by a 5’-nuclease allelic discrimination assay (Taqman drug metabolism 
genotyping assay SNP ID rs762551, gene CYP1A2, Applied Biosystems, UK). The 
assay is performed in three stages: 
1.  A reaction mixture is prepared and pipetted onto a microplate along with 
the DNA sample 
2. The DNA is amplified by a polymerase chain reaction (PCR) 
3. The plate is read and SNPs identified by a specialist software program 
Reaction Mix 
The reaction mix was prepared by adding master mix (Taqman Genotyping Master 
Mix, Fisher Scientific, UK), assay (Taqman rs762551 as described previously) and 
nuclease-free water to a 1.5 ml tube. The components were added in the following 
ratios: 
Master mix: 6.25 L/sample 
Assay: 0.625 L/sample 
H2O: 4.625 L/sample 
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The reaction mix was mixed thoroughly then 11.5 L was pipetted into each well of a 
microplate along with 1 L of DNA sample. The plate was covered, vortexed and 
centrifuged for 10 min at 1109 x g (Allegra 21R centrifuge, Beckman Coulter, US). 
PCR stage 
The plate containing the reaction mix and samples was then inserted into an Applied 
Biosystems 7500 Real Time PCR system and the PCR was run. The PCR was set up 
with the following stages: 
Pre-PCR read (holding stage): 1 min at 60 oC 
Holding stage/enzyme activation: 10 min at 95 oC 
Cycling stage (40 cycles): 
  Denaturation: 15 sec at 95 oC 
  Annealing/extension: 1 min at 60 oC 
Post-PCR read (holding stage): 1 min at 60 oC 
The Taqman assay contains forward and reverse PCR primers for amplifying the 
sequence of interest on the DNA and two labelled minor groove binder (MGB) probes. 
Each probe has a fluorescent reporter dye at the 5’ end of the probe (VIC dye on the 
allele 1 probe; FAM dye on the allele 2 probe) and a nonfluorescent quencher (NFQ) 
at the 3’ end. The SNP of interest is situated in the middle of each probe. The reporter 
dye is quenched if the probe is intact. 
PCR consists of many cycles of denaturation at high temperatures and 
annealing/extension at lower temperatures in order to amplify the DNA regions of 
interest. During the denaturation phase the double stranded DNA is separated into 
single strands. In the annealing phase the probes anneal only to complementary 
sequences on the single stranded DNA; DNA polymerase then cleaves the reporter 
dye from the probe resulting in an increase in fluorescence of that dye. Thus, an 
increase in fluorescence of either VIC or FAM dye indicates homozygosity for the 
corresponding allele. An increase in fluorescence of both indicates heterozygosity.  
Plate reading 
The fluorescence of each individual dye is read at the beginning and end of the PCR 
phase and the difference in readings is calculated by the PCR software (Applied 
Biosystems 7500 Real Time PCR system v 2.06). The software then uses these values 
to plot an allelic discrimination plot with ΔVIC on the x-axis and ΔFAM on the y-axis, 
allowing identification of the alleles present in each sample. 
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2.7 Estimation of insulin sensitivity and beta cell function 
The Homeostasis Model of Assessment (HOMA) was used to assess fasting insulin 
sensitivity (HOMA2_%S) and fasting beta cell function (HOMA2_%B), using the 
HOMA2 calculator, version 2.2.3 (University of Oxford, UK).  
The Matsuda Index (Matsuda & DeFronzo, 1999) was calculated as a measure of 
postprandial insulin sensitivity, according to the following equation: 
10,000 
√ ([fasted glucose x fasted insulin] x [mean glucose x mean insulin during OGTT]) 
 
The insulin:glucose AUC ratio (AUCI/G) was calculated as a measure of postprandial 
insulin secretion and the product of AUCI/G and Matsuda Index was used as an indirect 
marker of postprandial beta cell function (169). 
2.8 Statistical analysis 
All statistical analysis was carried out using SPSS Statistics software, version 22 
(Chicago, USA). The Shapiro-Wilks test was used to check normality of data (170). 
Repeated measures analysis of variance (RM ANOVA) and paired and unpaired t tests 
were used for comparisons between and within groups where data were normally 
distributed. A Bonferroni adjustment for multiple comparisons was applied when post 
hoc analysis was used. Non-normally distributed data were log transformed and re-
tested for normality. If a dataset contained values less than one then a fixed value was 
added to all data in the set (calculated to make the smallest value equal to one) prior 
to log transformation (171).  If found to be normally distributed after log transformation, 
parametric tests were carried out on the log transformed data. Equivalent non-
parametric tests were used where the data were not normally distributed. Fisher’s 
Exact tests were used for assessment of independence of variables. The incremental 
area under curve (IAUC) and total area under curve (AUC) for glucose and insulin for 
each treatment were calculated by the trapezoid method with area under baseline 
ignored for calculation of IAUC as recommended by the Food and Agriculture 
Organization (172) and described by Brouns et al. (173). Statistical significance was taken 
as p < 0.05. 
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3.1 Introduction 
Epidemiological evidence suggests an inverse association between the amount of 
coffee consumed and the development of T2DM  (2,87,174). This appears to hold true for 
both CC and DC (6). Intervention studies into the acute effects of coffee on glycaemic 
control are, however, not so conclusive and are often contradictory.   
Whilst systematic reviews have been conducted on the epidemiological data (175) and 
on the acute effects of caffeine (176), there has been no systematic review of the acute 
effects of coffee to date. This is of particular importance when it is considered that poor 
glycaemic control is a key risk factor for development of complications in T2DM (177). 
There are also currently no guidelines in the UK regarding coffee consumption for 
those with T2DM, perhaps because the evidence is unclear.  
3.2 Aims 
To perform a systematic review of all randomized controlled trials (RCTs) that 
compared the effects of coffee to a control drink on either an OGTT or CHO-containing 
meal in human populations. CC and DC were examined separately. 
3.3 Methods 
The Web of Science (all databases, including Medline) was searched on 9th October 
2015 with the following search criteria: 
TOPIC: (human AND (coffee OR caffeine) AND (glucose OR glycemic OR 
glycaemic OR glycemia OR glycaemia)) 
Refined by: [excluding] DOCUMENT TYPES: (BOOK OR PATENT OR CASE 
REPORT OR EDITORIAL OR LETTER) 
Timespan: All years. 
Search language=Auto   
To minimise publication bias, the following online resources were also searched on 
28th October 2015; ClinicalTrials.gov (http://www.clinicaltrials.gov), ICTRP: 
International Clinical Trials Registry Platform Search Portal WHO 
(http://apps.who.int/trialsearch/Default.aspx) and Open SIGLE: System for Information 
Chapter 3. 
60 
 
on Grey Literature in Europe (http://opensigle.inist.fr). The search terms ‘CAFFEINE’ 
or ‘COFFEE’ and ‘GLUCOSE’ were used.  
The searches produced 1048 results, including 22 duplicates. Based on the titles and 
abstracts 1018 were excluded, leaving 30 for more detailed examination. Papers 
excluded were either not relevant, measured caffeine instead of coffee, had no control 
or were not acute interventions; several were longer-term interventions and many were 
review papers or cohort studies. One relevant unpublished trial was found on 
clinicaltrials.gov; when the authors were contacted they reported that the trial had 
never started and had been withdrawn. The references for each of the 30 shortlisted 
papers along with the review papers were examined for further potential studies, but 
no further studies were identified. 
Of the 30 selected for detailed examination, three early studies were excluded as they 
were foreign language papers and no English translations were available (178–180). A 
further seven were rejected for reasons reported in Figure 3.3-1. This left 20 studies 
to be included in the review. 
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3.4 Results 
The 20 studies selected for inclusion in the review are summarised in Table 3.4-1. 
 
Figure 3.3-1  PRISMA flow diagram of search results. 
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Table 3.4-1  Studies selected for inclusion in systematic review. 
 
AUC: area under curve; BMI: body mass index; BW: bodyweight; CC: caffeinated coffee; CHO: carbohydrate; CF: caffeine; CQA: caffeoylquinic acids; DC: decaffeinated coffee; 
DR: dark roast; F: female; GI: glycaemic index; IAUC: incremental area under curve; LR: light roast; Lrg: large; M: male; Med: medium; N/A: not available; OGTT: oral glucose 
tolerance test; PL: placebo/control; RM ANOVA: repeated measures analysis of variance; SML: small; T2DM: type 2 diabetes mellitus
Study n Subject 
characteristics
Regular coffee 
intake
Washout period OGTT/meal Meal 
concurrent/ 
delayed
Capillary/ 
venous 
samples
Dose/ preparation Caffeine 
per kg BW 
(mg/kg)
Absolute 
amount of 
caffeine (mg)
Effect on blood 
glucose 
Effect on blood 
insulin 
Feinberg et 
al.,  1968
23
15 M,
8 F
Healthy
19 - 23 y
N/A None specified 1 g glucose/kg BW in 
400 ml water + lemon 
juice
Concurrent Unspecified CC: 5 g instant
PL: water 
(total volume 400 ml 
per treatment)
N/A 220 CC<PL at 30 min/ 60 
min
No effect
Young and 
Wolever, 
1998
12
6 M,
6 F
Healthy
26 ± 1.9 y
BMI 22.8 ± 1.0 kg/m
2
N/A None specified Mixed meal 
containing 50 g CHO, 
11.7 g fat, 11.8 g 
protein
Concurrent Capillary CC: 1 rounded tsp 
instant coffee
PL: water
(total volume 250 ml 
per treatment)
N/A N/A CC>PL at 45 min/ 60 
min
no effect on IAUC
Not measured
Johnston et 
al.,  2003
9
4 M,
5 F
Healthy
26 ± 3.2 y
BMI ≤ 25 kg/m2
N/A No caffeine the 
evening before 
each study day
25 g glucose in 400 ml 
water
Concurrent Venous CC: 8.7 g instant 
DC: 12 g instant 
(both providing 353 
mg CQA)
PL: water
(total volume 400 ml 
per treatment)
N/A N/A CC: no effect over 
180 min
CC > DC and PL for 30 
min AUC, 
DC: no effect
CC: no effect over 
180 min
CC > DC  for 30 min 
IAUC
Battram et 
al.,  2006
11 M Healthy
76.4 ± 1.9 kg
10/11 non-
caffeine users
Caffeine-free for 
7 days prior to 
study and 
throughout
75 g glucose OGTT + 60 min Venous CC: drip-filtered, 
unspecified volume 
giving 4.45 mg/kg 
caffeine
DC: equal volume to 
CC
PL: 4.45 mg/kg 
dextrose 
4.45 Mean 340 Control > DC IAUC,
trend for CC > DC
PL>DC at 60/90 min
Trend for CC > DC 
(IAUC)
Thom, 2007 12 Healthy
BMI < 25 kg/m
2
N/A None specified 25 g glucose in 400 ml 
water
Concurrent Unspecified CC: 10 g instant
DC: 10 g instant
PL: water
(total volume 400 ml 
per treatment)
N/A N/A CC/DC: no effect on 
AUC
Not measured
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Table 3.4-1 cont.  Studies selected for inclusion in systematic review.  
 
AUC: area under curve; BMI: body mass index; BW: bodyweight; CC: caffeinated coffee; CHO: carbohydrate; CF: caffeine; CQA: caffeoylquinic acids; DC: decaffeinated coffee; 
DR: dark roast; F: female; GI: glycaemic index; IAUC: incremental area under curve; LR: light roast; Lrg: large; M: male; Med: medium; N/A: not available; OGTT: oral glucose 
tolerance test; PL: placebo/control; RM ANOVA: repeated measures analysis of variance; SML: small; T2DM: type 2 diabetes mellitus
Study n Subject 
characteristics
Regular coffee 
intake
Washout period OGTT/meal Meal 
concurrent/ 
delayed
Capillary/ 
venous 
samples
Dose/ preparation Caffeine 
per kg BW 
(mg/kg)
Absolute 
amount of 
caffeine (mg)
Effect on blood 
glucose 
Effect on blood 
insulin 
Louie et al., 
2008
8
5 M,
3 F
Healthy
20 - 35 y
BMI 17.6 - 24.3 kg/m
2
≥ 1 cup/day None specified 586 g instant mashed 
potato (75 g available 
CHO)
+ 60 min Capillary CC: 4 g instant 
DC: 4 g instant 
PL: water
(total volume 250 ml 
per treatment)
N/A 150 CC > PL:  glucose 
score
CC>DC: glucose score
CC > DC: insulin 
score
Aldughpassi 
and Wolever, 
2008
10
4 M,
6 F
Healthy
31 ± 10 y
BMI 25 ± 4.7 kg/m2
N/A None specified One of 3 meals (each 
containing 50 g 
available CHO):
109 g white bread
84 g cheese puffs
64 g fruit leather
each with or without 
tea/coffee
Concurrent Capillary CC: 250 ml drip-
filtered ground (1 tbsp 
ground coffee to 300 
ml water)
Tea: 1 teabag steeped 
for 30 s in 250 ml 
boiling water
PL: 250 ml water
N/A N/A CC+tea > PL at 30 min 
for WB and CP, but 
not FL
no diff in IAUC/GI
Not measured
van Dijk et 
al.,  2009
15 M Healthy
39.9 ± 16.5 y
BMI 25 - 35 kg/m2
Coffee drinkers max 1 cup/day 
from 1 week 
prior then no 
coffee on the day 
before each visit
75 g glucose OGTT +30 min Venous DC: 12 g instant 
(providing 264 mg 
CGA)
PL: 1 g mannitol
(both dissolved in 270 
ml water)
N/A N/A DC: no effect on 
individual time-
points or AUC
DC: no effect on 
individual time-
points or AUC
Greenberg et 
al.,  2010
11 M Healthy
23.5 ± 5.7 y
BMI 23.6 ± 4.2 kg/m2
N/A No caffeine from 
1 week prior to 
1st visit
75 g glucose OGTT + 60 min Venous CC: 500-600 ml drip-
filtered ground (40 g 
ground CC to 8 cups 
water)
DC: same volume as 
CC (57 g ground DC to 
8 cups water)
PL: water
6 N/A PL < DC/CC at 10 
min/ 30 min
PL < DC/CC at 10 
min/ 30 min/ 60 
min/ AUC
Moisey et al., 
2010
10 M Healthy
20-27 y
BMI 23.9 ± 0.8 kg/m2
79.5 ± 3.6kg
3/10 non 
coffee drinkers, 
others (1-3 
cups/day)
No caffeine for 
48 h before each 
session
Cereal and skimmed 
milk (75 g available 
CHO)
Concurrent Venous CC: 535-812 ml drip 
filtered ground
DC: same volume as 
CC
PL: water
5 Mean 398 PL<DC/CC  iAUC 3hr
PL/DC<CC at 180 min
No effect on IAUC
PL<CC/DC 
immediately after 
meal ingestion
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Table 3.4-1 cont.  Studies selected for inclusion in systematic review. 
 
AUC: area under curve; BMI: body mass index; BW: bodyweight; CC: caffeinated coffee; CHO: carbohydrate; CF: caffeine; CQA: caffeoylquinic acids; DC: decaffeinated coffee; 
DR: dark roast; F: female; GI: glycaemic index; IAUC: incremental area under curve; LR: light roast; Lrg: large; M: male; Med: medium; N/A: not available; OGTT: oral glucose 
tolerance test; PL: placebo/control; RM ANOVA: repeated measures analysis of variance; SML: small; T2DM: type 2 diabetes mellitus
Study n Subject 
characteristics
Regular coffee 
intake
Washout period OGTT/meal Meal 
concurrent/ 
delayed
Capillary/ 
venous 
samples
Dose/ preparation Caffeine 
per kg BW 
(mg/kg)
Absolute 
amount of 
caffeine (mg)
Effect on blood 
glucose 
Effect on blood 
insulin 
Gavrieli et 
al., 2011
16 M Healthy
21-39 y
BMI 25.5 ± 2.3 kg/m2
1.3 ± 1.0  
servings/day
No caffeine for 3 
days before each 
session
1 slice white bread,     
5 g butter,  10 g sugar 
(~ 24 g CHO)
Concurrent Venous CC: instant 
DC: instant same 
amount of coffee as 
CC)
PL: water
(total volume 200 ml 
per treatment)
3 200-280 CC>PL at 60 min
no effect on AUC or 
IAUC
DC: no effect
No effect
Beaudoin et 
al.,  2011
10 M Healthy
22.9 ± 0.4 y
78.9 ± 4.8 kg
BMI 24.7 ± 0.8 kg/m2
N/A No caffeine for 
48 h before each 
session
75 g dextrose OGTT  
(6 h after 1 g lipid/kg 
BW)
+ 60 min Venous CC/DC: drip-filtered, 
unspecified volume
PL: water
5 Mean 395 CC>DC/PL at 60 min
no effect on IAUC
CC>PL at 60 min
CC>DC at 90 min
No effect on IAUC
Hätönen et 
al.,  2012
12
1 M,
11 F
Healthy 
34.8 ± 10.4 y
BMI 21.9±2.5 kg/m2
Habitual coffee 
drinkers, mean 
intake 
392ml/day 
filter coffee
None specified 50 g glucose Concurrent Capillary Sml CC: filter coffee 
made with 7 g 
grounds
Lrg CC: filter coffee 
made with 14 g 
grounds
PL: water
(all made up to total 
volume 550 ml)
N/A Sml: 151
Lrg: 303
No effect on IAUC
Did not compare 
timepoint data
No effect on IAUC
did not compare 
timepoint data
Krebs et al., 
2012
18
9 M,
9 F
T2DM
43 - 82 y
At least 3 
cups/week (30-
540mg CF/day)
No caffeine for 
24 h before each 
session
75 g glucose OGTT + 60 min Venous CC: double espresso
DC: double espresso
PL: water (same 
unspecified volume
N/A 180 (approx) CC > DC/PL AUC 
(trend)
Did not compare 
timepoint data
No effect on AUC
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 Table 3.4-1 cont.  Studies selected for inclusion in systematic review. 
 
AUC: area under curve; BMI: body mass index; BW: bodyweight; CC: caffeinated coffee; CHO: carbohydrate; CF: caffeine; CQA: caffeoylquinic acids; DC: decaffeinated coffee; 
DR: dark roast; F: female; GI: glycaemic index; IAUC: incremental area under curve; LR: light roast; Lrg: large; M: male; Med: medium; N/A: not available; OGTT: oral glucose 
tolerance test; PL: placebo/control; RM ANOVA: repeated measures analysis of variance; SML: small; T2DM: type 2 diabetes mellitus  
Study n Subject 
characteristics
Regular coffee 
intake
Washout period OGTT/meal Meal 
concurrent/ 
delayed
Capillary/ 
venous 
samples
Dose/ preparation Caffeine 
per kg BW 
(mg/kg)
Absolute 
amount of 
caffeine (mg)
Effect on blood 
glucose 
Effect on blood 
insulin 
Alkaabi et al., 
2013
23
12 M,
11 F
13 healthy
40.2 ± 6.7 y
75.4 ± 16.0 kg
BMI 27.4 ± 4.1 kg/m
2
10 T2DM
40.8 ± 5.7 y
83 ± 16.7 kg
BMI 30.7 ± 5.2 kg/m
2
N/A None specified GI study:
Khala dates (50 g 
available CHO) with or 
without coffee versus 
50 g glucose
Coffee served 
immediately 
after dates
Capillary CC: 100 ml (from 5 
tbsp medium roast 
ground Arabic coffee 
boiled with 1000 ml 
water then filtered)
PL: water
(all made up to total 
volume 250 ml)
N/A N/A No difference in GI Not measured
Gavrieli et 
al.,  2013
33
17 M,
16 F
16 normal weight
25.4 ± 6.1 y
64.0 ± 8.2 kg
BMI 21.3 ± 1.9 kg/m2
17 overweight/ obese
29.2 ± 7.6 y
87.7 ± 18.6 kg
BMI 30.0 ± 3.9 kg/m2
≥ 1 cup/day No caffeine for 
24 h before each 
session
1 slice white bread,     
5 g butter,  10 g sugar 
(~ 24 g CHO)
Concurrent Venous Sml CC: mean 6.0 g 
instant
Lrg CC: mean 11.9 g 
instant
PL: water
(all made up to total 
volume 200 ml)
Sml: 3 
Lrg: 6 
Mean 228
Mean 457
Sml/Lrg > PL for IAUC
interaction*time 
effect
Lrg > PL at 60/90/120 
min
No effect on 
AUC/IAUC
interaction*time 
effect
Lrg < PL at 15/30 
min
Lrg > PL at 60 min
Sml < PL at 15 min
Lrg < Sml at 15 min
Al-Mssallem 
and Brown, 
2013
10
5 M,
5 F
Healthy
30.8 ± 2.8 y
75.0 ± 5.4 kg
BMI 24.0 ± 1.2 kg/m2
N/A None specified GI study:
Khulas dates (50 g 
available CHO) with or 
without coffee versus 
50 g glucose
Concurrent Capillary CC: Arabic coffee: 
amount/volume 
unspecified
PL: water
N/A N/A Trend for difference 
in IAUC overall 
(p=0.08).
No post hoc tests
No difference in 
IAUC
Schubert et 
al.,  2014
12
3 M,
9 F
Healthy
26.3 ± 6.3 y
65.4 ± 8.3 kg
BMI 22.7 ± 2.2
22-742 mg/day 
caffeine
No caffeine for 
36 h before each 
session
No details Concurrent
One dose with 
meal, second 
dose + 120 
min
Venous DC: 5 g instant
CC: 5 g instant DC plus 
2mg/kg CF capsule 
PL: psyllium capsule 
250 mg
(all with 225 ml water)
N.B. Treatment given 
twice: at T0 then 
repeated at T120
4 Mean 278 No effect on AUC
Did not compare 
timepoint data
Not measured
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Table 3.4-1 cont.  Studies selected for inclusion in systematic review. 
 
AUC: area under curve; BMI: body mass index; BW: bodyweight; CC: caffeinated coffee; CHO: carbohydrate; CF: caffeine; CQA: caffeoylquinic acids; DC: decaffeinated coffee; 
DR: dark roast; F: female; GI: glycaemic index; IAUC: incremental area under curve; LR: light roast; Lrg: large; M: male; Med: medium; N/A: not available; OGTT: oral glucose 
tolerance test; PL: placebo/control; RM ANOVA: repeated measures analysis of variance; SML: small; T2DM: type 2 diabetes mellitus 
 
 
Study n Subject 
characteristics
Regular coffee 
intake
Washout period OGTT/meal Meal 
concurrent/ 
delayed
Capillary/ 
venous 
samples
Dose/ preparation Caffeine 
per kg BW 
(mg/kg)
Absolute 
amount of 
caffeine (mg)
Effect on blood 
glucose 
Effect on blood 
insulin 
Robertson et 
al.,  2015
10 M Healthy
Overweight
30.4 ± 14.2 y
BMI 27.8 ± 2.2
2.3 ± 1.6  
servings/day
No caffeine for 
48 h before each 
session
50 g glucose Concurrent Capillary Sml CC:  2 g instant (47 
mg CQA)
Med CC: 4 g instant 
(94 mg CQA)
Lrg CC: 8 g instant (188 
mg CQA)
PL: water
(all made up to total 
volume 400 ml)
Sml: 1.2
Med: 2.4
Lrg: 4.8
Sml: 100
Med: 200
Lrg: 400
Sml/Med > PL, RM 
ANOVA and 
Interaction*time 
effect
Sml>PL for IAUC 
Sml > PL for peak 
value (and trend for 
Med>PL)
No effect overall, 
RM ANOVA or  
IAUC
Rakvaag and 
Dragsted, 
2015
11
4 M,
7 F
Healthy
26.2 ± 0.6 y
68.6 ± 3.6 kg
BMI 23.2 ± 0.4
N/A No caffeine for 
48 h before each 
session
75 g glucose in 300 ml 
water with citric acid
+ 30 min Venous LR CC: 300 ml (taken 
from 45 g light roast 
ground  coffee made 
in cafetiere with 750 
ml water), providing 
399.6 mg CQA.
DR CC: 300 ml (as for 
LR, but using dark 
roasted beans), 
providing 66.6 mg 
CQA
PL: 300 ml water
Mean: 2 LR: 153.1
DR: 146.2
DR>PL, RM ANOVA
(and trend for DR>LR, 
p=0.06)
no diff in AUC/IAUC
DR>PL at 60 min
DR/LR>PL, RM 
ANOVA
DR>PL for 
AUC/IAUC
No difference in 
any time-points
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3.4.1 Participant characteristics 
The number of participants in each study ranged from 8 to 33. Most studies (18/20) 
were carried out on healthy participants, with only two studies examining the effects of 
coffee on individuals with T2DM (110,181). Mean age of participants was generally under 
35 y with the exception of the T2DM studies, where the participants were older (mean 
40.8 y and 43 - 82 y). Half of the studies did not specify whether their participants were 
habitual coffee drinkers or not; of those that did provide this information, 8/10 used 
habitual coffee drinkers. 
3.4.2 Methodology 
Of the twelve studies that reported one, the pre-study washout period ranged from no 
caffeine the evening before the study (147) to a requirement to be caffeine-free for 7 
days prior and to remain caffeine-free for the duration of the study (10). Half gave 
glucose, ranging from 25 to 75 g, dissolved in water (200 - 400 ml) as their CHO load, 
with the remainder giving mixed meals or individual foodstuffs providing between 24 
and 75 g of available CHO. Where a mixed meal was given, the accompanying coffee 
ranged in volume from 200 - 812 ml. One study did not specify the content of their test 
meal (182). Coffee was given concurrently with the glucose/meal in 65% of cases and 
up to 1 h beforehand in the remainder. 
Seven took capillary blood samples via the finger-prick technique, eleven took venous 
samples and two did not specify the collection method. Blood samples were taken over 
various amounts of time ranging from 2 h to 4.5 h. Frequency was every 15 - 30 min 
in most cases, with one study measuring hourly after the first 15 min (182). 
Twelve studies did not perform a simple comparison of CC/DC and control, but instead 
included other treatments. Of these, three also tested caffeine (10,126,182), four tested 
different strengths or roasts of coffee (183–186) and four tested other miscellaneous items 
such as CGAs, tea, different volumes of water, iced buns, sugar and cola (9,144,146,187). 
One employed a lipid preload 5 h before the OGTT and had two other comparisons 
not included here: OGTT without preload and preload without OGTT (7). One study 
gave CC to five participants and tea to another five and combined the results stating 
that both treatments gave similar results (188). 
3.4.3 Coffee dose 
Type of coffee varied between studies, with ten giving their participants instant coffee, 
six giving drip-filtered coffee, two using Arabic coffee, one using a French press and 
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one giving espresso coffee. Most gave a single dose of coffee after an overnight fast, 
however one gave a lipid preload 5 h before the OGTT (7) and another gave their coffee 
dose in two boluses, one at 0 min and the other at 120 min (182). Seven chose their 
coffee dose to deliver a set amount of caffeine per kg BW. Amounts given varied from 
3 - 6 mg/kg. Those giving instant coffee, gave doses in the range of approximately 2 g 
up to 12 g. Seven studies did not report the amount of caffeine in their dose; of those 
that did report it, the lowest dose was 100 mg and the highest stated a mean dose of 
526 mg. Only one study examined DC versus a control, without also looking at the 
effects of CC (144). Of the remainder, ten compared CC, DC and a control and the rest 
did not measure the effects of DC. 
3.4.4 Caffeinated coffee 
Effect on blood glucose 
Thirteen studies found CC increased postprandial glucose more than a control drink, 
although only five of these found a significant effect on the entire postprandial period; 
the remaining eight found either CC produced higher glucose than control at one or 
more individual time-points or reported a trend for an overall effect.  
Moisey et al. reported that both CC and DC increased the 3 h postprandial glucose 
IAUC more than control (8); all three treatments showed very similar results until 90 min 
post treatment, at which point both DC and control had returned to baseline. Between 
90 and 180 min, both DC and control dropped below baseline and remained there, 
whereas CC glucose dropped more slowly reaching baseline by 150 min. Gavrieli et 
al. demonstrated an 11.4% greater increase for their higher dose (6 mg/kg) and 8.1% 
for their lower dose (3 mg/kg), with the main difference occurring between 60 and 120 
min (184). Similarly to Moisey et al., their control treatment dipped below baseline in this 
time-frame. 
In contrast, Louie et al. demonstrated a 28% increase in the glucose score (calculated 
as the ratio of IAUC after treatment to the control IAUC) following CC ingestion, with 
the increase being most apparent between 30 and 90 min (9). They also appeared to 
show an increase in the glucose peak, although this was not tested statistically and 
appears to be a very small increase (in the region of +0.5 mmol/L). Similarly, Robertson 
et al. observed the main differences to be between 30 and 90 min, with no dip below 
baseline and a difference of 17% (1.4 mmol/L) in peak values (185). They also reported 
a time * treatment interaction, with coffee delaying the time to peak versus control. 
Rakvaag and Dragsted found the main differences to be between 30 and 120 min, with 
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no dip below baseline, and reported CC to produce higher glucose than control, 
post-peak, at 60 min (186), indicating a similar response pattern to both Louie et al. and 
Robertson et al. 
In contrast to all others, one early study (108) observed less of an increase in glucose 
at  30 and 60 min following CC consumption compared to their control, with values 
being 15% and 19%, respectively, lower. They did not compare overall response. It 
was the only study to vary the CHO load according to bodyweight, although it kept the 
coffee dose static (5 g instant CC) for all participants. 
When the studies comparing time-point data are examined in more detail, 3/11 found 
that CC increased the glucose peak versus control; these three increased the peak 
value by between 1 mmol/L (147) and 2 mmol/L (7). Of the remainder, two raised pre-
peak values, five increased post-peak values and one reduced them. 
Effect on blood insulin 
Of those that measured insulin, 12/14 found no overall effect of CC versus control; 
One found CC increased insulin versus control for AUC and various individual time-
points (126), and another found CC increased insulin overall, but not at any individual 
time-points (186). Gavrieli et al. found an interaction * time effect with CC reducing insulin 
versus control at 15 min but increasing it at 60 min, resulting in the insulin response 
curve shifting to the right (184). Two further studies reported increased insulin following 
CC at a single time-point only (7,8). 
3.4.5 Decaffeinated coffee 
Effect on blood glucose 
Nine studies found no overall effect of DC versus a control; one found DC worsened 
glucose response over the entire time period (8) and one found an improvement (10). 
When individual time-points were examined, three studies found no effect of 
DC (7,144,161), one found greater glucose compared to placebo at two time-points (126) 
and one found less of an increase in glucose for DC at two time-points (10). 
 Louie et al. found CC produced a larger glucose response than DC overall (9) and two 
others found a trend for the same (10,110); three found CC to produce higher blood 
glucose than DC at specific time-points (7,8,147). 
Effect on blood insulin 
Nine studies measured the effects of DC on insulin; seven of these found no effect. Of 
the remaining two, one found DC produced a larger AUC than control (126) and the other 
Chapter 3. 
70 
 
found no overall effect but reported DC to raise insulin more than control immediately 
after meal ingestion (8).  
Four of eight studies, that measured both CC and DC, reported CC to produce a larger 
insulin response than DC, either over the whole time-course or at individual 
time-points (7,9,10,147). 
3.5 Discussion 
3.5.1 Effects of caffeinated coffee 
Of the five studies that found an overall greater increase in glucose response following 
CC ingestion, in two cases the difference was mainly due to the control drink dipping 
below baseline. It is debateable whether CC could be said to have a detrimental effect 
on glucose in these instances, although it could be argued that because CC extended 
the time taken for glucose to return to fasting levels, then that in itself is a detrimental 
effect.  
It has been suggested that the increase observed in postprandial glycaemic response 
following CC consumption can be attributed primarily to caffeine, as caffeine in 
isolation has been demonstrated to increase the postprandial blood glucose response 
more than CC (10). Caffeine reaches peak levels in the blood approximately 30 min to 
one hour after ingestion and then slowly disappears with a half-life of about 5 h (79). It 
could be hypothesised, therefore, that studies giving CC in advance of a meal, would 
result in a greater increase in the postprandial glucose response in comparison with 
studies giving CC concurrently with a meal, as a result of higher blood caffeine 
concentrations. Several studies in this review chose to give their CC up to 60 min 
before the meal to maximise the effects of caffeine, however this does not appear to 
have resulted in an increased glycaemic excursion in their participants in comparison 
with the other studies. Furthermore, four out of the five studies which reported an effect 
of CC over the entire postprandial period gave their dose concurrently with the meal.  
It is interesting that Feinberg et al. found CC reduced the postprandial increase in 
glucose compared to control, however, given that all other studies showed either a 
worsening or no effect of CC on postprandial glucose, it is likely that this result is due 
to chance rather than any genuine beneficial effect. 
Although the majority of studies (13/19) found some sort of worsening of the glucose 
response versus a control, in many cases the effect was only found at individual 
time-points, which may not be statistically valid or clinically relevant. This is in contrast 
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to a recent systematic review on the acute effects of caffeine in T2DM  which found 
caffeine worsened postprandial glucose in all cases, both overall and at multiple 
time-points (176). This difference may be due to caffeine producing a greater effect than 
coffee, but equally may be due to the populations studied as those with IGT, such as 
is found in T2DM, may be more susceptible to the effects of CC. 
3.5.2 Effects of decaffeinated coffee 
Despite giving very high doses of DC in some cases (up to 12 g instant), over 80% of 
the studies found no overall difference in the glucose response compared to a control, 
with the remaining two, both of which gave relatively high doses,  being split between 
showing an improvement and a worsening. A similar result was found for insulin with 
7/9 showing no overall difference between DC and control.  
When CC was compared with DC, the rise in glucose and insulin was generally found 
to be lower for DC than CC, both overall and at specific time-points, but it is not clear 
whether other research teams performed the comparison and simply did not report it 
due to inherent publication bias.    
It would appear from these results that DC has no effect on postprandial glucose, either 
positive or negative. This is perhaps surprising given that it has been suggested that 
bioactive components in coffee, such as CGAs, may have a beneficial effect and may 
attenuate the acute negative effects of caffeine on glycaemia. Studies involving CGA 
on its own (144) and coffee enriched with CGA (146) have both demonstrated a reduction 
in glucose response versus control.  The lack of effect of DC in the studies examined 
here might be explained by insufficient amounts of CGA in the coffees tested. The 
CGA content of coffee can vary considerably (76), however the majority of these studies 
did not measure CGA content. Of the two that did, both gave DC containing less total 
CGA than that usually found to produce an effect; Johnston et al. gave 353 mg and 
van Dijk et al. gave 264 mg total CQA (the main CGA in coffee), compared to 
approximately 700 mg given by Thom and 1000 mg by van Dijk et al. However, Jokura 
et al. reported a reduction in postprandial glucose peak following GCE at a lower level 
of 355 mg total CQA, but with a higher number of participants (n=19) (145). 
3.5.3 Methodology 
Whilst most of the populations studied were relatively young, healthy people, the study 
designs themselves were quite heterogeneous.  Glucose doses varied considerably 
(25 - 75 g), as did the CHO content of mixed meals. Several different types of coffee 
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were used with a wide range of caffeine doses and the dosing regimen varied from 
concurrent dosing to 60 min in advance of the CHO load.  It is perhaps not surprising 
then that the results of the studies also varied.  
However, there does not appear to be any link between the results obtained and any 
of these parameters. Of the seven studies that found an overall increase (or trend for 
an increase) in glucose response with CC, there appears to be no consistency in the 
study design.  The amount of available CHO ranged from 24 to 75 g and was from 
both glucose and mixed meals. The amount of caffeine ranged from 100 to 457 mg, 
including the lowest and highest doses of all the included studies, and number of 
participants ranged from 8 to 33.  
It is possible that the lower doses of CHO (24 / 25 g) were insufficient to produce an 
overall response in most cases here, as 3 of 4 studies employing this lower amount 
did not see an overall effect and the one which did had greater numbers (n=33) (184) 
increasing its power to detect a smaller difference between treatments. A typical 2000 
kcal/day food intake should consist of 250 g CHO according to current guidelines (189); 
this equates to a mean intake of 83 g CHO per meal over the course of a day. 
Therefore, studies utilising a CHO dose of 25 g are not particularly representative of 
real-life behaviour.  
It has been suggested that 10 participants are sufficient for glycaemic index (GI) 
testing, however, as an individual’s response to a glucose load is known to vary from 
day to day (190), it is recommended that the reference food (glucose or white bread) is 
repeated twice (173). Six of the selected studies tested their reference food more than 
once; one also measured their test drinks more than once (191). Two of the five that 
found an overall effect on glucose measured their control more than once. One of 
these had the lowest number of participants and lowest CC dose (9), so it is likely that 
this will have increased the power of that particular study. Four other studies measured 
their control more than once and did not observe an overall effect; two of these 
reported differences at some time-points (187,188), the others did not compare individual 
time-points (181,183). 
Gavrieli et al., with 33 participants, is likely to have been the most statistically powerful 
study, despite only performing each test once, and, as previously discussed, they 
observed an overall effect on glycaemic response to a low CHO dose (184). However, 
Louie et al. and Robertson et al. with  8 and 10 participants respectively, also observed 
an overall increase to the postprandial glycaemic response (9,185), so participant 
numbers alone have not determined the results in these cases. Interestingly, Gavrieli 
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et al. reported a greater effect in their overweight group and Robertson et al. recruited 
only overweight participants. As overweight people are more likely to be insulin-
resistant this may have contributed to the observed effects; however, Robertson et al. 
reported their participants to have normal insulin sensitivity. Furthermore, Louie et al. 
studied normal-weight participants although, as previously discussed, they repeated 
their tests, thus increasing the power of their study to detect an effect.  
Capillary blood sampling via the finger-prick technique is considered the gold standard 
in GI testing as it samples primarily arterial blood and therefore more accurately 
reflects glucose absorption. It has been demonstrated to be more sensitive to smaller 
differences in blood glucose than venous sampling and consistently gives a higher 
AUC than venous samples in GI testing (192). Venous blood generally gives a lower 
glucose reading as some of the absorbed glucose will have been taken up by the 
tissues before it gets to the veins. Only seven of the twenty studies sampled capillary 
blood, however this does not explain why some studies observed an effect and others 
did not, as two of those that reported an overall effect sampled capillary blood and 
three took venous samples.  
The doses of coffee given, whilst being physiological in terms of daily consumption, 
are generally higher than a person would normally consume in one drink. A typical 
mug of instant CC, as consumed in the UK, would contain approximately 2 g of instant 
coffee granules and would provide between 40 and 100 mg caffeine depending on the 
type of bean, as discussed in the introduction to this thesis. Only two studies (185,187) 
gave what could be considered a normal dose of instant coffee but it is unclear from 
Young and Wolever how accurate their measurement was as they simply refer to 
serving a rounded teaspoon of instant CC (187). For filter coffee, 1 level tablespoon 
(weighing 6-7 g) per cup of coffee is the normal measure. Using this as guidance, it 
would appear that two of the eight filter coffee studies (183,188) gave a normal measure 
of filter coffee, with the others either higher or undeterminable. Dose does not appear 
to determine result however, as significant overall effects were observed for both 
low (185) and high (184) doses, nor was any overall dose-response effect observed in the 
three studies that compared different doses (183–185), although Gavrieli et al. observed 
a dose-response effect in their overweight/obese subgroup (184). 
The volume of liquid consumed can affect gastric emptying, and therefore glucose 
response, however the differing volumes (200 - 812 ml) given in these studies do not 
appear to have determined the results, as increased glucose responses were reported 
for volumes at both ends of the range. Furthermore, no overall difference in glycaemic 
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response was observed when volumes of water ranging from 50 to 1000 ml were 
compared (187). 
The majority of studies recruited healthy normal-weight participants. Of the two studies 
that measured glucose response in T2DM, one observed a trend for an increase in the 
overall response following CC ingestion (110), with CC resulting in a 4% greater AUC 
than control (p=0.06), whilst the other reported no difference (181). This difference in 
results may be explained by the differing methodologies employed as the participants 
in Alkaabi et al.’s study were instructed to take their diabetes medication before the 
study day, whilst those in Krebs et al.’s study were instructed to defer their medication 
until after the test. It should be noted, however, that the participants in both studies 
were relatively well-controlled by diet or oral hypoglycaemics, with mean HbA1c of 52 
and 49 mmol/mol and mean fasted glucose of 7.5 and 6.4 mmol/L for Krebs et al. and 
Alkaabi et al. respectively. If the participants had exhibited poorer glycaemic control 
they may have observed a larger difference between treatments. 
It has been demonstrated that 14 days of caffeine consumption, in caffeine-naïve 
individuals, results in partial but not complete acclimatisation to the acute effects 
caffeine has on glucose tolerance (193). It is advisable, therefore, to avoid using 
caffeine-naïve participants in acute studies in order to avoid exaggerated responses 
to caffeine exposure. Half of the studies in this review did not specify whether their 
participants were habitual coffee drinkers, which is a major confounder. Of the studies 
that provided this information, the majority reported regular coffee consumption in their 
participants. 
Twelve studies included other treatments alongside CC and DC. Only the results 
related to coffee are covered in this review, however it should be noted that when 
multiple comparisons are made and post hoc adjustments made as a result of this, the 
statistical power will be reduced. Post hoc adjustments were made in nine of these 
studies, with 2/9 reporting an overall effect of coffee (184,185). It is possible that more 
significant effects would have been reported had a simpler study design been 
implemented. However, of the three studies that did not adjust statistically for multiple 
comparisons, two did not observe an overall effect (144,146). The remaining study 
compared five different drinks with a control and observed an overall effect on the 
postprandial glucose response (9). However, they reported a p-value of 0.022 for the 
comparison between CC and control; if this had been adjusted to account for the other 
tests, statistical significance would have been lost.  
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3.6 Conclusion 
In summary, nearly 70% of acute studies reported a degree of increase in postprandial 
glucose response following CC ingestion, although the majority of these only observed 
a difference at individual time-points. Conversely, most studies reported no effect of 
DC on the postprandial glucose and insulin responses. It seems likely that CC does 
therefore have a detrimental effect on acute glycaemic control. What is unclear is 
whether a small overall increase or a small increase in peak values is physiologically 
and/or clinically relevant.  
Whilst there have been a relatively large number of studies looking at these acute 
effects, the majority have been in a young, normal-weight, healthy population. There 
is clearly a need for more studies examining the effects of coffee on those with T2DM, 
particularly in those with poor glycaemic control. Studies in less healthy populations, 
such as those with MS or who are overweight/obese would also be advisable. 
Finally, more research into the effects of normal doses of coffee would be beneficial. 
Instant coffee is the most commonly consumed coffee in the UK, yet only two of these 
twenty studies investigated the effects of a single cup of instant coffee. 
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4.1 Introduction 
Acute studies into the effects of CC on the postprandial glycaemic response have 
frequently reported a detrimental effect, with CC producing a greater postprandial 
glycaemic response than control (7,109,110). Caffeine has also been demonstrated to 
produce greater glucose and insulin responses than control (125,126), with some 
observing a larger effect from caffeine than CC (10). This has led to the hypothesis that 
bioactive components in coffee, other than caffeine, may be attenuating the 
documented acute negative effects of caffeine on glycaemia. Chlorogenic acids and 
their metabolites have been suggested as possible candidates with studies involving 
isolated CGAs (144) and coffee enriched with CGA (146) both demonstrating a reduction 
in glucose response versus control, however a significant confounder with testing this 
hypothesis is that the majority of acute studies to date have not reported the CGA 
content of their coffees.  
Previous studies have used large doses of CC, typically providing 3 - 6 mg caffeine 
per kg BW (126,161). This would be the equivalent of 2.5 – 5 standard-sized (260 ml) 
servings, taken as a single dose, for a 70 kg person, based on the median caffeine 
content of instant coffee (as discussed in Chapter 1). Only one previous study, to our 
knowledge, has investigated the glycaemic effects of a single “normal” serving of 
instant coffee (187), however there were several methodological concerns with that 
study which will be discussed later in this chapter. 
4.2 Aims 
This study was carried out in two parts:  
Part A was a dose-response study with the lowest dose set at a single serving of CC. 
The aims were to investigate whether there was an acute effect of a single “normal” 
dose of CC on the postprandial glucose and insulin responses and to further 
investigate whether there was any effect of increasing doses. 
Part B was a similar dose-response study where the CGAs and other coffee 
components were increased step-wise, as in Part A, whilst the caffeine dose remained 
constant. The aims of this part were to investigate the acute effects of increasing 
amounts of these non-caffeine coffee components. 
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4.3 Methods 
4.3.1 Participants 
Ten participants were recruited from the staff and student population of the University 
of Surrey by word of mouth, poster advertisement and internal emails. Written informed 
consent was obtained from all participants. Recruitment and data collection were 
carried out between August 2012 and February 2013. The study was given a 
favourable ethical opinion by the University of Surrey Ethics Committee 
(EC/2012/45/FHMS).  
Participants were required to be overweight (BMI > 25 kg/m2), but otherwise healthy 
adult males, aged over 18 y, taking no prescription medication. They had to have been 
weight stable for the previous three months and to have no history of heart disease, 
diabetes, liver disease or any gastrointestinal or endocrine disorders. Smokers were 
excluded from participation in the study. Additionally, potential participants had to be 
habitual coffee drinkers (>= 4 servings per week).  
4.3.2 Study design 
The study was an eight-way randomised double-blind crossover study investigating 
the acute effects of different doses of DC with added caffeine on postprandial glucose 
and insulin response. Rather than using off-the-shelf CC, caffeine was added to DC to 
allow the amounts of caffeine and non-caffeine components to be varied independently 
in each drink. 
The study was split into two parts. In Part A, three different doses of DC, with caffeine 
added in proportion to the DC, were compared with a control (water). This provided 
the equivalent of one, two and four servings of regular CC and allowed examination of 
the effects of escalating doses of CC. In Part B, the same three doses of DC were 
used, but this time each drink, including the control, contained the lowest amount of 
caffeine from Part A (100 mg). This allowed examination of the effects of escalating 
doses of the non-caffeine coffee components. The relative proportions of DC to 
caffeine for each drink are provided in Figure 4.3.2-1. The composition of each 
individual drink is detailed in Section 4.3.4. 
Chapter 4. 
78 
 
 
4.3.3 General protocol 
Potential participants were invited to attend a screening session (detailed in Chapter 
2) where the study was explained to them in detail. If they fulfilled the inclusion criteria 
and decided to take part in the study, a date was set for their first study day. Each 
participant attended eight study days lasting approximately three hours each time.  
For two days prior to each of the study days, participants were asked to refrain from 
exercise, alcohol and all coffee- and caffeine-containing food and drinks. They were 
asked to maintain the same diet the day before each visit and were given a 
standardised meal to consume the evening before. The standardised meal was a 
macaroni cheese ready meal (Tesco, Italian range, 450 g) providing 784 kcal, 31.2 g 
protein, 35.2 g fat, 80.5 g CHO and 10.1 g fibre.  
After a 12 h overnight fast, participants arrived at the CIU between 8:00 and 9:00 am. 
They provided a baseline fasted capillary blood sample via the finger-prick technique. 
They then consumed the test drink and provided further capillary blood samples every 
15 min for the next two hours. They were asked to rate each drink using a scale of 
1 - 5 for each of four measures: strength, palatability, taste and smell (Appendix 5). 
Figure 4.3.2-1  Diagrammatic representation of the relative proportions of decaffeinated coffee to 
caffeine for the test drinks. 
In Part A, caffeine rises in proportion to decaffeinated coffee, whereas in Part B caffeine remains constant 
at 100 mg. DC: decaffeinated coffee. 
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The participants were permitted to bring work/books/laptops with them but were 
required to minimise physical activity and to remain in the CIU for the duration of the 
study day. Study days were separated by a washout period of at least five days and 
participants were given £200 on completion of the trial, as compensation for their time. 
There were eight different test drinks with participants receiving each of the drinks over 
the course of the eight study days. A random sequence generator 
(https://www.random.org/sequences/) was used to generate the order for each 
participant. All treatments were double-blind; participants were simply advised that 
they were testing different coffees and were not told that they contained differing 
amounts of DC and caffeine. It was not possible to fully blind researchers and 
participants to the control drinks, however participants were not informed that there 
was any difference between the two control drinks and researchers were not aware 
which control drinks they were providing on each occasion. 
4.3.4 Drink composition 
Three different doses of DC were used (2, 4 and 8 g of instant DC granules), equivalent 
to that found in 1, 2 and 4 servings of coffee. In Part A, appropriate doses of caffeine 
were added to reflect the amount of caffeine found in the same doses of regular CC. 
As the DC was reported as containing 0.3% caffeine the amount of added caffeine was 
adjusted so that the total caffeine in each drink would be 100, 200 and 400 mg 
respectively. In Part B, the same three doses of DC were used, but caffeine was added 
such that they each had a total caffeine content of 100 mg. Detailed analysis of the 
DC, performed after the completion of the study, revealed the actual caffeine content 
to be 160 mg/100 g, resulting in all drinks having slightly less total caffeine than their 
target amounts. For reasons of clarity, the target caffeine content of each drink, rather 
than the actual caffeine content, will be referred to for the remainder of this thesis. The 
instant coffee granules were a commercially available DC, Kenco Decaff (The Kenco 
Coffee Company, Uxbridge, UK). The full coffee analysis can be found in Appendix 6. 
 All drinks were made by dissolving the DC and caffeine, along with 50 g glucose, in 
200 ml boiling water. An additional 200 ml cold water was added to allow quick 
consumption. The different drink combinations along with their total CQA content are 
summarised in Table 4.3.4-1. 
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4.3.5 Blood collection 
All blood samples were taken by finger prick with the use of a lancing device and 
collected into heparin fluoride microvette tubes (Sarstedt, Leicester, UK). These were 
refrigerated until the end of the study day then centrifuged and the plasma transferred 
into serum microvette tubes (Sarstedt, Leicester, UK). Plasma glucose concentrations 
were then immediately measured using the YSI 2300 STAT PlusTM (YSI Life Sciences, 
UK). Following glucose analysis the plasma was frozen at -20ºC until the end of the 
study for batch analysis of insulin. Plasma insulin was measured by ELISA as 
described in Chapter 2. 
4.3.6 Statistical analysis 
All statistical analysis was carried out using SPSS Statistics software, version 22. The 
Shapiro-Wilks test was used to check normality of data. Overall treatment effects were 
analysed by RM ANOVA. A Bonferroni adjustment for multiple comparisons was 
applied when post hoc analysis was used. Statistical significance was taken as p < 
0.05. A sample size of 10 was chosen in line with that recommended for GI testing, 
however a post hoc power calculation revealed the study to be underpowered to detect 
a difference in insulin. In excess of 23 participants would be required in order for the 
detected differences in insulin to be statistically significant at 80% power.  
Table 4.3.4-1  Test drink composition. 
Drink 
number
Instant 
DC (g)
Target  total 
caffeine (mg)
Actual total 
caffeine (mg)
Total CQA 
(mg)
Glucose 
(g)
Water 
(ml)
1 0 0 0 0 50 400
2 2 100 97 47 50 400
3 4 200 194 94 50 400
4 8 400 389 188 50 400
5 0 100 100 0 50 400
6 2 100 97 47 50 400
7 4 100 94 94 50 400
8 8 100 89 188 50 400
P
ar
t 
A
P
ar
t 
B
DC and caffeine powder were dissolved, along with 50 g glucose, in 200 ml boiling water to which 
200 ml cold water was added to allow quick consumption. CQA: caffeoylquinic acid; DC: 
decaffeinated coffee. 
Chapter 4. 
81 
 
4.4 Results 
4.4.1 Baseline characteristics 
The participants were overweight males (n=10) with a mean age of 30 y (SD 14) and 
mean BMI of 27.8 kgm-2 (SD 2.2). All were habitual coffee drinkers with a mean daily 
CC intake of 2.3 servings (range: 0.7 – 5.5) and a mean daily caffeine intake of 323 
mg (range: 61 – 690 mg). Baseline characteristics are reported in Table 4.4.1-1. 
Fasted glucose, insulin, HOMA2_%B and HOMA2_%S are reported as the mean 
values for all visits. 
  
4.4.2 Glucose and insulin 
The majority of the glucose time-point data, including fasted and peak values, and all 
IAUC data were normally distributed. Log transformation of the time-points did not 
result in all data being normally distributed. As 88% of time-points were normally 
distributed, parametric tests were carried out on the original glucose dataset.  
Half of all insulin time-point data were not normally distributed; log transformation 
resulted in normal distribution of the majority (85%), therefore parametric tests were 
carried out on the log-transformed insulin time-point data. Measures of insulin 
sensitivity and beta cell function were calculated as described in Chapter 2. The 
appropriate non-parametric and parametric tests were carried out on these measures. 
The HOMA2 calculator specifies acceptable ranges for steady state glucose (3.0 to 
25.0 mmol/L) and specific insulin (20 to 300 pmol/L). Fasted glucose values in this 
Table 4.4.1-1  Baseline participant characteristics. 
BMI: body mass index; CC: caffeinated coffee; HOMA: Homeostatic model 
of assessment; %S: sensitivity; %B: beta cell function. 
Mean (n=10) SD
Age (y) 30 14
Height (m) 1.78 0.09
Weight (kg) 88.5 11.9
BMI (kgm-2) 27.8 2.2
Body fat (%) 23.6 5.4
Fasted plasma glucose (mmol/L) 5.2 0.5
Fasted plasma insulin (pmol/L) 20 11
HOMA2_%B 48 18
HOMA2_%S 356 363
Daily CC intake (servings/day) 2.3 1.6
Daily caffeine intake (mg/day) 323 205
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study all fell within the specified range, but insulin did not, with nearly half of all fasted 
insulin measures being less than 20 pmol/L. This was not unexpected as capillary 
sampling is known to result in lower insulin measures than venous (194). All values were 
included in the analysis as we were interested in relative values rather than absolute. 
 Escalating doses of decaffeinated coffee and caffeine 
For Part A, where the amount of caffeine was varied in line with DC, there was a 
significant difference between treatments for glucose. Repeated measures ANOVA on 
the glucose time-points found a significant treatment effect (p=0.008) and a time * 
treatment effect (p=0.022), with the control drink displaying an earlier peak (15 min) 
than the other drinks (30 min). Post hoc analysis revealed a significant difference 
between the control drink and both the one and two serving equivalents (p<0.033). A 
similar result was observed for glucose IAUC, with an effect of treatment found (RM 
ANOVA, p=0.019) and post hoc analysis revealing a difference between the one 
serving equivalent and the control drink (p=0.008). When the glucose peak values 
were examined there was a significant difference between treatments (RM ANOVA, 
p=0.006), with post hoc analysis identifying a significant difference between the control 
and one serving equivalent (p=0.006) and a trend for a difference between the control 
drink and the two servings equivalent (p=0.056).  
There were no significant differences between treatments for insulin (p>0.391), nor 
were there any significant differences in any insulin sensitivity and beta cell function 
measures (p>0.563). The insulin sensitivity and beta cell function measures are 
reported in Table 4.4.2.1-1 and the two hour postprandial glucose and insulin 
responses are shown in Figure 4.4.2.1-1. 
 
Drink
Code DC (g) CF (mg) Mean SD Mean SD Mean SD Mean SD Mean SD
1 0 0 48 14 278 112 21 14 12.6 7.3 198 57
2 2 100 46 11 305 177 40 74 13.9 8.2 324 408
3 4 200 44 19 408 359 36 41 11.5 6.3 296 374
4 8 400 52 22 399 572 18 16 14.3 7.5 202 106
Matsuda * 
AUGI/GComposition HOMA2_%B HOMA2_%S
Matsuda 
Index AUCI/G ratio
Table 4.4.2.1-1  Insulin sensitivity and beta cell function measures for Part A. 
There were no significant differences between drinks for any measure (RM ANOVA, p>0.563); n=10. 
CF: caffeine; DC: decaffeinated coffee; HOMA: Homeostatic model of assessment; %S: sensitivity; 
%B: beta cell function; AUCI/G: ratio of insulin to glucose area under curve; Matsuda * AUGI/G: product 
of Matsuda index and AUCI/G ratio. 
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Figure 4.4.2.1-1  Postprandial glucose and insulin responses to a control drink and three 
escalating doses of decaffeinated coffee and caffeine, equivalent to 1, 2 and 4 servings of 
standard caffeinated coffee. 
Significant differences between treatments were observed for glucose time-points (RM ANOVA, p=0.008) 
and peak values (p=0.006), with no difference between treatments for insulin. Error bars are SEM (n=10). 
CF: caffeine; DC: decaffeinated coffee. 
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 Escalating doses of decaffeinated coffee, all with 100 mg caffeine 
For Part B of the study, where all drinks contained 100 mg caffeine, there were no 
significant differences in postprandial glucose and insulin responses between 
treatments, however there was a time * treatment effect for insulin (RM ANOVA, 
p=0.017). An overall difference in peak glucose values was also observed (RM 
ANOVA, p=0.049) with no significant differences found between individual treatments 
in post hoc analysis. The 2 h postprandial glucose and insulin responses for Part B are 
shown in Figure 4.4.2.2-1. 
 
 
Figure 4.4.2.2-1  Postprandial glucose and insulin responses to a control drink and escalating 
doses of decaffeinated coffee, all with 100 mg added caffeine. 
There was an overall difference in peak glucose values (RM ANOVA, p=0.049) and a time * treatment 
effect for insulin (RM ANOVA, p=0.017). Error bars are SEM (n=10). CF: caffeine; DC: decaffeinated 
coffee. 
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There were no significant differences in any insulin sensitivity and beta cell function 
measures (p>0.111). Insulin sensitivity and beta cell function measures for Part B are 
reported in Table 4.4.2.2-1.  
 
 
 Comparison of control drinks with and without added caffeine 
There was a difference in glucose IAUC between the two control drinks (paired t test, 
p=0.045), with a higher IAUC observed in the control drink containing caffeine. The 
two hour postprandial glucose and insulin responses for each control drink are shown 
in Figure 4.4.2.3-1.  
There were no significant differences in any insulin sensitivity and beta cell function 
measures between the two drinks (p>0.153). Insulin sensitivity and beta cell function 
measures for the two control drinks are reported in Table 4.4.2.3-1. 
 
There were no significant differences between drinks for any measure (RM ANOVA, p>0.111); n=10. CF: 
caffeine; DC: decaffeinated coffee; HOMA: Homeostatic model of assessment; %S: sensitivity; %B: beta 
cell function; AUCI/G: ratio of insulin to glucose area under curve; Matsuda * AUGI/G : product of Matsuda 
index and AUCI/G ratio. 
Table 4.4.2.2-1  Insulin sensitivity and beta cell function measures for Part B. 
Drink
Code DC (g) CF (mg) Mean SD Mean SD Mean SD Mean SD Mean SD
5 0 100 54 23 300 210 21 13 10.4 6.6 173 54
6 2 100 45 14 287 101 39 66 10.0 5.2 262 328
7 4 100 40 22 630 679 50 70 10.0 5.7 327 322
8 8 100 55 18 253 185 74 181 11.6 6.8 201 82
Composition HOMA2_%B HOMA2_%S
Matsuda 
Index
Matsuda * 
AUGI/GAUCI/G ratio
Table 4.4.2.3-1  Insulin sensitivity and beta cell function measures for control drinks with and 
without added caffeine. 
There were no significant differences between drinks for any measure (p>0.153); n=10. CF: caffeine; DC: 
decaffeinated coffee; HOMA: Homeostatic model of assessment; %S: sensitivity; %B: beta cell function; 
AUCI/G: ratio of insulin to glucose area under curve; Matsuda * AUGI/G : product of Matsuda index and 
AUCI/G ratio. 
Drink
Code DC (g) CF (mg) Mean SD Mean SD Mean SD Mean SD Mean SD
1 0 0 48 14 278 112 21 14 12.6 7.3 198 57
5 0 100 54 23 300 210 21 13 10.4 6.6 173 54
Composition HOMA2_%B HOMA2_%S
Matsuda 
Index AUCI/G ratio
Matsuda * 
AUGI/G
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4.4.3 Test drink organoleptic properties 
Parts A and B were examined separately. As the data were ordinal rather than 
continuous, non-parametric tests were used. Friedman’s ANOVA was used to test for 
an overall difference for each quality measure. Where significant differences were 
found, post hoc pairwise comparisons (Wilcoxon Signed Rank) were used to establish 
the sources of any differences. For Part A, no overall differences were found however 
trends were observed for differences in palatability (p=0.084) and smell (p=0.092).  
For Part B, an overall difference was found for palatability (p=0.003) and taste 
(p=0.002) with no significant differences between individual pairs after adjustment for 
multiple comparisons. An overall difference in strength (p<0.001) was detected with 
post hoc analysis revealing drink 8 to have been perceived as stronger than drink 5 
Figure 4.4.2.3-1  Postprandial glucose and insulin responses to control drinks with and without 
added caffeine. 
There was a difference in glucose IAUC between the two control drinks (paired t test, p=0.045). Error bars 
are SEM (n=10). CF: caffeine; DC: decaffeinated coffee. 
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(p=0.007) and a trend for a difference between drinks 8 and 6 (p=0.096). A difference 
in smell (p=0.001) was also found with post hoc analysis revealing a difference 
between drinks 5 and 6 (p=0.005). 
Mean responses for each of the four drink quality measures, strength, palatability, taste 
and smell, are reported in Table 4.4.2.3-1.  
 
4.5 Discussion  
4.5.1 Escalating doses of decaffeinated coffee and caffeine 
A significant difference was observed between drinks for Part A of the study where the 
added caffeine escalated proportionately to the DC, with post hoc analysis revealing 
differences between both the one and two serving equivalents and the control drink for 
overall glucose response and glucose peak values.  
This is consistent with the majority of studies in the systematic review (Chapter 3), 
where almost 70% reported an increased postprandial glucose response following 
ingestion of CC. Young and Wolever, the only other study to our knowledge to use a 
“normal” dose of instant CC, observed a smaller effect  than that observed in the 
current study, reporting an increased effect of CC at two time-points only (187). Similarly 
to the current study, their CHO dose was 50 g, their coffee was given concurrently with 
their meal and they took capillary blood samples. However their participants were 
younger, with a healthy BMI, whereas those in the current study were all overweight. 
It is likely that overweight participants are more insulin-resistant and possibly more 
susceptible to the glucose-raising effects of CC. Furthermore, they gave their 
Participants rated all drinks on a scale of 1-5 for palatability, strength, taste and smell. Parts A and 
B were analysed separately. Mean values within a column with unlike superscript letters were 
significantly different (Wilcoxon Signed Rank, p<0.008); n=10. CF: caffeine; DC: decaffeinated 
coffee. 
Table 4.4.2.3-1  Study test drinks: results of organoleptic qualities questionnaire. 
Drink
Code DC (g) CF (mg) Mean SD Mean SD Mean SD Mean SD
1 0 0 2.9 1.3 2.6 1.1 2.8 1.2 2.8 0.8
2 2 100 3.9 0.6 2.7 0.7 3.6 1.0 3.2 0.6
3 4 200 3.7 0.8 3.3 0.7 3.6 1.0 3.6 0.8
4 8 400 3.0 1.2 3.3 0.9 2.9 1.4 3.5 0.8
5 0 100 2.7 1.1 2.1
a
1.1 2.5 1.1  2.6
c
0.8
6 2 100 3.7 0.7 2.5 0.8 3.6 0.7  3.7
d
0.5
7 4 100 4.1 0.6 3.1 0.7 3.8 0.8 3.7 0.8
8 8 100 3.8 0.8 3.6
b
0.8 3.4 0.8 3.5 0.8
P
ar
t 
B
Composition Palatability Strength Taste Smell
P
ar
t 
A
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participants a mixed meal, which is likely to have been absorbed more slowly than the 
glucose used in this study. The CC consumed in this study contained approximately 
100 mg caffeine; whilst this is within the normal range for instant CC, it is towards the 
top end of that range, as discussed in Chapter 1. It is possible that the larger effect 
observed here is a result of a higher dose of caffeine, however as Young and Wolever 
did not report their caffeine content, this cannot be confirmed.  They also did not report 
the exact amount of CC consumed in their study, instead reporting the dose to be a 
rounded teaspoon. If their CC was not weighed, it is likely that their dose may have 
varied considerably. Additionally their participants were permitted to add milk to their 
CC, further increasing the likelihood of confounding.  The authors did not report what 
percentage of participants opted to add milk, but they did state that it was standardised 
between visits for those who did.  
A difference was observed in the time taken to reach peak plasma glucose, with the 
control drink peaking at 15 min and the three test drinks peaking later, at 30 min. This 
is consistent with the hypothesis that coffee may exert a beneficial effect by delaying 
glucose absorption (140,147). The mean peak plasma glucose concentration following the 
control drink was 8.25 mmol/L whereas the peak following the two serving equivalent 
was 9.62 mmol/L, a mean increase of 17% (1.37 mmol/L) in peak values. The 
magnitude of this increase is consistent with two other studies in the systematic review 
which observed increases in peak glucose of approximately 1 mmol/L (147) and 
2 mmol/L (7). 
No dose-response effect of coffee on blood glucose or insulin was observed in this 
part of the study. This is in contrast to a recent study which reported a dose-response 
effect on both glucose and insulin when using caffeine alone (195). That study gave their 
participants doses of 1, 3 and 5 mg/kg BW and reported linear increases in glucose 
AUC of 11.2 mmol/L.120 min and insulin AUC of 5.8% for each 1 mg/kg increase in 
caffeine. The mean caffeine contents of the drinks in the current study were similar, 
with participants receiving mean caffeine doses of 1.15, 2.30 and 4.60 mg/kg, however 
no linear increase in postprandial glucose and insulin response was observed as a 
result. In contrast the greatest increase in glucose IAUC (equivalent to 49 mmol/L.120 
min for each 1 mg/kg) was observed between the control drink and the lowest coffee 
dose (100 mg added caffeine) with a smaller increase between the one and two serving 
equivalents (17 mmol/L.120 min per mg/kg) and a decrease between the two and four 
serving equivalents (-13 mmol/L.120 min per mg/kg). For insulin IAUC, a 22% increase 
was observed for each 1 mg/kg between control and the one serving equivalent, with 
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a decrease between the next two drinks (-15% per mg/kg) and a subsequent increase 
between the two highest doses (8% per mg/kg).  
Gavrieli et al. compared two different amounts of instant CC, providing 3 and 6 mg/kg 
BW, to a control (184). Although they calculated their doses per kg BW, the mean 
amounts of caffeine in their two CC doses, 228 mg and 457 mg, were similar to the 
two higher amounts of caffeine used in this study (200 mg and 400 mg, in drinks 3 and 
4 respectively). However, the mean amounts of instant CC they gave their participants, 
6.0 g and 11.9 g, were 50% higher than the two highest doses (4 and 8 g) in the current 
study, so it is likely that their total CGA content was higher. They reported a higher 
glucose IAUC in both coffee doses compared with control and also observed a time * 
treatment effect for glucose and insulin responses. In line with this study, they 
observed no significant overall dose-response effect, despite having a higher number 
of participants (n=33). Interestingly they reported a greater effect in their female and 
their overweight participants, which cannot be explained by body size as doses were 
proportional to bodyweight. Furthermore when they performed their analysis on the 
overweight/obese subset of their participants they did observe a dose-response effect 
on glucose IAUC. Their overweight/obese participants were of a similar age, weight 
and BMI to participants in the current study, so a difference in baseline characteristics 
cannot explain the difference in results between the studies. The lack of a dose-
response effect in the current study may however be due to high inter- and intra-
individual variation in glycaemic response, which was apparent when individuals’ 
responses were examined and is in line with that previously demonstrated (190). A larger 
sample size may have had sufficient power to detect a dose-response effect, 
particularly when one considers that the two studies to observe such an effect had 
higher numbers, with Gavrieli et al. recruiting 17 participants to their overweight/obese 
group and Beaudoin et al. recruiting 24 participants to their caffeine study.  
Surprisingly, post hoc analysis found the increased glucose response only applied to 
the one and two serving equivalents and not to the highest dose. It is unlikely that a 
greater insulin response to the high caffeine levels had suppressed the glucose 
response in this case, as no significant differences between drinks for the insulin 
response were found. Furthermore, although Beaudoin et al. reported a dose-
response effect on insulin, there was no resultant suppression of glucose (195).  
4.5.2 Escalating doses of decaffeinated coffee, all with 100 mg caffeine 
There was no overall treatment effect on either postprandial glucose or insulin for Part 
B of the study, where all drinks, including the control, contained 100 mg caffeine. There 
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was however an overall difference in glucose peak values and a time * treatment effect 
for insulin, with no significant differences between individual pairs in post hoc 
comparisons.  
These findings suggest that a relatively small dose of caffeine, 100 mg, may be 
sufficient to override any potential beneficial effects of increasing amounts of other 
coffee compounds. However it should be noted, as discussed previously, that this 
amount of caffeine is towards the upper end of the range typically found in a single 
serving of CC. Furthermore, the total amount of CGAs in the coffee, 29.1 mg/g (23.5 
mg/g CQA), equivalent to 58.1 mg (47 mg CQA) in the lowest dose, is relatively low in 
comparison to the amounts found in brewed (27 – 94 mg CQA/serving) and espresso 
(24 – 422 mg CGA/serving) coffees, as discussed in the introduction to this thesis, 
although it is comparable to typical amounts found in instant DC.  
Whilst there was no dose-response effect of increasing the non-caffeine components 
of coffee, a non-significant reduction in glucose IAUC with each increasing dose was 
observed, unlike in Part A. However, it is inadvisable to form any conclusions based 
on these non-significant differences, particularly when one considers that whilst the 
lowest mean glucose IAUC (207 mmol/L.120 min) was observed following the highest 
dose of DC, the actual IAUC value was very similar to the mean IAUC observed in the 
control drink (210 mmol/L.120 min). 
4.5.3 Comparison of control drinks with and without added caffeine 
Whilst no overall difference was observed between the two control drinks when the 
time-point data were analysed, the control drink with added caffeine (Part B) produced 
a significantly higher glucose IAUC than the control without caffeine (Part A). This 
result is in line with others who have compared the effects of caffeine on the 
postprandial glucose response (10,125). Unlike several others (10,125,196) there was no 
increased insulin response to the caffeine in the current study, however these other 
studies gave higher doses of caffeine (typically 5 mg/kg). As noted previously, 
Beaudoin et al. observed a dose-response effect on insulin with caffeine doses starting 
at 1 mg/kg, however their study had 24 participants and therefore greater power to 
observe an effect at smaller doses (195). 
4.5.4 Test drink organoleptic properties 
For Part A, no significant differences were found for any measure however trends were 
observed for differences in palatability and smell. For Part B, overall differences were 
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found for palatability and taste with no significant pairwise differences. An overall 
difference in strength was also detected with post hoc analysis revealing the highest 
dose CC to have been perceived as stronger than the control and a trend for a 
difference between the highest and lowest doses of CC.  A difference in smell was 
also found with post hoc analysis revealing a difference between the control and the 
lowest dose CC. 
When individual responses were examined, there was a large amount of inter-
individual variation on each of the ratings. Ratings of palatability in particular varied 
with scores for the highest dose spanning the entire range from completely 
unpalatable (1) to extremely palatable (5), depending on whether the individual 
preferred strong or weak coffee. A similar range of responses was observed for the 
control drinks, corresponding to how much the participant liked sweet drinks. 
Interestingly, the participants were better able to detect differences in coffee strength 
in Part B, where the amount of caffeine in each drink was 100 mg, although only a 
trend was observed between highest and lowest doses. Many participants commented 
that the sweetness of the drinks overrode other factors and made it difficult to rate the 
drinks. It should also be noted that participants did not have the opportunity to directly 
compare individual drinks as each drink was rated on the study day and greater 
variation in response can be expected when rated on different days. 
An obvious difference between the control and coffee drinks is the presence or 
absence of coffee with its characteristic bitter taste. As the hedonic properties of 
food/drink have been demonstrated to impact acutely on postprandial nutrient 
handling (197), it was important to exclude this as a simple pre-ingestive mechanism 
contributing to any observed differences. There were no significant differences in Part 
A for either palatability or taste which would indicate that the impact of the coffee on 
glucose metabolism was due to a true post-ingestive mechanism. However, there was 
a slight trend for an overall difference in palatability and examination of the data 
revealed ratings for both palatability and taste dropped non-significantly with the 
highest dose coffee, such that the mean ratings for this dose were very similar to the 
control ratings. This may therefore have made some contribution to the lack of 
observed effect of the highest coffee dose. However, this does not explain why other 
studies have demonstrated an  increased postprandial glucose response following 
doses similar to the highest dose in the current study (8,126).  
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4.5.5 Limitations/confounders 
Doses were not adjusted according to participants’ bodyweights in contrast to several 
previously discussed studies (7,109,110,184,195) in order to reflect normal nutritional intake 
patterns. When the caffeine content was converted to mg/kg BW the lowest dose (100 
mg caffeine) gave a mean value of 1.15 mg/kg (range 0.9 – 1.5 mg/kg) and the highest 
dose (400 mg caffeine) was 4.6 mg/kg (range 3.7 – 6.1 mg/kg). This variation in dose 
between participants may be a confounder in determining a dose-response 
relationship. To examine this, a post hoc analysis was performed on the glucose IAUC 
data from Part A. Firstly the data was re-analysed with the three participants with the 
smallest and largest bodyweights omitted (equivalent to 0.9, 1.4 and 1.5 mg/kg at the 
lowest coffee dose), leaving seven participants (range 1.0-1.2 mg/kg). The previously 
observed overall difference in IAUC remained, but with reduced significance (p=0.041) 
and no significant pairwise differences. The analysis was then repeated with all 10 
participants categorised into high or low bodyweight, which was added into the 
analysis as a cofactor. Again, an overall difference in glucose IAUC between drinks 
was observed (p=0.028), but with no difference between the high and low group and 
no interaction effect. These results suggest that the dosing methodology did not impact 
on the results. 
Another possible confounder may be different genetic polymorphisms in the CYP1A2 
gene which have been demonstrated to affect the rate of caffeine metabolism in 
humans (198), as discussed in Section 1.4.5. Unfortunately the participants were not 
genotyped for these polymorphisms as this may have partly explained the high inter-
individual variations observed. 
As previously discussed, the relatively low number of participants may be insufficient 
to determine a dose-response relationship. Furthermore, a post hoc power calculation 
detailed in Section 4.3.6 revealed the study to be underpowered to detect a difference 
in insulin. 
As noted earlier in this chapter (Section 4.3.4), independent analysis of the instant DC, 
performed after the conclusion of the study, revealed the caffeine content to be 
approximately half that originally reported by the suppliers. This resulted in the highest 
doses having 11 mg less caffeine than their target amounts. This equates to an 11% 
reduction in target amount for the highest dose in Part B, but only a 3% reduction for 
the highest dose in Part A. Whilst this is not ideal, it does not appear to have impacted 
on the results. It is unlikely that the unexpected lack of effect on the postprandial 
glucose response, of the highest dose in Part A, was caused by the reduced caffeine 
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content, as the absolute caffeine content was higher than that of the two lower doses, 
which did increase the glucose IAUC.  
The ratio of caffeine to total CGA in the study was not ideal. If one considers that a 
typical 2 g serving of instant CC contains 41 - 85 mg CGA and 50 - 100 mg caffeine, 
then it becomes apparent that the lowest dose was disproportionately high in caffeine. 
Whilst quite feasible, 100 mg caffeine was at the high end of the normal range, 
whereas the total CGA content (58 mg) was in the low-mid range.  
A large amount of inter-individual variation was observed in the postprandial glucose 
response to the test drinks. This could perhaps have been reduced if a starchy meal 
had been provided along with the test drinks, rather than glucose, as OGTTs have 
been demonstrated to result in CVs 2 - 3 times higher than white bread (199). However, 
the use of glucose in this study had some benefit, in that it served to somewhat 
disguise the taste and strength of the coffees as previously discussed. 
4.6 Conclusion 
In support of the hypothesis, this study has demonstrated that a single serving of 
instant CC, as typically consumed in the UK, is sufficient to disrupt postprandial 
glucose metabolism. It is not known however, whether the observed differences, whilst 
statistically significant, are physiologically relevant. The participants were healthy, 
albeit overweight, insulin-sensitive individuals with normal glucose tolerance and the 
observed increase in postprandial glucose response following CC ingestion was 
quickly resolved in this group. It is not known how those with IFG or T2DM would 
respond to a similar intervention. 
In Part B of the study, there was no beneficial effect of increasing doses of non-caffeine 
components on postprandial glucose and insulin metabolism when each drink 
contained 100 mg caffeine. This is in contrast to the literature demonstrating beneficial 
effects of CGAs and suggests that the amount of caffeine in a single serving of CC 
may attenuate any possible beneficial effects of these other coffee components. 
However, as discussed, the drinks were relatively low in total CGA content and 100 
mg caffeine is a relatively large dose for a single serving. It is possible an effect may 
have been observed if the balance of caffeine to CGA was altered. It could also be 
argued that caffeine should not have been included in Part B of the study. However, 
whilst the aim was to investigate the effects of escalating doses of the non-caffeine 
components it was decided to do this within the framework of a caffeinated drink as 
most people in the UK who drink coffee do not drink DC. 
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Whilst these results, and others previously discussed, demonstrate that an acute dose 
of CC can temporarily disrupt postprandial glucose metabolism, it should be noted that 
the majority of these investigations have been carried out in healthy people. It is 
important that further studies are carried out in those with IFG and T2DM where the 
effects of coffee may be clinically relevant.  
It should also be noted that the results of acute studies cannot be simply translated 
into chronic effects. Longer-term interventions investigating these chronic effects are 
now needed as the current evidence for a beneficial effect of coffee in terms of reduced 
risk of diseases such as T2DM is based on cohort studies which cannot prove a causal 
relationship. 
 
This work has been published in the British Journal of Nutrition: 
Robertson TM, Clifford MN, Penson S, Chope G and Robertson MD. (2015). A single 
serving of caffeinated coffee impairs postprandial glucose metabolism in overweight 
men. Br J Nutr. 114, 1218–25. 
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5.1 Introduction 
As discussed in the introduction to this thesis, coffee contains several bioactive 
compounds, such as CGAs and their derivatives, which may attenuate some of the 
acute glucose-raising effects of caffeine. Indeed, studies involving CGA alone (144) and 
coffee enriched with CGA (146) have demonstrated a reduction in glucose AUC 
compared to a control. It would seem reasonable that DC might produce a similar 
effect.  Studies investigating the effect of DC however have displayed mixed results 
with some finding no effect on postprandial glucose (144,146), some reporting a reduced 
glucose IAUC (10) and some observing higher glucose at several time-points (126) or an 
increase in IAUC (8). One limitation of these previous studies is the high doses of DC 
given to participants, with no studies, to our knowledge, investigating the effects of a 
single serving. 
The postprandial glycaemic response has been observed to be greater in the afternoon 
and evening than in the morning (200–202). This is likely due to circadian rhythms in both 
insulin (203) and cortisol (204) production, as cortisol pulses have been observed following 
lunch and evening meals (205) and higher insulin has been observed in the morning (202). 
It has been hypothesised that the timing of coffee intake may modulate the 
preventative effect of coffee on T2DM risk suggested by the epidemiology; a 
prospective cohort study of almost 70,000 women reported an association between 
both CC and DC and reduced risk of T2DM, but only if the coffee was consumed at 
lunchtime (91). It is possible that the acute effects of coffee on postprandial glycaemia 
may also vary at different times of day. Whilst CC and, to a lesser extent, DC 
consumed with a morning meal have been demonstrated to produce a higher 
postprandial glucose and insulin response to a later meal (8), no studies to our 
knowledge have examined the effects of repeated dosing or the effects of DC 
consumed at lunchtime on the postprandial glycaemic response.  
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5.2 Aims 
The aims of this study were: 
 To investigate whether a single serving of DC has an effect on postprandial 
blood glucose and insulin when taken with a mixed meal in the morning. 
 To investigate whether a single serving of DC has an effect on postprandial 
blood glucose and insulin when taken with a mixed meal in the afternoon 
(second meal of the day). 
 To investigate whether a single serving of DC taken with a mixed meal in the 
morning has a carry-over effect on the second meal postprandial glucose and 
insulin responses. 
 To investigate whether there is any effect of repeated doses of DC on the 
postprandial glucose and insulin responses. 
5.3 Methods 
This study was carried out with the assistance of two undergraduate students, Eithne 
McGonigle and Olivia Chesterman, as their final year project.  
5.3.1 Participants 
Participants were recruited from the student population at the University of Surrey by 
word of mouth, poster advertisement and internal emails. Written informed consent 
was obtained from all participants. The study was given a favourable ethical opinion 
by the University of Surrey Ethics Committee (EC/2012/110/FHMS). Recruitment and 
data collection were carried out between December 2012 and March 2013. 
Participants were required to be healthy adults, aged 18 - 40 y, taking no prescription 
medication other than oral contraceptives. They were required to be weight stable and 
to have no history of heart disease, diabetes, liver disease or any gastrointestinal or 
endocrine disorders. They were ineligible if they were regular smokers. Women not 
using hormonal contraceptives were excluded from the study, as women display 
variability in their glycaemic response throughout the menstrual cycle with impaired 
glucose metabolism having been observed during the luteal phase (206). All participants 
were required to be habitual coffee drinkers, with a minimum intake of four cups per 
week. Ten participants were recruited to the study, consistent with that recommended 
for GI testing (173).  
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5.3.2 Study design 
A four-way open-label randomised crossover study comparing the effects of DC with 
a control on the postprandial glycaemic response to a mixed meal at different times of 
day. 
5.3.3 General protocol 
Potential participants were invited to attend a screening session (detailed in Chapter 2) 
where the study was explained to them in detail. If they fulfilled the inclusion criteria, 
and decided to take part in the study, a date was set for their first study day. 
Each participant attended four study days each lasting approximately 6 h. On each 
study day they consumed a standardised study meal along with a test drink for 
breakfast and lunch. Capillary blood samples were taken for 2 h following each meal. 
The detailed study day protocol can be found in Section 5.3.3.3.  
There were four different drink combinations (Table 5.3.3-1) with participants receiving 
each of the combinations over the course of the four study days. A random sequence 
generator (https://www.random.org/sequences/) was used to generate the order for 
each participant. Study days were separated by a washout period of at least three days 
and participants were given £100 on completion of the trial, as compensation for their 
time. 
  
 Test drink composition 
The test drink was either DC or a control drink (water). The DC consisted of 2 g instant 
DC granules dissolved in 100 ml boiling water and made up to 200 ml with cold water 
to facilitate rapid consumption. It was sourced from the same batch of commercially 
available DC (Kenco Decaff) used in the dose-response study (Chapter 4). The control 
drink was 200 ml cold water.   
 
Table 5.3.3-1  Test drink combinations. 
Combination Breakfast Lunch
1 Control Control
2 DC Control
3 DC DC
4 Control DC
Test drink
DC: decaffeinated coffee. 
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 Study meal composition 
A standardised study meal consisting of cornflakes, milk, yoghurt and sugar was given, 
along with the test drink, for both breakfast and lunch on each study day. Details of the 
study meal are provided in Table 5.3.3.2-1. 
 
 Study day protocol 
The timeline for the study day is provided in Figure 5.3.3.3-1. 
 
 
For two days prior to each study day the participants were asked to refrain from 
exercise and all caffeine-containing food and drinks. On the day prior to each study 
day they were also asked to avoid alcohol. They were provided with a standardised 
meal to consume on the evening prior to each study day, a vegetarian lasagne (Tesco, 
Italian range, 450 g) providing 509 kcal, 14.5 g protein, 26.0 g fat, 51.9 g CHO and 
4.8 g fibre.  
After a 12 h overnight fast, participants arrived at the CIU between 8:00 and 9:00 am. 
They provided a baseline fasted capillary blood sample via the finger-prick technique. 
They then consumed their first test drink of the day along with the study meal and 
provided further capillary blood samples over the next 2 h (taken at 15, 30, 60, 90 and 
120 min time-points from the start of the meal).  
Figure 5.3.3.3-1  Study day timeline for the repeated-dose study. 
CHO: carbohydrate. 
Table 5.3.3.2-1  Standardised study meal composition. 
Meal items
Portion size 
(g)
Energy
(kcal)
CHO
(g)
Fat
(g)
Protein
(g)
Kellogg's Corn Flakes® 50 189 42 0 4
Semi-skimmed milk 225 113 11 4 8
Sugar 8 32 8 0 0
Activia® Pouring Yoghurt, vanilla 150 99 14 2 5
Total 433 75 7 17
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This process was then repeated for the lunchtime drink and meal, with the second 
baseline sample taken at 200 min, the meal taken at 215 min and subsequent samples 
at 230, 245, 275, 305 and 335 min time-points. Each study session lasted 
approximately six hours, during which time the participants were required to stay in the 
CIU.  They were permitted to bring work/books/laptops with them but were required to 
minimise physical activity.  
5.3.4 Blood Collection 
All blood samples were taken by finger prick with the use of a lancing device and 
collected into heparin fluoride microvette tubes (Sarstedt, Leicester, UK). These were 
refrigerated until the end of the study day then centrifuged and the plasma transferred 
into serum microvette tubes (Sarstedt, Leicester, UK). Plasma glucose concentrations 
were then measured using the YSI 2300 STAT PlusTM (YSI Life Sciences, UK). 
Following glucose analysis, the plasma was frozen at -20 ºC until the end of the study 
for subsequent batch analysis of insulin by ELISA, as described in Chapter 2.  
5.3.5 Statistical analysis 
All statistical analysis was carried out using SPSS Statistics software, version 22. The 
Shapiro-Wilks test was used to check normality of data. Paired t tests were used for 
comparisons between treatments when the data were normally distributed and the 
equivalent non-parametric tests were used when they were not. Time-point data were 
analysed by RM ANOVA. Statistical significance was taken as a p-value < 0.05. 
A sample size of 10 was chosen in line with that recommended for GI testing, however 
a post hoc power calculation revealed the study to be underpowered to detect a 
difference in insulin. In order for the observed differences in insulin to be statistically 
significant at 80% power, would have required in excess of 34 participants (based on 
IAUC results from the repeated dosing comparison, Section 5.4.2.5). 
The following combinations were compared to test the specific aims of the study: 
 The means of combinations 1 and 4 (control first) and 2 and 3 (DC first) for the 
morning meal only, were compared to examine whether there was any effect 
of DC versus control on the morning meal glycaemic and insulinaemic 
responses. 
 Combinations 1 (control/control) and 4 (control/DC) were compared to test for 
an effect of lunchtime coffee on the glycaemic response to the second meal. 
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 Combinations 1 (control/control) and 2 (DC/control) were compared to examine 
whether there was any carry-over effect of morning DC on the glycaemic 
response to a second meal. 
 Combinations 1 (control/control), 2 (DC/control) and 3 (DC/DC) were compared 
for evidence of a repeated-dose effect. 
 
5.4 Results 
5.4.1 Baseline characteristics 
Participants were healthy females (n=10) with a mean age of 21 y (SD 2) and BMI of 
21.6 kgm-2 (SD 2.1). Baseline characteristics are reported in Table 5.4.1-1. All were 
regular coffee drinkers with a mean weekly coffee intake (CC and DC combined) of 16 
servings (range: 4 – 42) and a mean daily caffeine intake of 312 mg (range: 158 – 559 
mg). Fasted glucose, insulin, HOMA2_%B and HOMA2_%S are reported as the mean 
values for all visits. 
 
  
BMI: body mass index; CC: caffeinated coffee; HOMA: Homeostatic 
model of assessment; %S: sensitivity; %B: beta cell function. 
Table 5.4.1-1  Baseline participant characteristics. 
Mean (n=10) SD
Age (y) 21 2
Height (m) 1.65 0.06
Weight (kg) 58.8 7.6
BMI (kgm-2) 21.6 2.1
Body fat (%) 21.7 4.4
Fasted plasma glucose (mmol/L) 4.8 0.3
Fasted plasma insulin (pmol/L) 27 23
HOMA2_%B 67 25
HOMA2_%S 275 232
Daily CC intake (servings/day) 2.2 1.9
Daily caffeine intake (mg/day) 312 139
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5.4.2 Glucose and insulin 
The majority of the glucose time-point data were normally distributed; log 
transformation of the time-points did not result in all data being normally distributed. 
As 44/48 time-points were normally distributed, parametric tests were carried out on 
the original dataset for glucose. The majority of the insulin time-point data (28/48) were 
not normally distributed; log transformation resulted in most (42/48) being normally 
distributed. Parametric tests were therefore carried out on the log-transformed insulin 
time-point data. Measures of insulin sensitivity and beta cell function were calculated 
as described in Chapter 2. None were normally distributed, either before or after log 
transformation; non-parametric tests were carried out on this data. 
Glucose and insulin values at 200 min were used to calculate HOMA2_%B and 
HOMA2_%S for the afternoon session. Although the participants were not fully fasted 
at 200 min, this was the last measure taken prior to the second meal. Furthermore, 
glucose and insulin values had returned to fasted levels at this time-point for 3 of 4 
treatments with no significant differences between 0 and 200 min measures for insulin 
or glucose for any treatment, but a trend for higher glucose (+0.15 mmol/L) at 200 min 
for treatment 4 (p=0.053). As in the dose-response study (Chapter 4), fasted glucose 
values all fell within the acceptable range for the HOMA2 calculator but insulin did not. 
All values were included in the analysis however, as we were interested in relative 
values rather than absolute. 
  
Chapter 5. 
102 
 
 Circadian rhythms in postprandial glucose and insulin response 
Mean glucose values were higher 120 min after the second meal (335 min time-point) 
than 120 min after the first meal (RM ANOVA, p=0.002), indicating a time-of-day effect, 
however there was no difference in the change between treatments (treatment * time, 
p=0.823). There were no significant differences between pre-meal glucose values (0 
and 200 min) for any treatment, but there was a trend for a difference for treatment 1 
(control/control), where mean fasted glucose was 0.15 mmol/L higher at 200 min 
(paired t test, p=0.053). The postprandial glucose response across both meals for all 
treatments is shown in Figure 5.4.2.1-1. 
 
 
 
  
Figure 5.4.2.1-1 Postprandial glucose response over the course of two meals for each of four 
drink combinations. 
Baseline blood samples were taken at -15 and 200 min followed by the standardised study meals which 
were taken, along with the study drinks, at 0 and 215 min. Glucose values were higher 120 min after the 
second meal than after the first (RM ANOVA, p=0.002). Error bars are SEM (n=10). 
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Similarly for insulin, mean values were higher 120 min after the second meal than after 
the first meal (RM ANOVA, p=0.003), with no difference in the change between 
treatments (treatment * time, p=0.868), indicating a time-of-day effect on insulin 
response. There were no significant differences between pre-meal insulin values (0 
and 200 min) for any drink combination. The postprandial insulin response across both 
meals for all treatments is shown in Figure 5.4.2.1-2. 
 
 
 
  
Figure 5.4.2.1-2 Postprandial insulin response over the course of two meals for each of four drink 
combinations. 
Baseline blood samples were taken at -15 and 200 min followed by the standardised study meals which 
were taken, along with the study drinks, at 0 and 215 min. Insulin values were higher 120 min after the 
second meal than after the first (RM ANOVA, p=0.003). Error bars are SEM (n=10). 
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 Effects of decaffeinated coffee at a morning meal 
The means of time-points and IAUCs were calculated for treatments 1 and 4 (control 
at breakfast) and for 2 and 3 (DC at breakfast) in order to compare the effects of DC 
with control on the postprandial glucose and insulin response to the morning meal.  
There were no significant differences between treatments for plasma glucose IAUC 
over either the first 120 or 200 min (paired t test, p>0.434), nor were there any 
differences when the time-points were compared over the same periods (RM ANOVA, 
p>0.352). The mean postprandial glucose response for each treatment is shown in 
Figure 5.4.2.2-1. 
 
 
There were also no significant differences between treatments for plasma insulin IAUC 
over either the first 120 or 200 min (Wilcoxon Signed Rank, p>0.168), nor were there 
any differences when the time-points were compared over the same periods (RM 
ANOVA, p>0.445). The mean postprandial insulin response for each treatment is 
shown in Figure 5.4.2.2-2. There were no significant differences between DC and 
control for any of the insulin sensitivity and beta cell function parameters (Wilcoxon 
Signed Rank, p>0.138). 
 
Figure 5.4.2.2-1  Postprandial glucose response to a mixed meal taken with either decaffeinated 
coffee or control. 
There were no differences between treatments over the first 120 or 200 min for either IAUC (paired t test, 
p>0.434) or time-point data (RM ANOVA, p>0.352). DC: decaffeinated coffee. Error bars are SEM 
(n=10). 
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Figure 5.4.2.2-2  Postprandial insulin response to a mixed meal taken with either decaffeinated 
coffee or control. 
There were no differences between treatments over the first 120 or 200 min for either IAUC (Wilcoxon 
Signed Rank, p>0.168) or time-point data (RM ANOVA, p>0.445). DC: decaffeinated coffee. Error bars 
are SEM (n=10). 
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 Effect of decaffeinated coffee at lunchtime 
 There was no difference in either IAUC (Wilcoxon Signed rank test, p>0.138) or time-
point data (RM ANOVA, p>0.371) between treatments 1 (control/control) and 4 
(control/DC) for the postprandial glucose and insulin responses to the second meal. 
There was however an effect on HOMA2_%B (Wilcoxon Signed Rank, p=0.037), with 
higher values observed for DC at lunchtime (78.2, SD 36.0) than control (60.6, SD 
21.3). There was also a trend for an effect on the AUCI/G ratio (Wilcoxon Signed Rank, 
p=0.074), with DC at lunchtime resulting in a higher AUCI/G ratio (20.9, SD 9.7) than 
control (18.5, SD 7.6). The postprandial glucose and insulin responses to the two 
treatments are shown in Figure 5.4.2.3-1. 
 
Figure 5.4.2.3-1  Postprandial glucose and insulin responses to breakfast and lunch, when the 
lunchtime meal is accompanied by either decaffeinated coffee or control. 
There were no differences between treatments for either IAUC (p>0.138) or time-point data (p>0.371), for 
glucose (A) or insulin (B), following the second meal. DC: decaffeinated coffee. Error bars are SEM (n=10). 
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 Effects of morning decaffeinated coffee on the postprandial response 
to a subsequent meal 
There were no differences in either IAUC (glucose: paired t test, p=0.535; insulin: 
Wilcoxon Signed rank, p=0.799) or time-point data (RM ANOVA, p>0.673) or any 
insulin sensitivity or beta cell function measures (Wilcoxon Signed Rank, p>0.332), 
over the entire study day (0-335 min), between treatments 1 (control/control) and 2 
(DC/control), nor were there any differences in any measure when the morning 
(p>0.113) and afternoon (p>0.284) meals were examined separately. The postprandial 
glucose and insulin responses to the two treatments are shown in Figure 5.4.2.4-1. 
 
Figure 5.4.2.4-1  Postprandial glucose and insulin responses to breakfast and lunch, when 
breakfast is accompanied by either decaffeinated coffee or control. 
There were no differences between treatments for either IAUC (p>0.534) or time-point data (p>0.673), for 
glucose (A) or insulin (B), over the entire study day. DC: decaffeinated coffee. Error bars are SEM (n=10). 
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 Effect of multiple doses of decaffeinated coffee 
There was no difference between either IAUC (glucose: paired t test, p=0.396; insulin: 
Wilcoxon Signed rank, p=0.333) or time-point data (RM ANOVA, p>0.153) over the 
entire study day (0-335 min), between treatments 1 (control/control), and 3 (DC/DC) 
for glucose or insulin. Nor was there any difference in any measure when the results 
for the morning meals were compared (p>0.168). There was however a trend for an 
effect on the insulin time-point data following the second meal (RM ANOVA, p=0.058) 
and a trend for an effect on the second meal AUCI/G ratio (Wilcoxon Signed Rank, 
p=0.074) with DC at breakfast and lunchtime resulting in a lower insulin response and 
a lower AUCI/G ratio than control. The postprandial glucose and insulin responses to 
the two treatments are shown in Figure 5.4.2.5-1. 
Figure 5.4.2.5-1  Postprandial glucose and insulin responses to breakfast and lunch, when both 
meals are accompanied by either decaffeinated coffee or control. 
There were no differences between treatments for either IAUC (p>0.332) or time-point data (p>0.153), for 
glucose (A) or insulin (B), over the entire study day. There was a trend for a lower insulin response to the 
afternoon meal following DC at both meals (p=0.058). DC: decaffeinated coffee. Error bars are SEM 
(n=10). 
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When one (treatment 2) and two doses (treatment 3) of DC were compared with control 
(treatment 1), there was no difference in either IAUC or time-point data (RM ANOVA, 
p>0.482) over the entire study day (0-335 min) for glucose or insulin. Nor were there 
any differences in insulin sensitivity or beta cell function measures between the three 
treatments (Friedman’s ANOVA, p>0.272). 
 
5.5 Discussion  
5.5.1 Circadian rhythms in postprandial glucose response 
A time-of-day effect, consistent with the literature, was observed with glucose and 
insulin levels being higher 120 min after the second meal than after the first. Glucose 
and insulin levels at 120 min were also higher than the fasted levels for all treatments 
which is perhaps surprising, given the study was carried out in young healthy women, 
however in most cases they had returned to fasted levels immediately prior to the 
second meal. 
5.5.2 Effect of decaffeinated coffee at morning meal 
There were no significant differences between DC and control for glucose or insulin 
over either the first 120 or 200 min, nor were there any differences for the insulin 
sensitivity and beta cell function measures. This lack of an effect of a single dose of 
DC on postprandial glucose and insulin response is in line with the majority of studies 
from the systematic review (Chapter 3), where 8/11 found no effect on glucose and 7/9 
found no effect on insulin. 
Of the studies that found an effect of DC on glucose, one observed a lower IAUC 
following DC in comparison with a control (10), one observed a greater glucose IAUC (8), 
and one reported higher glucose values at two time-points (0 and 30 min) following 
DC (126). Two of these three studies also observed an effect of DC on insulin, with one 
reporting a greater insulin AUC following DC (126) and the other observing that DC 
raised insulin more than control immediately after meal ingestion (8). 
As discussed in Chapter 3, methodologies varied considerably across studies with no 
apparent methodological explanation for the different results. All three studies that 
found an effect of DC on glucose and/or insulin used filter coffee at relatively high 
strength and volume, all took venous samples and all studied healthy males (n = 10 - 
11), so these parameters do not explain the conflicting results. Of the two that found 
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DC to raise glucose, one gave their DC concurrently with the meal (8) and the other 
gave it 60 min beforehand. A mix of habitual coffee drinkers and coffee-naïve 
participants were used. It is unlikely that a difference in caffeine content between DCs 
can explain the observed results, as both the study which found a decrease in glucose 
IAUC and the one that found an increase in IAUC measured plasma caffeine 
concentration throughout their tests and reported no difference at any time point 
between their DC and control legs. 
The increase in glucose observed in two studies was unexpected, as the impairment 
in postprandial glucose metabolism observed following CC is generally attributed to 
caffeine. It is possible that there are other unidentified coffee components that may 
also have a glucose raising effect, however it is perhaps more likely that these are 
chance results, given that most studies have found no acute effect of DC. Indeed, in 
the current study, when post hoc comparisons were made for each combination of 
control v DC for the morning meal (4 combinations of treatment: 1v2 / 1v3 / 4v2 / 4v3), 
a significant difference between treatments was observed for glucose IAUC over both 
120 min (paired t test, p=0.011) and 200 min (paired t test, p=0.039) for one of the four 
combinations. In the comparison of treatment 4 with 3, DC produced a higher glucose 
IAUC than control. Given that three of four comparisons produced no significant 
differences between control and DC, it seems likely, in this case, that this difference is 
due to daily variation in glycaemic response.  
The reduced glucose IAUC following DC, reported by Battram et al. may be a result of 
a high CGA content in their coffee, however this cannot be verified as the concentration 
was not reported. Interestingly, three of their participants (total n=11), were tested at 
lunchtime having had a light breakfast. They did not report whether these participants 
reacted differently to the others, but this may have been a confounding factor to their 
results given the previously suggested potential for lunchtime coffee to have a 
beneficial effect on reduction of T2DM risk. 
 Most of the previous studies that found no effect of DC used instant coffee, with doses 
ranging from 2 – 12 g. As the dose used in the current study was small, 2 g, with a low 
amount of total CGA (47 mg) and caffeine (3.2 mg), it is perhaps unsurprising there 
was no observable effect of a single acute dose at breakfast-time. 
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5.5.3 Effect of decaffeinated coffee at lunchtime 
 There was no significant difference in the postprandial response to the second meal 
between treatments 1 (control/control) and 4 (control/DC) for either glucose or insulin. 
There was however a difference in steady-state beta cell function, with treatment 4 
resulting in higher HOMA2_%B immediately prior to the lunchtime meal. There was 
also a trend for an effect on the AUCI/G ratio with DC at lunchtime resulting in a higher 
AUCI/G ratio than control.  
Post hoc analysis of the morning data revealed a difference in insulin between 
treatments at 200 min (Wilcoxon Signed Rank, p=0.028), with treatment 4 displaying 
higher insulin than treatment 1. A difference was also observed for the glucose data 
with treatment 4 producing a smaller IAUC over the first 120 min (paired t test, 
p=0.028).  
The difference in insulin observed at 200 min explains the difference in HOMA2_%B. 
However, as both treatments involved consumption of the control drink at breakfast, 
and the 200 min sample was taken immediately prior to the second test drink and meal, 
this difference must be attributed to normal daily variation in insulin, rather than an 
effect of DC. The trend for a difference in AUCI/G ratio may also be partially explained 
by the difference in 200 min insulin between the two treatments.  
There were no differences between treatments for the second meal postprandial 
glucose or insulin response, however post hoc analysis revealed a trend (p=0.060) for 
lower glucose at 245 min following DC (mean 6.95 mmol/l, SD 0.54) compared with 
control (mean 7.47 mmol/L, SD 0.74). This lower second meal peak following DC may 
be explained by normal daily variation in glucose response as the morning glucose 
IAUC was also lower for this treatment, however there was no difference in peak values 
in the morning. 
In summary, a slight reduction in peak postprandial glucose was observed following 
DC at lunchtime, which may be indicative of some beneficial effect of DC. This would 
support the epidemiology suggesting a protective effect of coffee at lunchtime on 
T2DM risk (91). However, the observed effect was small and may simply be a result of 
normal daily variation in glucose and insulin. To our knowledge, this has not been 
tested before, so further research is required before any conclusions can be drawn. 
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5.5.4 Effects of morning decaffeinated coffee on the postprandial response to 
a subsequent meal 
There was no effect of DC consumed with a morning meal on the postprandial glucose 
and insulin responses to a subsequent meal. There was no difference in any measure 
over the entire study day (0-335 min), between treatments 1 (control/control) and 2 
(DC/control), nor were there any differences in any measure when the morning and 
afternoon meals were examined separately.  
This is in contrast to Moisey et al. who, whilst they did not find an overall carry-over 
effect of DC on a second meal, did observe a trend for higher glucose IAUC (p=0.07) 
and a significantly higher glucose peak at 215 min (35 min after the start of their second 
meal/OGTT) for DC than for control (8). They also reported higher glucose IAUC after 
their morning meal for DC. There were several differences between the study protocols 
which might explain this discrepancy. Moisey and colleagues collected venous blood 
samples and recruited males, whereas the current study recruited females and 
collected capillary blood samples. The participants were however of a similar age and 
healthy BMI range in the two studies. Perhaps the most important difference between 
protocols was in the type and dose of coffee. Moisey et al. used a single large dose of 
filter coffee whereas a more typical single serving of instant coffee was given in this 
study. However, as discussed in Section 5.5.2, where the effects of DC at a morning 
meal were examined, these differences in study design are unlikely to explain the 
difference in results as another study with a very similar design to theirs reported a 
contrasting reduction in postprandial glycaemic response following a similar dose of 
DC (10).  
Additionally, in contrast to the current study, Moisey et al.’s participants’ glucose levels 
had returned to baseline values by 90 min following their first meal and appeared to 
exhibit a degree of reactive hypoglycaemia with values continuing to fall until 150 min 
and remaining below baseline at 180 min when they ate their second meal. Whilst the 
composition of their first meal (a high GI rice- and corn-based cereal with skimmed 
milk, providing 75 g available CHO) was comparable to that consumed in this study, 
the higher fat content of the current study meal may have slowed glucose absorption 
thus reducing the likelihood of reactive hypoglycaemia in this study.  
Moisey et al. calculated their second meal IAUC using their fasted (-13 min) value as 
a baseline, in contrast to the 200 min values used in the current study. This gave them 
an overall treatment p-value of <0.001 (one-way RM ANOVA) when comparing CC, 
DC and control, with post hoc analysis revealing a trend for a greater postprandial 
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response in DC than control (p=0.07). When they re-ran their analysis using their 180 
min values as baseline their overall p-value was reduced to a trend (p=0.07). They did 
not report results of any post hoc analysis, so it is unknown whether any difference 
between DC and control remained under this scenario. It is likely, however, that their 
trend for an overall effect of DC disappeared with this analysis. In contrast, the results 
of the current study did not change when the analysis was re-run using the fasted 
glucose values. 
Although Moisey et al. did not report either the CGA or caffeine content of their DC, it 
is likely that both will be higher than that consumed in the current study, due to the 
relatively large volumes of DC (535 - 812 ml). However, as discussed in Section 5.5.2, 
a higher caffeine dose is unlikely to explain their results as they reported no difference 
in plasma caffeine levels between DC and control at any time-point.  
Interestingly, examination of their data reveals an apparent reduction in the glucose 
peaks, for both DC and control, following the second meal in comparison with the first 
meal, although this was not tested statistically or discussed in their paper. This is 
somewhat anomalous with the increase in postprandial glycaemia that is normally 
observed throughout the day. Low GI and high RS breakfasts have been demonstrated 
to improve the postprandial glycaemic response to a standardised lunch in comparison 
to a high GI breakfast (207,208), but this is a relative improvement only, with an increase 
in postprandial glycaemic response between breakfast and lunch still being observed. 
As Moisey et al. reported their breakfast to be high GI, this apparent reduction in 
postprandial response at lunchtime is unusual, particularly as their second meal was 
a 75 g dextrose OGTT, which one would expect to result in a higher glucose excursion 
than a mixed meal. 
In summary, unlike Moisey et al., the current study found that DC consumed with a 
morning meal did not result in an increased postprandial glucose response to a second 
meal compared to control. To our knowledge, no other studies have investigated this. 
It should be noted however that Moisey et al. also observed an increased postprandial 
response with DC for their first meal. This is in contrast to the majority of studies, which 
have reported no effect of DC at a single meal. Additionally, the apparent reduction in 
postprandial glucose excursion at their second meal also contradicts the literature. 
Clearly, further research is required before drawing conclusions as to the presence or 
absence of a second meal effect of DC. 
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5.5.5 Effect of multiple doses of decaffeinated coffee 
There was no difference between either IAUC or time-point data over the entire study 
day (0-335 min), between treatments 1 (control/control), and 3 (DC/DC) for glucose or 
insulin. There was however a trend for an effect on the insulin time-point data and a 
trend for an effect on the AUCI/G ratio following the second meal, with DC at breakfast 
and lunch resulting in lower insulin secretion after the second meal. This may be 
indicative of a metabolic effect of multiple dosing. 
It may also indicate an effect of DC at lunchtime as was discussed in Section 5.5.3. 
However, if this is an effect of DC at lunchtime, it has manifested differently. When DC 
was consumed at lunchtime only (treatment 4), a reduction in the glucose peak 
response and an increase in the AUCI/G ratio was observed, whereas two doses of DC 
has resulted in no effect on glycaemic response and a reduction in the AUC I/G ratio. 
This may reflect actions of different coffee components, as the colonic metabolites 
from the first coffee dose would have been absorbed into the circulation by the time 
the second meal took effect, however, this is perhaps unlikely as there was no 
observed reduction in insulin at the second meal for treatment 2, which also gave DC 
at the first meal. 
There was no difference in either IAUC or time-point data over the entire study day 
(0 - 335 min), between treatments 1 (control/control), 2 (DC/control) and 3 (DC/DC) for 
glucose or insulin. Nor were there any differences in any insulin sensitivity or beta cell 
function measures, indicating no dose-response effect of DC when individual doses 
are taken with two meals. This is in line with the first study, reported in Chapter 4, 
which found no dose-response effect of increasing amounts of coffee at a single meal. 
As discussed in Chapter 4, it is likely, with 10 participants, that this study was also 
underpowered to find a dose-response effect.  
5.6 Study limitations 
As discussed previously, the DC was relatively low in total CGA content which may 
explain the lack of significant effect. The only study in the systematic review to analyse 
their coffee for CGA content found no effect of DC on glucose and insulin 
response (147); their DC provided 353 mg total CQA in a 12 g serving, making it perhaps 
unlikely that the current study would demonstrate an effect with its much lower CQA 
content (47 mg).  
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For practical reasons, the effects of two servings given more than three hours apart 
were examined. It is possible that more of an effect would be observed from more 
frequent servings across a longer study day, particularly as the glycaemic response 
deteriorates later in the day.  
Individuals vary in their glycaemic response from day to day, so many studies that 
measure GI test subjects on more than one occasion to minimise this effect (209). If 
each test had been repeated, one could be more confident that the observed effects 
were a genuine effect of the treatment. However as previously noted, this study was 
designed as an undergraduate final year project and thus had certain time constraints. 
5.7 Conclusion 
In contrast to the first study, where an increase was observed in the postprandial 
glycaemic response following a single serving of CC, the current study found no effect 
of a single, “normal” serving of instant DC on postprandial glucose and insulin 
responses to a mixed meal in young healthy women. This supports the hypothesis that 
a “normal” serving of DC would have no effect on the postprandial glycaemic response. 
It is also in agreement with the majority of previous studies which have reported no 
acute effects of a single larger serving of DC. There was also no carry-over effect of 
morning DC, in contrast to Moisey et al., who reported an increased postprandial 
response to a second meal following morning DC. However, as previously discussed, 
Moisey et al. were also one of the few groups to find an effect of morning DC. With no 
other studies for comparison, it is not possible at present to determine whether a carry-
over effect exists. 
Some interesting trends were observed for an effect of DC at lunchtime, with a single 
lunchtime serving resulting in a reduction in postprandial glycaemic peak and two 
servings of DC, taken at breakfast and lunch, resulting in a reduced postprandial 
insulin response to the lunchtime meal. To our knowledge, this is the first study to 
investigate the effects of lunchtime DC and the effects of repeated dosing, so it is quite 
possible that the findings are not reflective of a true effect of DC and are instead a 
result of random daily variation in response. It should also be noted that the magnitude 
of the observed effect was small, so it is perhaps questionable whether this effect is 
physiologically relevant.  Nevertheless, if verified by future studies, these beneficial 
effects of lunchtime DC may partly explain the reduction in T2DM risk associated with 
lunchtime coffee drinking. 
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Whilst it appears that a single acute dose of DC in the morning has little effect on the 
postprandial glycaemic and insulinaemic responses, it is not clear whether it has any 
effects when taken later in the day. Further investigations examining the effects of 
more frequent dosing, continuing later in the day, are recommended. This would more 
closely reflect normal coffee consumption patterns and would provide a more accurate 
picture of the acute effects of coffee drinking throughout the day.  
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6.1 Introduction 
There have been few longer-term intervention studies into the effects of coffee on 
glucose metabolism. The majority of these have examined the effects in habitual coffee 
drinkers (11–13) and have examined the effects on fasted glucose and insulin levels, not 
the postprandial response. It could be argued that habitual coffee drinkers will already 
have gained any potential longer-term benefits of coffee drinking and may therefore 
not be the most appropriate population to study; however, despite this, there have 
been very few interventions in coffee-naïve individuals.   
One study, which did examine the effects of coffee in non-coffee drinkers, observed a 
reduction in the postprandial glycaemic response to an OGTT, following a 16-week 
intervention where participants drank five cups of coffee per day (112). This reduction 
was observed for both CC and DC. 
It should also be considered that any potential beneficial effects of coffee, in terms of 
reducing risk of developing T2DM, may not be directly related to glucose metabolism, 
but may be through actions on other risk factors related to development of T2DM, such 
as features of the MS. Metabolic Syndrome is characterised by a combination of 
disorders which increase the risk of developing T2DM. These include raised fasted 
glucose, raised TAG, low HDL cholesterol and raised BP.  
Gender differences have been reported in glucose and lipid metabolism; men having 
been observed to have higher fasted glucose, higher postprandial insulin and TAG, 
less postprandial NEFA suppression and lower fasted TAG and HDL cholesterol than 
women (210–212). There is also potential for coffee to affect men and women differently 
as several epidemiological studies have reported differences between the genders 
with respect to coffee drinking and T2DM risk (213,214). To date, however, no longer-term 
intervention has examined whether coffee drinking differentially affects men and 
women with respect to glucose metabolism. 
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6.2 Aims 
The primary aim of this study was to investigate the effects of 12 weeks of CC 
consumption on glucose metabolism and features associated with the MS in coffee-
naïve individuals.  
A secondary aim was to investigate whether men and women reacted differently to the 
intervention. 
A further secondary aim (covered in Chapter 7) was to examine whether there were 
any differences between slow and fast caffeine metabolisers, both at baseline and in 
their response to the intervention. 
6.3 Methods 
6.3.1 Participants 
Participants were recruited from the student and staff population at the University of 
Surrey and from the local community, by word of mouth, poster advertisement and 
internal emails. Written informed consent was obtained from all participants. The study 
was given a favourable ethical opinion by the University of Surrey Ethics Committee 
(EC/2013/68/FHMS) and registered with the ISRCTN, trial number ISRCTN42321643 
(http://www.controlled-trials.com/). Recruitment and data collection were carried out 
between September 2013 and July 2014. 
Participants were required to be healthy adult males and females, aged over 18 y, 
taking no prescription medication other than oral contraceptives. They had to have 
been weight stable for the previous 3 months and to have no history of heart disease, 
diabetes, liver disease or any gastrointestinal or endocrine disorders. They were 
ineligible if they were regular smokers or if they drank more than 4 cups per week of 
either tea or coffee.  
6.3.2 Study design 
A 12 week open-label parallel-arm intervention investigating the effects on non-coffee 
drinkers of drinking 4 cups of caffeinated coffee per day on various risk factors for 
T2DM. 
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6.3.3 General protocol 
The timeline for the study is shown in Figure 6.3.3-1. 
 
 
Potential participants were invited to attend a screening session (detailed in Chapter 2) 
where the study was explained to them in detail. If they fulfilled the inclusion criteria 
and decided to take part in the study, a date was set for their first study day. They were 
given some instant CC portions to take home and instructed to commence a two day 
CC trial (Section 2.3.3.1), 16 days before their first study date. They were contacted 
by telephone after they had completed the two day trial to find out whether they had 
suffered any adverse effects of the CC and to confirm they still wanted to take part in 
the study. If they wished to continue they were then fully enrolled onto the study. They 
then undertook a 14 day caffeine-washout period, where they were instructed to 
abstain from all caffeine-containing foods and drinks, such as tea, coffee, energy 
drinks and chocolate. They were advised not to drink decaffeinated teas and coffees 
as these also contain small amounts of caffeine.  
Participants were randomised to either the CC or control group prior to their first study 
day using a stratified random block design to ensure sufficient numbers in each group 
and an even split of males and females. Thirty participants were recruited in total, with 
20 allocated to the CC intervention and 10 to the control group. One from the CC group 
dropped out immediately prior to their second study day for personal reasons, resulting 
in 29 participants completing the trial. 
After the 14 day washout period each participant attended their first study day. Details 
of the study day protocol are provided in Section 6.3.3.3. At the end of the study day, 
they were notified of their allocated group and given instructions for the following 12 
weeks. The CC group were given a supply of individual CC portions and asked to 
consume four per day, for the next 12 weeks and to continue to refrain from all caffeine-
containing food and drinks, apart from the supplied CC, for the duration of the study; 
the control group were instructed to remain caffeine-free during this period.  
Figure 6.3.3-1  Study timeline for 12 week coffee intervention. 
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During the trial, all participants were randomly visited either once or twice, with little 
advance notice, and asked to provide a saliva sample which was later analysed for 
caffeine content in order to monitor compliance. 
At the end of the trial, participants in the CC group were instructed to stop drinking the 
supplied CC two days before their final study day to ensure they were completely 
caffeine-free for the study day. The procedure for the second study day was identical 
to the first, except that no buccal swabs were taken. The coffee group were instructed 
to return all unused CC portions. Participants were given £150 on completion of the 
trial, by way of thanks for their participation. 
 Two day trial 
Before starting the intervention, all participants underwent a two day trial to check for 
any adverse effects of the CC and to ensure they were able to comply with the 
requirements of the intervention. They were given eight individual portions of instant 
CC and instructed to consume four per day over two days.  They were instructed to 
dissolve the CC granules in a cup of hot water and to drink the CC without addition of 
milk or sugar. They were free to choose the timing of their drinks, but were advised to 
spread consumption throughout the day and to try to consume them all before 4 pm to 
avoid any potential sleep disturbance from the caffeine. They were followed up after 
the trial to check whether they had suffered any adverse effects and to confirm whether 
they still wished to take part in the study. 
 Coffee portions 
The coffee portions used in this study were a commercially available instant CC (Carte 
Noire, Jacobs Douwe Egberts GB Ltd, UK). Each portion contained 2 g instant CC 
granules, the equivalent of a teaspoon. The coffee was analysed by Sciantec 
Analytical Services (Selby, UK) for caffeine, trigonelline and CGA content (detailed in 
Table 6.3.3.2-1) and for total and free CHO content (see Appendix 4). 
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  Study day protocol 
For two days prior to each study day, the participants were asked to refrain from 
exercise and all caffeine-containing food and drinks. On the day prior to each study 
day they were also asked to avoid alcohol. They were provided with a standardised 
meal to consume on the evening prior to each study day, which comprised of macaroni 
cheese (Tesco, Italian range, 450 g) providing 784 kcal, 31.2 g protein, 35.2 g fat, 
80.5 g CHO and 10.1 g fibre.  
After a 12 h overnight fast, participants arrived at the SCRC between 8:00 and 9:00 
am. After a ten minute rest, BP, weight and body composition were measured and a 
buccal swab was taken for later DNA analysis (first visit only) according to the methods 
set out in Chapter 2. A cannula was inserted into an antecubital vein by a trained 
phlebotomist and an initial fasted blood sample was taken. Participants then consumed 
the liquid meal within 10 minutes. Further venous blood samples were taken at 15, 30, 
60, 90, and 120 minutes after the first mouthful of the liquid meal. Each study session 
lasted approximately 3 h, during which time the participants were required to stay in 
the SCRC.  They were permitted to bring work/books/laptops with them but were 
required to minimise physical activity. 
 Liquid meal 
The liquid meal consisted of 2 x 200 ml bottles of Fortisip (Nutricia, Trowbridge, UK). 
Participants were allowed to choose from three flavours, toffee, vanilla and banana on 
the first study day, which they then had to repeat at the second study day. The 
macronutrient composition of the meal is reported in Table 6.3.3.4-1. 
Table 6.3.3.2-1  Instant coffee analysis. 
Compound (%)
Amount per 
portion (mg)
Caffeine 2.19 43.8
Trigonelline 0.73 14.5
3-CQA 0.55 10.9
4-CQA 0.68 13.5
5-CQA 0.85 16.9
3,4-diCQA 0.04 0.8
3,5-diCQA 0.05 1.0
4,5-diCQA 0.03 0.6
Chlorogenic Acid (Total) 2.18 43.6
CQA: caffeoylquinic acid 
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 Blood Collection 
All blood samples were taken by an experienced phlebotomist. Serum samples were 
collected into Z Serum Separator Clot Activator Vacuette tubes and plasma samples 
into heparin fluoride tubes. Serum samples were left to stand at room temperature for 
30 min to allow clotting before being transferred onto ice. Plasma samples were put 
straight onto ice. At the end of the study day all samples were centrifuged and aliquoted 
into storage tubes before being frozen at -20 oC until they were batch analysed at the 
end of the study. 
6.3.4 Statistical analysis 
All statistical analysis was carried out using SPSS Statistics software, version 22. The 
Shapiro-Wilks test was used to check normality of data. One- and two-way RM ANOVA 
was used to compare groups over all time-points. Individual time-point data were also 
analysed to determine the source of statistical differences for purposes of hypothesis 
generation. T tests were used for comparisons between groups when the data were 
normally distributed and the equivalent non-parametric tests were used when they 
were not. Fisher’s Exact tests were used for assessment of independence of variables. 
Primary analysis compared the CC and control groups. Additional analysis included 
gender as a cofactor to investigate whether men and women reacted differently to the 
intervention, given the known gender differences in glycaemic and lipidaemic 
response. Statistical significance was classed as a p-value < 0.05. 
Table 6.3.3.4-1  Liquid test meal macronutrient composition. 
Macronutrient
Amount in 
meal
Macronutrient as % 
of total energy
Energy (kcal) 600
Protein (g) 24 16
Fat (g) 23 35
Saturated fat (g) 2 4
Carbohydrate (g) 74 49
Sugars (g) 27 18
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6.4 Results 
6.4.1 Participant compliance 
Salivary caffeine 
Participant compliance was assessed by measurement of caffeine in random saliva 
samples. All participants provided at least one sample, with 79% of the CC group and 
70% of the controls providing two. Within the CC group, all participants had at least 
one sample with a caffeine concentration over 3 µM; three had one sample less than 
1 µM. In the control group, all samples were less than 1 µM. The mean salivary caffeine 
concentrations for each participant are shown in Figure 6.4.1-1; panel A displays the 
concentrations for all participants, whereas panel B displays the participants with 
concentrations less than 10 µM, allowing the spread of concentrations at this lower 
level to be displayed more clearly. 
 
Coffee portions  
In the CC group, the number of returned CC portions was used to determine daily 
intake. Median daily intake was 3.9 servings (97.5% of target), with individual 
participant mean daily intakes ranging from 3.5 – 4.3 servings/day. 
Figure 6.4.1-1  Mean salivary caffeine concentrations.  
Each point represents the mean caffeine concentration for one participant. Panel A: caffeine 
concentrations for all participants (n=27); panel B: participants with caffeine concentrations < 10 uM. 
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6.4.2 Genotyping 
Participant DNA, extracted from buccal swabs taken at the first study day, was 
genotyped for the rs762551 SNP in the CYP1A2 gene (method detailed in Chapter 2). 
The allelic discrimination plot for the assay is shown in Figure 6.4.2-1. 
 
The distribution of genotypes was as expected within the population and did not 
deviate from the Hardy-Weinberg equilibrium according to a Pearson χ2 test with 1 df 
for either the Asian (p=0.439) or Caucasian (p=0.592) participants. There were two 
participants with the C/C genotype, both of which had been randomised to the control 
group. Although one C allele is deemed sufficient to be considered a slow caffeine 
metaboliser (155), it has been suggested that this A/C genotype confers an intermediate 
phenotype to A/A (fast) and C/C (slow); this has been demonstrated when phenotyping 
is based on caffeine clearance ratios, where a trimodal distribution has been 
observed (215).  It was therefore decided to exclude the two C/C participants from all 
analyses because both were in the control group, resulting in an imbalance between 
coffee and control groups for this genotype, which could bias the data when comparing 
groups. The removal of these two participants from the control group resulted in a more 
equal balance of genotypes between groups.  The A/C genotype will be considered to 
confer a slow phenotype for the remainder of this thesis.  
  
Figure 6.4.2-1  Allelic discrimination plot for the rs762551 SNP of the CYP1A2 gene.  
The plotted points represent the genotypes allocated to each of the study participants (n=27). 
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Most of the CC group (52.6%) were fast metabolisers, whereas only 37.5% of the 
control group were, however this difference was not statistically significant (Fisher’s 
Exact, p=0.678). The majority of females were slow metabolisers (69.2%), whereas 
most males were fast metabolisers (64.3%), but this difference in the proportion of fast 
to slow metabolisers between males and females again was not statistically significant 
(Fisher’s Exact, p=0.128). The relative proportion of Caucasian to Asian participants 
was not statistically different between fast and slow metabolisers (Fisher’s Exact, 
p=1.000); nor were there any significant differences in ethnic distribution between CC 
and control groups (Fisher’s Exact, p=1.000). The distribution of genotypes and 
ethnicities across treatment group is reported in Table 6.4.2-1. 
 
6.4.3 Participant characteristics 
Baseline values for age, height, weight, SBP, DBP, BMI and body fat percentage were 
examined. All anthropometric data were normally distributed apart from age. There 
were no statistically significant differences between CC and control groups at baseline 
(p>0.388). When genders were compared there were differences between males and 
females, with males having a lower body fat percentage (p=0.002) and higher fasted 
glucose (p=0.047) and SBP (p=0.030) than females. There were no significant 
differences between control and CC groups for any of the tested parameters for either 
females (p>0.150) or males (p>0.062). The baseline participant characteristics are 
reported in Table 6.4.3-1. 
Table 6.4.2-1  Number of participants in each group, split by gender, genotype and ethnicity. 
Allocation Gender
Number of 
participants A/A (fast) A/C (slow) Caucasian Asian
Coffee Male 10 7 3 6 4
Female 9 3 6 5 4
Coffee group total 19 10 9 11 8
Control Male 4 2 2 3 1
Female 4 1 3 2 2
Control group total 8 3 5 5 3
Genotype (phenotype) Ethnicity
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Pre-intervention coffee and caffeine intake 
Pre-intervention coffee and caffeine intake were estimated as described in Section 
2.2.2; neither were normally distributed. Median caffeine intake was 80 mg per week 
(range 0 – 410 mg) and median coffee intake was zero servings per week (range 0 – 
4 servings) for all participants. There were no significant differences between CC and 
control groups for either caffeine or coffee intake (Mann-Whitney U, p>0.549). 
 
6.4.4 Comparison of coffee and control groups 
 Anthropometrics 
Weight, body fat, BMI, SBP and DBP were measured at each of the two study visits. 
There were no within-group (paired t test, p>0.267) or between-group (RM ANOVA, 
p>0.216) differences. Changes between the two visits are reported in Table 6.4.4.1-1. 
There was high inter-individual variation in these measures. 
 
BMI: body mass index; BP: blood pressure. 
Table 6.4.3-1  Baseline participant characteristics by treatment group and gender. 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age at start (y) 22 2.5 25 7.2 24 5.6 26 5.3 26 10.0 26 7.4
Height (m) 1.64 0.05 1.74 0.09 1.69 0.09 1.70 0.10 1.64 0.09 1.67 0.09
Weight (kg) 58.7 8.0 74.7 11.6 67.1 12.8 67.8 19.7 61.2 9.6 64.5 14.7
Systolic BP (mmHg) 114 6.3 125 9.6 120 9.9 117 11.7 116 7.3 117 9.0
Diastolic BP (mmHg) 72 4.5 73 7.8 72 6.3 74 12.4 70 8.2 72 9.9
BMI (kgm
-2
) 21.8 2.2 24.8 3.1 23.4 3.0 23.0 4.0 22.8 2.7 22.9 3.1
Body fat % 25.3 6.6 18.1 7.5 21.5 7.8 29.1 10.3 13.8 4.5 21.5 11.0
Fasted glucose (mmol/L) 4.5 0.5 4.8 0.3 4.6 0.4 4.4 0.3 4.7 0.3 4.6 0.3
Fasted insulin (pmol/L) 65 24 69 24 67 23 56 24 55 13 55 12
Coffee group Control group
Female (n=9) Male (n=10) All (n=19) Female (n=4) Male (n=4) All (n=8)
Table 6.4.4.1-1  Changes in anthropometric measures between the 
two study visits by treatment group. 
BMI: body mass index; BP: blood pressure.  
Mean change SD Mean change SD
Weight  (kg) 0.1 2.0 1.0 2.2
BMI (kgm-2) 0.1 0.7 0.4 0.8
Body fat % 0.0 1.8 0.6 1.9
Systolic BP (mmHg) -0.1 8.5 1.8 9.4
Diastolic BP (mmHg) -0.6 8.2 0.2 10.8
Control group (n=8)Coffee group (n=19)
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 Glucose 
All glucose time-point data were normally distributed apart from the 15 min sample on 
visit 2; log transformation of the time-points did not result in all data being normally 
distributed. As 11/12 time-points were normally distributed, parametric tests were 
carried out on the original dataset.  
 
Baseline data 
There were no differences between coffee and control groups at visit 1, either for fasted 
glucose (unpaired t test, p=0.792) or IAUC for the 2 h postprandial response (unpaired 
t test, p=0.906) nor was there any treatment * time effect (p=0.830) when the time-
points were analysed by RM ANOVA. The 2 h postprandial glucose response for each 
group is shown in Figure 6.4.4.2-1. 
 
 
  
Figure 6.4.4.2-1  Baseline postprandial glucose response by treatment group.  
There were no significant differences between treatments either for fasted glucose or IAUC (unpaired t 
test, p>0.791). Error bars are SEM (coffee group: n=19; control group: n=8). 
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When CC and control groups were combined, males had a higher fasted glucose 
(mean 4.75 mmol/L, SD 0.28) than females (mean 4.45 mmol/L, SD 0.46) at baseline 
(unpaired t test, p=0.047). There was no difference in baseline IAUC between genders, 
however there was a trend for an effect of gender when time-points were analysed 
(RM ANOVA, p=0.079). The 2 h glucose response for each gender is shown in Figure 
6.4.4.2-2. 
 
 
  
Figure 6.4.4.2-2  Baseline postprandial glucose response by gender.  
There was a significant difference between genders for fasted glucose (t test, p=0.047) and a trend for a 
difference between genders over all time-points (RM ANOVA, p=0.079). Error bars are SEM (males: 
n=14; females: n=13). 
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Effect of treatment 
Fasted glucose values were compared between groups and visits by one-way RM 
ANOVA. A within-group effect of visit was found (p=0.010), with both CC and control 
groups displaying an increase from visit 1 to 2, but there was no between-group 
difference (visit * treatment p=0.435). Adding gender as a cofactor did not change this 
result. Fasted glucose by visit and group is shown in Figure 6.4.4.2-3. 
 
 
  
Figure 6.4.4.2-3  Fasted glucose by visit and treatment group. 
There was a difference between visits for all participants (RM ANOVA, p=0.010), but no difference 
between groups. Error bars are SEM (coffee group: n=19; control group: n=8). 
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There was no difference between groups and visits in the postprandial period when 
the time-point data were analysed (one-way RM ANOVA, p>0.333). However, when 
the IAUCs were analysed, a within group effect was again found (one-way RM ANOVA, 
p=0.019), with both CC and control groups displaying a decrease from visit 1 to 2, but 
again there was no between-groups difference (visit * treatment, p=0.694), nor was 
there any effect of gender when it was added as cofactor. The 2 h glucose response 
for each visit, by group, is shown in Figure 6.4.4.2-4. 
 
 
Figure 6.4.4.2-4  Postprandial glucose response by visit and treatment group. 
Panel A: coffee; panel B: control. There was a difference in IAUC between visits for all participants (RM 
ANOVA, p=0.019), but no between groups difference. Error bars are SEM (coffee group: n=19; control 
group: n=8). 
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 Insulin 
Half (8/16) of the insulin time-point data were normally distributed; log transformation 
of the time-points resulted in all data being normally distributed. Parametric tests were 
therefore carried out on the log-transformed data.  
 
Baseline data 
There were no differences between CC and control groups at visit 1, either for fasted 
insulin (unpaired t test, p=0.307) or IAUC for the 2 h postprandial response (unpaired 
t test, p=0.293) nor was there any treatment * time effect (p=0.830) when the time-
points were analysed by one-way RM ANOVA. There were no differences between 
genders for any of the baseline measures (data not shown). The 2 h postprandial 
insulin response for each group is shown in Figure 6.4.4.3-1. 
 
 
  
Figure 6.4.4.3-1  Baseline postprandial insulin response by treatment group. 
There were no significant differences between treatments either for fasted insulin or IAUC (p>0.292). 
Error bars are SEM (coffee group: n=19; control group: n=8). 
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Effect of treatment on serum insulin 
Fasted insulin values were compared between visits and groups by one-way RM 
ANOVA. An effect of visit was found (p=0.011), in addition to a visit * treatment effect 
(p=0.015). Post hoc analysis revealed a trend for an increase in the control group after 
adjustment for multiple comparisons (paired t test, p=0.070), with no significant 
difference between visits for the CC group. Adding gender as cofactor did not affect 
the result. The change between visits is shown in Figure 6.4.4.3-2. 
 
  
Figure 6.4.4.3-2  Fasted insulin by visit and treatment group.  
RM ANOVA found an overall effect of visit (p=0.011), and a visit * treatment effect (RM ANOVA, p=0.015). 
Error bars are SEM (coffee group: n=19; control group: n=8). 
Chapter 6. 
133 
 
There was no difference in IAUC between groups over the two visits, but there was a 
strong trend for a visit * time * treatment effect (RM ANOVA, p=0.054) with the CC 
group displaying a later peak at visit 2 (60 min) than at visit 1 (30 min). Adding gender 
as cofactor did not affect this result. The postprandial insulin responses by visit for 
each group are shown in Figure 6.4.4.3-3. 
 
 
Figure 6.4.4.3-3  Postprandial insulin response by visit and treatment group.  
Panel A: coffee group. Panel B: control group. There was no difference in IAUC between groups, but 
there was a trend for a difference in the response over time between the groups when time-points were 
analysed (RM ANOVA, visit * time * treatment interaction, p=0.054). Error bars are SEM (coffee group: 
n=19; control group: n=8). 
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 Measures of insulin sensitivity and response 
Measures of insulin sensitivity and beta cell function were calculated as described in 
Chapter 2. These measures were not normally distributed at one or both visits, but all 
were normally distributed after log transformation so parametric tests were applied to 
the log-transformed data. 
Baseline data 
There were no differences between the CC and control groups at baseline for any 
measure (unpaired t test, p>0.090), nor were there any differences between genders. 
Effect of treatment 
Repeated measures ANOVA was used to compare the difference in measures 
between visits and groups. There was no difference in any measure apart from 
HOMA2_%S (fasted insulin sensitivity) which had an overall effect of visit (p=0.006) 
and a visit by treatment effect (p=0.015). Post hoc analysis revealed a significant 
decrease in insulin sensitivity in the control group (paired t test, p=0.031), with no 
change in the CC group (p=0.678), however the decrease in the control group was no 
longer significant after adjustment for multiple comparisons. These results were not 
changed when gender was added as cofactor. Mean values by visit for each group are 
reported in Table 6.4.4.4-1. 
 
 
  
Table 6.4.4.4-1  Insulin sensitivity measures by visit and treatment group. 
* Significant difference between visits by group (RM ANOVA, p<0.05). HOMA: Homeostatic model of 
assessment; %S: sensitivity; %B: beta cell function; AUCI/G: ratio of insulin to glucose area under curve; 
Matsuda * AUGI/G : product of Matsuda index and AUCI/G ratio. 
Mean Mean
Mean SD Mean SD Change Mean SD Mean SD Change
HOMA-2 %S 82.25 33.23 80.56 33.82 -1.69 90.75 20.95 67.56 17.90 -23.19 *
HOMA-2 %B 141.87 41.42 130.44 32.48 -11.43 128.00 22.33 134.55 28.54 6.55
Matsuda 5.70 2.74 5.52 2.34 -0.18 6.42 1.02 5.39 1.16 -1.02
AUCI/G 79.94 30.85 79.46 35.17 -0.48 62.52 22.43 63.46 17.18 0.94
Matsuda*AUCI/G 393.36 124.11 383.46 120.05 -9.90 393.44 128.71 331.53 78.10 -61.91
Visit 1 Visit 2
Coffee  (n=19) Control (n=8)
Visit 1 Visit 2
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 Triacylglycerol (TAG) 
None of the TAG time-point or IAUC data were normally distributed. Log transformation 
resulted in all data, apart from IAUC at visit 2, being normally distributed, therefore 
parametric tests were carried out on the log-transformed time-point and baseline IAUC 
data. Non parametric tests were carried out on other IAUC data.  
 
Baseline data 
There were no differences between CC and control groups at visit 1 for fasted TAG 
(unpaired t test, p=0.803).  There was however a difference in IAUC between the 
groups for the 2 h postprandial response (unpaired t test, p=0.008) with the CC group 
having a higher mean IAUC (26.4 mmol/L.120 min) than the control group 
(8.7 mmol/L.120 min). There was also a trend for a group * time effect (p=0.085) when 
the time-points were analysed by RM ANOVA, with the TAG appearing to rise faster 
in the CC group than in the control.   The 2 h postprandial TAG response for each 
group is shown in Figure 6.4.4.5-1. 
 
 
  
Figure 6.4.4.5-1  Baseline postprandial TAG response by treatment group.  
There was a significant difference between groups for IAUC (unpaired t test, p=0.008). Error bars are 
SEM (coffee group: n=19; control group: n=8). 
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When groups were combined and genders compared, there was no difference 
between men and women for fasted TAG (unpaired t test, p=0.320), however there 
was a trend for lower IAUC in women (unpaired t test, p=0.084) and a trend for a time 
* gender effect when time-point data were analysed (one-way RM ANOVA, p=0.061), 
with TAG appearing to rise faster in men. The 2 h postprandial TAG response split by 
gender is shown in Figure 6.4.4.5-2. 
 
When baseline IAUC for TAG was analysed by two-way ANOVA with both group and 
gender as cofactors, the effect of group remained (p=0.006) and an effect of gender 
was also found (p=0.028), with females having a lower IAUC than males. Baseline 
IAUC for each group, split by gender is shown in Figure 6.4.4.5-3. 
Figure 6.4.4.5-2  Baseline postprandial TAG response by gender.  
There was a trend for a time * gender effect (one-way RM ANOVA, p=0.061). Error bars are SEM (males: 
n=14; females: n=13). 
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Effect of treatment 
Fasted TAG values were compared between visits by one-way RM ANOVA. No effect 
of visit, treatment or visit * treatment effect was found (p>0.521). The mean fasted TAG 
values for each group are reported in Table 6.4.4.5-1. 
 
  
Two-way ANOVA revealed a difference between groups (p=0.006) and genders (p=0.028), with the 
coffee group displaying a greater IAUC than the control group and males producing a greater IAUC than 
females. Error bars are SEM (coffee group males: n=10; coffee group females; n=9; control group males: 
n=4; control group females: n=4). 
Figure 6.4.4.5-3  Baseline TAG IAUC by treatment group and gender. 
Table 6.4.4.5-1  Mean fasted TAG by visit 
and treatment group. 
TAG: triacylglycerol; SD: standard deviation. 
Group Visit Mean SD
Coffee (n=19) 1 0.98 0.36
2 1.08 0.48
Control (n=8) 1 0.95 0.43
2 0.97 0.39
Fasted TAG (mmol/L)
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There was a significant difference between groups for IAUC at visit 2 (Mann-
Whitney U, p=0.034), as at visit 1, however there was no difference in the change from 
visit 1 to visit 2 between groups (Mann-Whitney U, p=0.449).  The IAUC by visit for 
each group is shown in Figure 6.4.4.5-4. 
 
 
There was no difference between groups and visit when the time-points were 
compared by one-way RM ANOVA, however there was a trend for a time * group effect 
(p=0.061); examination of the time-point data for visit 2 (not shown) suggests the 
coffee group TAG to be rising faster than controls as at visit one. Adding gender as 
cofactor did not change the significance of the results.  
 
  
Figure 6.4.4.5-4  TAG IAUC by visit and treatment group.  
There was a difference between groups at each visit (Mann-Whitney U, p<0.035), but no significant 
difference between groups for change in IAUC between visits. Different letters denote a significant 
difference between groups for that visit. Error bars are SEM (coffee group: n=19; control group: n=8). 
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 Non-Esterified Fatty Acids (NEFA) 
Only 2 of the 12 NEFA time-points and neither AUC were normally distributed, however 
baseline fasted NEFA was normally distributed.  Log transformation (base 10 and 
natural log) did not improve the normality of the data. Non-parametric tests were 
therefore carried out wherever possible. When this was not possible, for example with 
repeated measures on time-point data, then parametric tests were carried out on the 
original data.  
 
Baseline data 
There were no differences between CC and control groups at visit 1 for fasted NEFA 
(unpaired t test, p=0.979) or total AUC (Mann-Whitney U, p=0.418), nor was there any 
difference between groups when time-course data were compared (RM ANOVA, 
p>0.742).  The 2 h postprandial NEFA response for each group is shown in Figure 
6.4.4.6-1. 
 
  
Figure 6.4.4.6-1  Baseline postprandial NEFA response by treatment group.  
There were no significant differences between groups for either fasted NEFA or 2 h AUC (p>0.417). 
Error bars are SEM (coffee group: n=19; control group: n=8). 
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When men and women were compared there was no difference for either fasted NEFA 
(unpaired t test, p=0.591) or 2 h AUC (Mann-Whitney U, p=0.220). However, when 
time-points were analysed by RM ANOVA, a time * gender effect was found (p=0.009) 
along with a slight trend for gender (p=0.098). The baseline NEFA response for men 
and women is shown in Figure 6.4.4.6-2; it reveals greater postprandial NEFA 
suppression in females than in males.  
 
 
  
Figure 6.4.4.6-2  Baseline postprandial NEFA response by gender.  
There was a time * gender effect (one-way RM ANOVA, p=0.009). Error bars are SEM (males: n=14; 
females: n=13).  
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Effect of treatment 
There was no difference between groups at visit 2 for either fasted NEFA or 2 h AUC, 
nor was there any difference between groups in change from baseline for these 
measures (Mann-Whitney U, p>0.695). The AUC at each visit by group is shown in 
Figure 6.4.4.6-3. 
 
 
When time-points were compared between visits, no effect of visit, treatment or visit * 
treatment effect was found for any measure (one-way RM ANOVA, p>0.503), however 
when gender was added as a cofactor to treatment group, a time * gender effect was 
found (p=0.010). Examination of the time-point data for visit 2 (not shown) suggests 
that females were displaying greater NEFA suppression than males at visit two, similar 
to that observed at baseline. 
  
Figure 6.4.4.6-3  NEFA AUC by treatment group and visit.  
No significant differences were found between groups for either fasted or 2 h AUC (Mann-Whitney U, 
p>0.695). Error bars are SEM (coffee group: n=19; control group: n=8). 
Chapter 6. 
142 
 
 Total cholesterol 
Fasted cholesterol was normally distributed at both visits.  
 
Baseline data 
There were no differences between coffee and control groups at visit 1 for fasted 
cholesterol (unpaired t test, p=0.983), nor was there any difference between genders 
(unpaired t test, p=0.465). 
 
Effect of treatment 
Fasted total cholesterol was compared between visits and groups by one-way RM 
ANOVA. No effect of visit, treatment or visit * treatment effect was found (p>0.477), 
nor was there any difference between groups at visit 2 (unpaired t test, p=0.549). Re-
performing the analysis with gender as cofactor did not change the significance of any 
results. Fasted total cholesterol for each group at each visit is shown in Figure 
6.4.4.7-1. 
 
  
Figure 6.4.4.7-1  Mean total cholesterol by visit and treatment group.  
There was no difference between groups at baseline (unpaired t test, p=0.983) nor was there any effect 
of treatment (RM ANOVA, p>0.477). Error bars are SEM (coffee group: n=19; control group: n=8). 
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 HDL cholesterol 
HDL cholesterol was normally distributed at visit 2, but not at visit 1; both were normally 
distributed after log transformation therefore parametric tests were conducted. 
 
Baseline data 
There were no differences between CC and control groups at visit 1 for HDL 
cholesterol (unpaired t test, p=0.218), nor was there any difference between males 
and females (unpaired t test, p=0.254). 
 
Effect of treatment 
HDL cholesterol was compared between visits and groups by one-way RM ANOVA. 
No effect of visit, treatment or visit * treatment effect was found (p>0.159), nor was 
there any difference between groups at visit 2 (unpaired t test, p=0.137). Re-
performing the analysis with gender as cofactor did not change the significance of any 
results. HDL cholesterol for each group at each visit is shown in Figure 6.4.4.8-1. 
 
  
Figure 6.4.4.8-1  Mean HDL cholesterol by visit and treatment group. 
There was no difference between groups at baseline (unpaired t test, p=0.218) nor any effect of treatment 
or visit (RM ANOVA, p>0.159). Error bars are SEM (coffee group: n=19; control group: n=8). 
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 Inflammatory markers, IL-6 and TNF-
Neither IL-6 nor TNF- were normally distributed for either visit. Log transformation 
resulted in normal distribution of TNF- but not IL-6. Non-parametric tests were 
therefore carried out on IL-6 data and parametric tests were carried out on the log-
transformed TNF- data. 
 
Baseline data 
There were no differences between coffee and control groups at visit 1 for IL-6 (Mann-
Whitney U, p=0.775) or TNF- (unpaired t test, p=0.499), nor were there any significant 
differences between genders. There was however a slight trend (unpaired t test) for 
women to have lower TNF- (mean 1.47 pg/ml; SD 0.98) than men (mean 3.53 pg/ml; 
SD 3.64). 
 
Effect of treatment 
No effect of visit, treatment or visit * treatment was found for TNF- (RM ANOVA, 
p>0.155) however there was a trend for a difference between treatments for TNF- at 
visit 2 (unpaired t test, p=0.073). The addition of gender as a cofactor did not 
significantly change these results. There was no difference between groups for IL-6 
either at visit 2, or for the change between visits (Mann-Whitney U, p>0.359). Mean 
IL-6 and TNF- for each group at each visit is shown in Figure 6.4.4.9-1. 
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Figure 6.4.4.9-1  Mean IL-6 and TNF- by visit and treatment group.  
Panel A: IL-6; Panel B: TNF-. There were no differences between treatment groups, either at baseline 
or in their response to the intervention, however there was a trend for a difference between groups at 
visit 2 for TNF-(unpaired t test, p=0.073). Error bars are SEM (coffee group: n=19; control group: n=8). 
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6.5 Discussion  
6.5.1 Summary of results 
There was no difference between CC and control groups at baseline for any measure 
other than TAG, where the postprandial IAUC was higher in the CC group than in 
controls. When genders were compared at baseline there were several differences, 
with women exhibiting lower fasted glucose and greater postprandial NEFA 
suppression than men and a trend for lower postprandial glucose and TAG. Women 
also had higher body fat and lower SBP. 
Fasted insulin increased and insulin sensitivity (HOMA2_%S) decreased in the control 
group, but not in the CC group. A delayed insulin peak was observed in the CC group 
at the second visit. Fasted glucose increased and IAUC glucose decreased in both 
groups between visits, but there was no difference between groups. There was no 
effect of CC on TAG, NEFA, total and HDL cholesterol, nor was there any significant 
effect on inflammatory markers, although there was a trend for higher TNF- in the CC 
group at visit 2. 
There were no differences between men and women in their response to the 
intervention. 
6.5.2 Effects on glucose metabolism 
Although there were overall changes in fasted and IAUC glucose between visits, there 
was no difference between groups. When the visits were compared within each 
individual group, in post hoc paired t tests, a significant difference between visits was 
only observed for the control group, which displayed a mean increase in fasted glucose 
of 0.4 mmol/L (p=0.010) and a decrease in IAUC (p=0.031). However, after adjustment 
was made for multiple comparisons, the difference in IAUC was no longer significant. 
Given that the initial analysis found no difference between groups, and that the 
changes in both groups were in the same direction, it seems likely that the changes in 
glucose parameters between visits were simply a result of repeated measurement or 
order effects.  
This lack of effect of CC on fasted glucose is consistent with that reported by previous 
studies examining CC and/or caffeine, in both habitual coffee drinkers (11,12) and in 
coffee-naïve individuals (112,193), but in disagreement with a recent study investigating 
the effects of an instant green/roast coffee blend, which observed a decrease in fasted 
glucose following eight weeks of coffee drinking (216). They did not report a detailed 
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coffee analysis, but stated that their coffee contained 85.1 ± 1.6 mg/g total 
hydroxycinnamic acids, mainly CGA. Their coffee therefore contained higher amounts 
of CGAs and lower caffeine, providing a daily dose of 511 mg hydroxycinnamic acids 
and 120 mg caffeine in comparison to the coffee used in the current study which 
contained 174 mg total CGAs and 175 mg caffeine. The higher amount of CGAs in 
their coffee, may explain the reduction in fasted glucose, as in vitro and animal studies 
have reported CGAs to cause a reduction in hepatic glucose output (142,143). It should 
also be noted that Sarriá et al. employed a cross-over design, with more participants 
(n = 52), both of which would increase the power of their study to detect a small 
difference in fasted glucose. 
The lack of effect of CC on postprandial glucose is consistent with studies in habitual 
coffee drinkers (11,13), but is in contrast to the only other study to date performed in 
coffee-naïve individuals, which reported a reduction in postprandial glucose after their 
CC intervention (112). In that study, the participants were overweight with IFG, in 
contrast to the current study which was a mix of normal-weight and overweight, all with 
normal fasted glucose. In the current study, only four participants had a baseline fasted 
value over 5 mmol/L, with the highest being 5.5 mmol/L, which is still within the normal 
range. Furthermore, Ohnaka et al. measured AUC, not IAUC; although they observed 
no significant change in fasted glucose between visits, it is still possible that individual 
changes in fasted values may have affected their AUC values. When individual 
responses in the current study were inspected, many had an increase in AUC but a 
decrease in IAUC or vice versa, demonstrating the need to take fasted glucose into 
account. Ohnaka et al. compared before and after values for individual groups and 
between groups without adjusting for multiple comparisons, thus increasing the 
probability of generating a Type I error (a false positive). As they did not report their 
statistics in detail, it is not possible to determine whether their differences would have 
remained significant after correction for multiple comparisons and indeed when they 
compared ΔAUC for CC, DC and control by one way ANOVA they only found a 
statistical trend (p=0.08).  
6.5.3  Effects on insulin and insulin sensitivity 
In line with most other studies (11,13,112), no change in fasted insulin was observed in the 
CC group.  This is in contrast to van Dam et al., who found CC increased fasted insulin 
after 4 weeks, however they used a very high dose of CC in their study (equivalent to 
13 cups/day) and indeed observed no significant effect on fasted insulin in a second 
trial, reported in the same paper, using a lower dose of approximately 10 cups/day (12). 
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They reported a large number of drop-outs on the first trial due to side–effects from the 
high CC consumption, which led them to hypothesise that raised levels of stress 
hormones, such as noradrenaline, may have been implicated in the observed insulin 
increase. Another group, in a cross-over trial, gave either 400 mg caffeine/day or 
placebo for one week to a group of habitual caffeine users (mean daily pre-trial intake 
= 358 mg) and found caffeine raised fasted insulin (217). This is the equivalent amount 
of caffeine to that found in 4 - 6 cups of CC, so would not be considered an excessive 
dose. As their participants took their last caffeine or placebo dose the day before each 
study day, with no extended caffeine-washout period, it is likely that their participants 
may not have been entirely caffeine free after the caffeine leg of the trial, as detectable 
levels of caffeine have previously been found after a 15 h fast (127). They did not take 
any baseline measures before the trial, only taking blood samples at the end of each 
7 day intervention period, so it is impossible to tell whether caffeine increased fasted 
insulin or caffeine abstention decreased it. Given that their caffeine dose was similar 
to their participants’ normal caffeine intake, the latter is perhaps the more likely 
explanation. If this is correct it would imply that long-term caffeine intake does have a 
hyperinsulinaemic effect and that the longer-term interventions to date have not been 
of a sufficient duration to reveal this effect.   
The current study found no change in postprandial insulin in the CC group, in line with 
other longer-term CC interventions (11,13,112). In contrast, a study which gave caffeine to 
coffee-naïve individuals for two weeks observed an increased insulin IAUC following 
the caffeine intervention, however, it was effectively an acute study as caffeine was 
also given on the day of the test (193).   
Interestingly, in the current study, CC appeared to delay the insulin peak at the second 
visit, changing the time taken to reach peak insulin from 15 to 30 min. This is 
comparable to the reduced first-phase insulin response documented in T2DM. It is 
uncertain what the physiological significance of this is however, given that there was 
no consequent increase in glycaemia at this time, unlike in T2DM (218).  It should also 
be noted that there were no statistically significant differences between the mean 
insulin values at the two time-points, despite this treatment * time effect. 
Fasted insulin sensitivity (HOMA2_%S), decreased unexpectedly in the control group 
with no change in the CC group, indicating reduced insulin sensitivity at visit 2 for the 
controls. This was represented by increases in both fasted glucose and insulin values 
in the control group.  
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It is possible that the unexpected observed changes in the control group were as a 
result of total caffeine abstention, although this is unlikely as all participants had been 
caffeine-free for two weeks prior to the first study day. Nevertheless, the timescale for 
caffeine withdrawal to impact on metabolism has not been established. Because these 
changes occurred in the control group rather than the intervention group, these results 
should be interpreted with caution, but are most likely due to random variation in 
glucose and insulin responses.  
6.5.4 Effects on fasted lipids 
No effect of CC on fasted TAG, total or HDL cholesterol was observed. This is in 
agreement with other interventions that have used moderate daily intakes (11,13,116).  
However, CC has been observed to elevate both total and HDL cholesterol at a higher 
dose of 8 cups/day (11). Fried et al. also compared different doses of filtered CC and 
observed an increase in total, LDL and HDL cholesterol in their higher-dose group (720 
ml/day), but not in their lower-dose group (360 ml/day) (116). This is somewhat 
consistent with the results of two meta-analyses, both of which found a dose-response 
effect of coffee, taken over 14 - 71 days, on total and LDL cholesterol and TAG, but 
not on HDL cholesterol (118,119). These meta-analyses concluded that most of the effect 
came from studies that used boiled coffee and noted that filtered coffee had minimal 
effect on blood lipids. This could be explained, as boiled coffee contains high amounts 
of the diterpenes cafestol and kahweol, which are known to be lipid raising (114,115), 
whereas filtered coffee contains less of these compounds as the coffee is in contact 
with the water for less time and the paper filter “traps” most of the lipid fraction. One of 
these meta-analyses suggested that caffeine may also be contributing to the effects 
on lipids as their subgroup analysis revealed no effect of DC (119), however the other 
found no difference in the response between trials comparing CC with DC, concluding 
that caffeine has a negligible lipid-raising effect (118). One study found a decrease in 
total and LDL cholesterol with no change to HDL cholesterol and TAG following one 
week of high dose instant CC drinking (24 g instant CC granules/day, equivalent to 12 
cups/day), however it was poorly designed with no control for comparison so no 
conclusions can be drawn (219). 
Interestingly, the studies discussed previously which did report increased blood lipids 
were carried out with filtered CC, contrary to the meta-analysis results, however their 
coffee compositions were not reported and others have reported filtered coffee to 
contain large amounts of diterpenes. For example, Corrêa et al. found an increase in 
total and HDL cholesterol but no effect on TAG with two different roasts of filtered 
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CC (113). Their participants consumed 3 - 4 cups/day, a similar dose to that consumed 
in the current study, but their CC was very strong, containing 210 - 334 mg total CGA 
and 231 - 244 mg caffeine per cup, whereas the coffee consumed in this study 
contained only 44 mg CGA and 44 mg caffeine per cup; in fact the total daily dose in 
the current study (174 mg CGA, 175 mg caffeine) was less than one of their cups. 
They also reported high levels of cafestol and kahweol. These high levels of 
diterpenes, and possibly caffeine, may explain the lipid-raising effects observed, 
despite being produced by the paper filtration method. 
The increase in HDL observed in these studies is interesting and may indicate some 
beneficial effect of coffee, however the magnitude of the increase was small (0.08 - 
0.09 mmol/L) in comparison to the reported increases in total (0.24 - 0.40 mmol/L) and 
LDL cholesterol (0.15 - 0.17 mmol/L).  
The diterpene content of the CC used in the current study was not measured, however, 
as it was instant coffee, it is likely to be low (220). It is therefore probable that the CC 
dose was too low in diterpenes to have had an effect on lipids. This would suggest that 
drinking a moderate amount of instant CC on a regular basis would not induce a 
detrimental effect on blood lipids.  
6.5.5 Effects on postprandial TAG 
The current study found no effect of CC on postprandial TAG. Although there do not 
appear to be any other longer-term interventions with which to compare these results, 
one can compare and contrast these findings with acute studies. Acute studies have 
demonstrated no effect of CC (221) and coffee bean extract (222) on postprandial TAG, 
although Bloomer et al. did report a trend (p=0.07) for an overall difference between 
treatments, with CC appearing to elevate TAG at 4 h more than control (221), however 
they did not report a post hoc analysis to confirm this. 
Bloomer et al. gave their participants a high-fat milkshake, providing 0.8 g/kg fat (which 
equates to 56 g for a 70 kg person), which is substantially larger than the fat content 
of the liquid meal consumed in the current study (23 g). Furthermore, the TAG 
response was measured for 2 h in the current study; as TAG typically takes 3 - 5 h to 
reach peak levels, only the initial rise was observed. It is possible therefore that the 
meal contained insufficient fat or that measures were taken over too short a time period 
to produce sufficient elevation in TAG for an observable effect. 
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6.5.6 Effects on fasted and postprandial NEFA 
There was no effect of CC on fasted or postprandial NEFA in the current study. Whilst 
there do not appear to be any other longer-term interventions looking at the effects of 
CC on fasted or postprandial NEFA, there have been several acute studies. 
Acute CC and caffeine ingestion have both been demonstrated to increase fasted 
NEFA (193,223). Some have observed that this increase only occurs in normal-weight 
individuals and not in the obese (135), however it should be noted that fasted levels in 
the obese were typically much higher and the elevation observed in the normal-weight 
group resulted in levels comparable to the baseline levels found in the obese. 
Daubresse et al. also noted that DC had no effect on fasted NEFA in either group, 
suggesting that caffeine is responsible for the effect (135). A degree of acclimatisation 
to these effects of caffeine seems to occur as trials comparing the effects of caffeine 
on NEFA levels before and during exercise found that acute caffeine ingestion 
increased NEFA levels more in caffeine-naïve individuals than in regular caffeine 
users (224,225). Also, Dekker et al. observed that an acute dose of caffeine resulted in 
less of an increase in NEFA and adrenalin levels after 14 days of caffeine use in 
previously caffeine-naïve individuals (193). Fisher et al. also found caffeine caused less 
of an increase in adrenalin in the habitual caffeine users (225), which may explain the 
reduced NEFA increase as adrenalin stimulates adipose tissue lipolysis through its 
effects on cAMP and HSL. 
When postprandial studies are examined, results are more inconsistent. One study 
found caffeine, but not CC, elevated fasted NEFA more than control in the hour 
preceding an OGTT, but noted that levels were not different between treatments by 
the end of the OGTT (10). They also noted that DC reduced the overall NEFA response 
compared to both caffeine and control, observing greater postprandial NEFA 
suppression following DC consumption than that produced by both caffeine and 
placebo, suggesting that components other than caffeine may oppose the effects of 
caffeine. Another study found that CC had no effect on NEFA for the first 2 h after a 
mixed meal, but elevated NEFA above control levels in the third hour (8). In this case 
insulin had returned to near fasting levels and so would have a reduced ability to 
suppress NEFA, whereas it is likely that there was still a substantial amount of caffeine 
in the blood continuing to elevate NEFA compared to control. 
When caffeine was infused intravenously at a steady rate of 0.6 mg/kg/h (15 min after 
a priming dose of 3 mg/kg) during a hyperinsulinaemic-euglycaemic clamp procedure, 
caffeine was found to increase fasted NEFA more than control and to maintain 
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elevated NEFA levels over the entire 2 h time-course of the study (226). This apparently 
stronger effect of caffeine is consistent with that observed by Battram et al. and gives 
further weight to the argument that non-caffeine components of coffee may be 
attenuating the acute effects of caffeine. 
A high intra-individual variation in fasted NEFA has been demonstrated, with one study 
reporting  a  CV of 45% in individuals measured on successive mornings (51), although 
others have found lower variation over longer periods; Magkos et al. reported a CV of 
24% and concluded that 6 - 10 participants in a crossover study and 12 - 20 per group 
in a parallel-arm design would be sufficient to detect differences of 25 - 30% in fasted 
NEFA (227). As there were 19 participants in the coffee group and only 7 in the control 
in the current study, it is quite plausible that it was underpowered with respect to NEFA 
measurement. 
Perhaps more importantly, however, the major difference between this study and the 
aforementioned acute studies is the absence of CC immediately prior to the meal. This 
means that the participants in the current study had no caffeine or other coffee 
components in their blood at the time of meal consumption.  
6.5.7 Effects on inflammatory markers 
The link between coffee and inflammatory markers is unclear. Some epidemiological 
studies suggest an association between coffee drinking and raised levels of both IL-6 
and TNF-  (105,228), some have found no association with IL-6 (102) and others have 
found lower levels of TNF- in coffee drinkers (106). A recent meta-analysis of 10 
prospective cohorts found an association between IL-6 and T2DM risk (54). Animal 
models have demonstrated a reduction in TNF- in rats, following 8 weeks of DC 
consumption (229), and a reduction in IL-6 and TNF- in mice following 5 weeks of CC 
consumption (230), with both studies giving coffee doses equivalent to normal coffee 
consumption in humans. Longer-term interventions in humans however have 
produced contradictory results, with some finding no effect of CC on these 
markers (11,113) whilst others have observed an increase in IL-6 (13), reflecting the 
ambiguous results in epidemiological data. 
Several of coffee’s key components have exhibited both antioxidant and 
anti-inflammatory effects in vitro, including caffeine (231), CGAs (232), cafestol and 
kahweol (233,234), whilst a temporary increase in antioxidant capacity following acute 
coffee drinking has been demonstrated in vivo (235). This has led to suggestions that 
coffee may exert a beneficial effect on health via antioxidant and anti-inflammatory 
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effects. Dietary antioxidants however are present in far smaller quantities than their 
endogenous counterparts and it is debatable as to how large a contribution they make 
to the overall antioxidant activity in the body. 
Consistent with 2/3 of the previous human interventions, the current study found no 
significant effect of coffee on TNF- and IL-6. There was however a trend for an 
increase in TNF- at visit 2 within the CC arm, which may be indicative of a real 
increase. The CC was relatively low in caffeine and total CGAs, and as noted 
previously, likely to be low in the diterpenes; it is possible therefore that it simply did 
not contain sufficient antioxidants to initiate a detectable change.  
Plasma IL-6 levels are known to vary from day to day and can be influenced by a range 
of factors including diet and menstrual cycle stage (236). The current study did not 
control the previous day’s diet, apart from the evening meal, nor was there any control 
of menstrual cycle, although as the intervention lasted 12 weeks it is likely that the 
female participants were in the same stage at each visit, provided they had a regular 
cycle. It is possible however that this lack of stricter controls contributed to greater 
variation in response. 
When individual responses were examined, large inter-individual variation was 
apparent with almost half of each group exhibiting an increase between visits and half 
exhibiting a decrease, for both IL-6 and TNF-. Under these circumstances it is unlikely 
that the lack of effect was simply due to study power. 
6.5.8 Gender differences 
Cross-sectional studies have reported IGT to be more common in women and IFG to 
be more prevalent in men (237,238). Whilst none of the participants had IFG, higher fasted 
glucose was observed in the males, perhaps indicating greater susceptibility to 
development of IFG in later life. It has been suggested that gender differences in IGT, 
as measured by 2 h glucose load, are attributable to height differences as taller people, 
usually men, have more muscle mass and thus higher rates of glucose disposal (238). 
Interestingly, no correlation between gender and height was found in the current study 
(Pearson’s correlation, p=0.142) and there was no difference in the 2 h glucose values. 
There was however a trend for a lower overall glucose response in women, in contrast 
to Couillard et al., who reported a lower glucose IAUC in men along with higher fasted 
glucose and higher postprandial insulin (210). However, when their participants were 
matched for abdominal visceral adipose tissue, the difference in postprandial insulin 
and glucose disappeared, leading the authors to conclude that increased abdominal 
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adiposity in men may be the cause of the gender differences. Abdominal adiposity was 
not measured in the current study, so it is unknown whether this was a factor in the 
results. 
Gender differences in lipid metabolism have also been observed, with men generally 
having higher fasted TAG, lower HDL and higher total and LDL cholesterol than 
women (210,211). Men have also been reported to have higher postprandial TAG and 
NEFA, although the difference in NEFA was only apparent more than 2 h after the test 
meal (210). Others have also observed greater NEFA suppression in women than in 
men (212,239). When the participants in Couillard et al.’s study were matched for 
abdominal visceral adipose tissue, the difference in postprandial TAG disappeared, 
but the difference in NEFA remained. Changes in adiposity have also been correlated 
with changes in fasted cholesterol, HDL and TAG (240). Others have observed no 
difference in fasted or postprandial TAG between men and women following a large 
lipid load, despite finding significant differences between genders for height and body 
fat (241).  
Contrary to the larger cohort studies, the current study did not find any significant 
gender differences in fasted TAG (males: mean 1.03 mmol/L, SD 0.45; females: mean 
0.89 mmol/L, SD 0.29), total cholesterol (males: mean 4.03 mmol/L, SD 0.58; females: 
mean 4.20 mmol/L, SD 0.62) or HDL cholesterol (males: mean 1.22 mmol/L, SD 0.23; 
females: mean 1.33 mmol/L, SD 0.25). The participants were all healthy with few (<=2) 
having levels outside the healthy range for any individual measure; this perhaps 
explains the lack of difference between genders. A trend was observed, however, for 
higher postprandial TAG in men and greater NEFA suppression in women in line with 
previous studies. It has been suggested that differences in postprandial TAG between 
men and women may be explained by enhanced skeletal muscle TAG clearance in 
women (242). Interestingly the men in the current study displayed minimal NEFA 
suppression, similar to what may be observed in T2DM, which was an unexpected 
finding. 
Differences in inflammatory markers have also been observed, with women having 
been reported to have lower TNF- and a stronger correlation between adiposity and 
IL-6 than men (243). Unlike the epidemiology, there was no significant difference 
between men and women for either IL-6 or TNF- in the current studyhowever a slight 
trend for lower TNF- was observed in women. This lack of significant effect is possibly 
due to the high inter-individual variation previously described or may simply be that the 
population was too healthy for small differences to be detected with the study power.  
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Epidemiology has variously demonstrated a reduced risk of T2DM with coffee drinking 
in men, but not in women (213), a reduced risk for both (3) and a reduced risk in women 
with only a slight trend in men (214). Few studies have compared gender responses to 
the acute effects of coffee on the postprandial glucose and insulin response, with these 
reporting mixed findings. One study found women to have a greater increase in 
postprandial glucose than men and men to have a reduction in peak insulin following 
acute CC consumption (184), whereas another found no difference between genders 
when an acute caffeine dose was given (195). None of the existing interventions 
investigating CC’s longer-term effects on glucose metabolism have compared gender 
responses. 
A meta-analysis of longer-term interventions examining the effect of coffee on fasted 
lipids found that the effects of coffee were significantly higher in those studies that 
included women (119), suggesting perhaps that women are more susceptible to the 
effects that coffee has on fasted lipids, however no direct comparisons between men 
and women were made.  
Adding gender as a cofactor to the analysis in the current study did not materially affect 
any results, with no differences observed between men and women in their response 
to CC for any variable. This is perhaps unexpected given that some epidemiology and 
acute studies have observed gender differences, however, the evidence is limited and 
contradictory and direct comparison cannot be made between a longer-term 
intervention and acute studies and cross-sectional analyses. 
6.5.9 Potential confounders 
It has previously been established that oral contraceptive use affects caffeine 
metabolism, with some studies demonstrating an almost doubling of the half-life from 
3 - 5 h to 6 - 10 h (244–246). Oral contraceptive use was not an exclusion criteria for this 
study, however only two of the 15 women recruited to the study were taking oral 
contraceptives, so this is unlikely to have been a significant confounder.  
There is also conflicting evidence as to whether age affects postprandial glucose 
metabolism, with some authors finding an effect of age (247,248) and others suggesting 
little or no effect after adjustment for obesity/bodyweight and/or fitness levels (249,250). 
One study found that an effect of age remained after these adjustments, but in women 
only (251). As there was no significant difference between CC and control groups for 
age it is unlikely to have been a significant confounder in this study. 
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Caffeine withdrawal symptoms, such as headache, tiredness and irritability, typically 
appear within 12 – 24 h of caffeine abstinence, peak within 20 – 51 h and can last from 
2 – 9 d (252). The participants in the CC group had been caffeine-free for approximately 
64 h on their second study visit, so are likely to have passed the time of peak 
withdrawal symptoms, but may have still been suffering from some unrecognised 
symptoms. All were asked if they thought they had suffered from caffeine withdrawal, 
with most reporting some level of tiredness or headache on the day immediately 
following their last coffee dose. Several reported still feeling tired on the study day, but 
none reported any residual headache. A greater NEFA response to acute caffeine 
ingestion has been observed following four days of caffeine withdrawal in comparison 
with a control group who had not experienced caffeine withdrawal (253), however this 
NEFA rise was in response to caffeine and no caffeine was given on the study days in 
the current study.  
The evening meal on the day prior to each study day was kept the same as food taken 
on the evening prior to an OGTT has been demonstrated to have a carry-over 
effect (254); a high-fat evening meal (62% energy from fat, 31% energy from CHO) was 
observed to result in lower fasted TAG and a greater postprandial glucose and TAG 
response to an OGTT the following morning, compared to a high CHO meal (16% 
energy from fat, 76% energy from CHO). The evening meal for the current study 
contained 40% energy from fat and 41% from CHO, which is much lower than the high 
fat meal used by Robertson et al. (254).  
Genetic variability may also be confounding the results. Several SNPs in the ADORA2 
gene, which codes for the adenosine receptor A2bR, are associated with IL-6 and CRP 
levels (255). The Nco-1 polymorphism in the TNF- gene is associated with higher 
TNF- concentrations, greater insulin AUC and reduced insulin sensitivity (256). As the 
participants were not genotyped for these polymorphisms, these are potential 
confounders, particularly as when individual responses were examined (data not 
shown) the variation in response to the intervention was very diverse. 
Due to the complex and intertwining nature of glucose and lipid regulation, it is 
impossible to rule out the confounding of results by other factors. For example, 
correlations exist between fasted NEFA and BMI, fasted glucose, glucose AUC and 
fasted TAG (48). With such a small study population, it was not possible to control for 
all these factors or advisable to include them in the analysis as covariates.  
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6.5.10 Weaknesses 
There is a possibility of order effects in the current study as this was not a crossover 
trial, however there was a control group. Ideally it would have been designed as a 
crossover intervention, however, because the aim was to examine the effects of CC 
on coffee-naïve individuals, this was not possible; as it is not known how long any 
effects of CC would take to be reversed, a suitable washout period could not be 
accurately determined. The order effect could have been minimised by including a 
dummy study day at the start of the intervention to allow participants to become familiar 
with the protocol and reduce any effects that may have resulted from stress during the 
first visit. This is something that should be considered for future work and has become 
routine for some interventions within the group. Duplicate study visits could also be 
considered for the future in order to reduce intra-individual variation, but this would 
have a time, cost and study burden implication for participants. 
The study population was very heterogeneous with marked individual variability. Whilst 
this makes the results more applicable to the general population it also reduces the 
power of the study to find between-group differences. It is possible that larger 
differences would have been detectable in a more homogeneous population. 
6.6 General discussion/conclusion 
To our knowledge, this is only the second study to examine the longer-term effects of 
CC drinking in coffee-naïve individuals, and the first to examine those effects in healthy 
people with apparently normal glucose metabolism. Furthermore it appears to be the 
first to investigate gender differences in postprandial glucose and lipid metabolism in 
response to longer-term CC consumption. 
Contrary to the hypothesis that longer-term coffee drinking would reduce the 
postprandial glycaemic response, it would appear from these results that regular 
moderate consumption of instant CC does not affect fasted or postprandial glucose or 
lipid metabolism in healthy adults. It may however cause a delayed insulin peak. These 
results are in contrast to the only other study that has been performed in coffee-naïve 
individuals, which found a reduction in glucose response following 16 weeks of instant 
CC consumption (112). Compliance cannot explain the difference in results as it was 
comparable in both trials; median salivary caffeine concentrations in the current study 
were 8.9 µM in the coffee group and 0.1 µM in the control group, whereas Ohnaka et 
al. reported median concentrations of 6.9 - 8.2 µM in their coffee group. There are 
however several differences between the two protocols. Ohnaka et al. studied 
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overweight, older men, who already had IFG, whereas the current study group were 
generally normal weight and younger with healthy fasted glucose. It is perhaps not 
possible to see an improvement in a group that is already very healthy.  
It is possible that an intervention in younger healthy adults would have to be extended 
over a much longer time-frame than 12 weeks to see an effect, as it could be 
hypothesised that coffee exerts its effects by preventing/attenuating the decline in 
health status which occurs over time, rather than causing a reduction in any of these 
parameters.  If this is the case then an intervention may need to last for several years 
for the true effects to become evident. 
It should be noted, however, that the CC consumed in this study was relatively low in 
caffeine and CGAs and likely also low in diterpenes. Since these are the components 
that have been suggested to be responsible for the effects of coffee, it is possible that 
it did not contain sufficient quantities of these components to produce a significant 
effect on any of the measured parameters.  
Given the amount of variation in response between participants, particularly in the CC 
group, it is possible that some other unknown factor is interacting with the effects of 
coffee. One such possibility is explored further in Chapter 7. 
Finally, it should be acknowledged that the study design does not reflect a real world 
scenario, as participants were tested after a two day washout period and regular coffee 
drinkers are unlikely to abstain from coffee for this period of time and are indeed likely 
to have some level of caffeine in their system for most of the day.  Nevertheless, the 
results are valid in that they reflect the effects of longer-term CC consumption, without 
being compromised by the known acute effects of CC and caffeine.   
In conclusion, this study found no effects on glucose and lipid metabolism following 
moderate instant CC consumption in healthy adults. Combined with the limited 
literature, there is insufficient evidence to make a definitive statement as to whether 
CC drinking has a detrimental or beneficial effect at this stage. There is clearly a need 
for further research, perhaps over a longer time period with a larger sample size and 
different study populations. 
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7.1 Introduction 
The results of previous coffee studies may be confounded by individual differences in 
caffeine metabolism. As discussed in the introduction to this thesis (Chapter 1), a 
particular SNP in the CYP1A2 gene, rs762551, has been demonstrated to affect 
caffeine metabolism (198), with carriers of the C allele being classed as being of a slow 
metaboliser phenotype whereas those who are homozygous for the A allele are 
considered to be of a fast metaboliser phenotype. Case-control and prospective cohort 
studies have reported an association between coffee drinking and increased risk of 
myocardial infarction (257), hypertension (258,259) and IFG (160) in those who are slow 
caffeine metabolisers but not in fast metabolisers.  
It is possible that these polymorphisms in the CYP1A2 gene will modulate the effects 
of coffee on glucose and lipid metabolism however, to date, no acute or longer-term 
interventions have investigated this. The secondary aim of the 12 week intervention, 
detailed in Chapter 6, was to examine whether there were any differences between 
fast and slow metaboliser phenotypes. This chapter reports on the outcome of this 
secondary analysis. 
7.2 Aims 
To examine whether there were any differences in glucose and lipid metabolism 
between fast and slow phenotypes in all participants at baseline. 
To examine whether there were any differences in the effects of the intervention on 
these measures between slow and fast phenotypes in the coffee group. 
To further examine whether there were any gender-phenotype interactions. 
7.3 Methods 
The methods and protocol are as detailed in Chapter 6. 
Chapter 7. 
160 
 
7.3.1 Statistical analysis 
All statistical analysis was carried out using SPSS Statistics software, version 22. The 
Shapiro-Wilks test was used to check normality of data. Two-way RM ANOVA was 
used to compare groups over time-points. Student’s t tests were used for comparisons 
between groups when the data were normally distributed and the equivalent non-
parametric tests were used when they were not. Fisher’s Exact tests were used for 
assessment of independence of variables. Statistical significance was classed as a 
p-value < 0.05. 
7.4 Results 
This section will report each measure in turn. For each measure, the results from the 
analysis by phenotype, of baseline measures in the whole cohort (n=27) will be 
reported first, followed by the results from the comparison of phenotypes in the coffee 
group (n=19) at baseline and after the intervention. The control group was excluded 
from this second part of the analysis because, as a control, changes were not 
anticipated in this group. Furthermore, as numbers in the control group were low (n=8), 
the study was underpowered to perform this analysis in this group. 
The results are summarised in tables in Section 7.4.3. 
7.4.1 Baseline participant characteristics 
All participants (n=27) 
There were no statistically significant differences between the slow and fast 
metaboliser phenotypes at baseline for any of the anthropometric measures when the 
CC and control groups were combined, although there was a trend for those with the 
fast phenotype to be younger (p=0.063) with higher SBP (p=0.075). When males and 
females were examined separately and the two phenotypes were compared, male 
slow metabolisers had a higher fasted glucose (p=0.022) and there was a trend for 
male slow metabolisers to have a higher body fat percentage (p=0.050) and to be older 
(p=0.070) than male fast metabolisers; there were no differences for any of the tested 
parameters between female slow and fast metabolisers (p>0.129). The baseline 
participant characteristics, split by phenotype, are reported in Table 7.4.1-1. 
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Coffee group at baseline (n=19) 
There were no statistically significant differences between the slow and fast 
metaboliser phenotypes in the CC group at baseline for any of the anthropometric 
measures (p>0.218). The majority of females were slow metabolisers (67%), whereas 
most males were fast metabolisers (70%), but this difference in the proportion of fast 
to slow metabolisers between males and females was not statistically significant 
(Fisher’s Exact, p=0.179). When males and females were examined separately and 
the two phenotypes were compared, male slow metabolisers had a higher body fat 
percentage (p=0.039) and a trend for higher weight (p=0.079) and higher BMI 
(p=0.064) than male fast metabolisers; there were no differences for any for the tested 
parameters between female slow and fast metabolisers (p>0.173).  
When age was analysed by two-way RM ANOVA there was a trend for an effect of 
gender (p=0.053), phenotype (p=0.053) and a phenotype * gender interaction 
(p=0.053). Examination of the marginal means revealed that slow males (mean 32 y; 
95% CI: 25.9, 37.4) were older than the other gender/phenotype combinations (fast 
males: mean 22 y; 95% CI: 18.2, 25.8; fast females: mean 22 y; 95% CI: 16.3, 27.7; 
slow females: mean 22 y; 95% CI: 17.9, 26.1).  
Similarly, when body fat percentage was analysed by two-way RM ANOVA, a 
phenotype * gender interaction was found (p=0.013), along with a trend for an effect 
of gender (p=0.057). Examination of the marginal means revealed fast males to have 
the lowest body fat percentage (mean 15.0%; 95% CI: 10.1, 19.9), followed by slow 
females (mean 23.1%; 95% CI: 17.8, 28.4) and slow males (mean 25.3%; 95% CI: 
17.8, 32.8), with fast females having the highest body fat percentage (mean 29.7%; 
95% CI: 22.2, 37.2). 
Table 7.4.1-1  Baseline characteristics for all participants, by phenotype and gender. 
* Trend for a difference between slow and fast phenotypes (p<0.10). ¥ Trend for a difference between 
male slow and fast phenotypes (p<0.10). ¥¥ Significant difference between male slow and fast 
phenotypes (p< 0.05). BMI: body mass index; BP: blood pressure; SD: standard deviation. 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age at start (y) 23 3.6 22 2.8 22 3.0 23 4.1 32 9.6 26 7.6
Height (m) 1.69 0.06 1.69 0.11 1.69 0.10 1.64 0.08 1.74 0.04 1.68 0.08
Weight  (kg) 63.1 5.2 67.2 11.1 65.9 9.6 60.7 15.0 77.5 13.1 66.7 16.2
Systolic BP (mmHg) 120 9.9 123 9.4 122 9.3 112 6.3 121 11.3 116 9.1
Diastolic BP (mmHg) 71 6.4 71 7.4 71 6.8 73 7.9 74 8.7 74 7.9
BMI (kgm
-2
) 22.1 0.8 23.3 1.8 22.9 1.6 22.2 3.3 25.7 4.3 23.5 3.9
Body fat (%) 29.9 4.7 14.2 4.4 19 8.7 25 8.5 21.7 8.5 23.8 8.3
Fasted glucose (mmol/L) 4.2 0.4 4.6 0.2 4.5 0.4 4.6 0.4 5.0 0.3 4.7 0.4
Fasted insulin (pmol/L) 65 23 61 21 62 21 61 22 72 24 65 22
Fast  phenotype Slow phenotype
Female (n=4) Male (n=9) All (n=13) Female (n=9) Male (n=5) All (n=14)
¥
*
*¥
¥¥
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The baseline participant characteristics for the CC group, split by phenotype, are 
reported in Table 7.4.1-2. 
 
 
Pre-intervention coffee and caffeine intake 
Pre-intervention coffee and caffeine intake were estimated as described in Chapter 2; 
there were no significant differences between fast and slow metabolisers for either 
caffeine or coffee intake (Mann-Whitney U, p>0.549). 
 
7.4.2 Effects of coffee intervention: comparison of fast and slow metabolisers 
 Anthropometrics 
Weight, body fat, BMI, SBP and DBP were measured at each of the two study visits. 
Paired samples t tests were run for each phenotype to establish whether there were 
any changes between the two visits; no within group differences were found for any 
measure (p>0.180). All anthropometrics were further analysed by RM ANOVA for any 
differences in the changes between the two phenotypes; there were no between group 
differences for any measure (p>0.097). Nor were there any differences between visits 
for any measure when the male and female, fast and slow phenotype subgroups were 
analysed independently (data not show, paired t test, p>0.155). The changes between 
visits for each phenotype are reported in Table 7.4.2.1-1. 
¥ Trend for a difference between male slow and fast phenotypes (p<0.10). ¥¥ Significant difference 
between male slow and fast phenotypes (p< 0.05). BMI: body mass index; BP: blood pressure; SD: 
standard deviation. 
Table 7.4.1-2  Baseline characteristics, within the coffee group, by phenotype and gender. 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age at start (y) 22 3.6 22 3.0 22 3.0 22 2.3 32 10.5 25 7.4
Height (m) 1.68 0.07 1.73 0.10 1.71 0.09 1.62 0.03 1.76 0.03 1.66 0.08
Weight  (kg) 62.9 6.4 70.5 10.0 68.3 9.4 56.5 8.3 84.5 10.2 65.8 16.3
Systolic BP (mmHg) 115 5.3 124 10.6 121 10.0 113 7.0 128 8.1 118 10.1
Diastolic BP (mmHg) 72 7.4 71 7.4 71 7.0 72 3.4 78 7.6 74 5.4
BMI (kgm-2) 22.3 0.8 23.6 1.9 23.2 1.7 21.6 2.7 27.4 3.9 23.5 4.1
Body fat (%) 29.7 5.8 15 4.8 19.4 8.5 23.1 6.3 25.3 8.8 23.8 6.7
Fasted glucose (mmol/L) 4.2 0.5 4.7 0.2 4.5 0.4 4.6 0.6 5.0 0.3 4.7 0.5
Fasted insulin (pmol/L) 67 27 63 24 64 23 64 25 83 22 70 24
Fast  phenotype Slow phenotype
Female (n=3) Male (n=7) All (n=10) Female (n=6) Male (n=3) All (n=9)
¥¥
¥
¥
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 Plasma glucose 
Baseline data: all participants (n=27) 
When the baseline glucose data for all participants was analysed by phenotype there 
were no differences found between fast and slow phenotypes for fasted glucose 
(unpaired t test, p=0.141) or IAUC (unpaired t test, p=0.524), nor was there any 
phenotype * time interaction (RM ANOVA, p=0.442). There was, however, a difference 
at 90 min (unpaired t test, p=0.040), with the slow phenotype having a higher mean 
glucose at this time-point. The 2 h postprandial glucose response for each phenotype 
is shown in Figure 7.4.2.2-1. 
 
Figure 7.4.2.2-1  Baseline postprandial glucose response for all participants, by phenotype.  
There were no significant differences between phenotypes either for fasted glucose or IAUC (unpaired t 
test, p>0.141). Error bars are SEM (fast: n=13; slow: n=14). 
BMI: body mass index; BP: blood pressure; SD: standard deviation. 
Table 7.4.2.1-1  Changes in anthropometric measures between the two study 
visits by phenotype within the coffee group. 
Mean change SD Mean change SD
Weight  (kg) 0.1 0.8 0.0 2.9
BMI (kgm-2) 0.0 0.3 0.1 1.0
Body fat (%) 0.1 1.1 -0.1 2.3
Systolic BP (mmHg) 0.9 7.1 -1.2 10.2
Diastolic BP (mmHg) 2.4 7.7 -3.8 7.9
Fast (n=10) Slow (n=9)
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The baseline glucose data were further analysed by two-way ANOVA with gender and 
phenotype as cofactors; an effect of gender (p<0.014) and of phenotype (p<0.019) 
was found for both fasted glucose and glucose time-point data, but there was no 
gender * phenotype interaction (p>0.203). Examination of the data revealed that 
females and those with the fast metaboliser phenotype had lower fasted glucose and 
a lower overall glucose response. Post hoc analysis comparing the glucose time-point 
data for phenotypes within gender (one-way RM ANOVA) revealed a difference in 
glucose response between fast and slow phenotypes for females only (p=0.009), with 
no significant difference in males (p=0.580).The 2 h glucose response for all 
participants, split by gender and phenotype is shown in Figure 7.4.2.2-2. 
 
 
Effect of phenotype on plasma glucose in the coffee group (n=19) 
There was no difference in fasted glucose between fast and slow phenotypes in the 
CC group at baseline (unpaired t test, p=0.300). Baseline data were further analysed 
by two-way ANOVA, with gender and phenotype as cofactors (data not shown). An 
effect of gender (p=0.041) and a trend for an effect of phenotype (p=0.075) was 
observed for fasted glucose and an effect of gender and of phenotype (p<0.020) was 
Figure 7.4.2.2-2  Baseline postprandial glucose response for all participants, by gender and 
phenotype.  
There was a significant difference between genders and between phenotypes for fasted glucose (two-
way ANOVA, p<0.014) and for overall glucose response (two-way RM ANOVA, p<0.019). Error bars are 
SEM (fast females: n=4; fast males: n=9; slow females: n=9; slow males: n=5). 
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observed for the overall baseline postprandial glucose response, similar to that 
observed when all participants were included in the analysis.  
There were no within or between group differences in the change in fasted glucose 
between visits for fast and slow phenotypes (RM ANOVA, p>0.135). This did not 
change significantly when gender was added as a cofactor. 
Repeated measures ANOVA on IAUC data found an effect of visit (p=0.049) and a 
visit * phenotype effect (p=0.024), with the fast phenotype exhibiting a slight increase 
in IAUC between visits and the slow phenotype displaying a decrease between visits. 
When time-point data were analysed by RM ANOVA there was a visit * phenotype 
effect (p=0.048), with the CC intervention resulting in an apparent overall increase in 
glucose response in the fast phenotype group and a decrease in the slow phenotype 
group. The 2 h postprandial glucose response at each visit for each phenotype in the 
CC group is shown in Figure 7.4.2.2-3. 
 
Figure 7.4.2.2-3  Postprandial glucose response by visit and phenotype, within the coffee group. 
Panel A: slow; Panel B: fast. The effect of coffee varied by phenotype (RM ANOVA, p=0.048). Error bars 
are SEM (fast: n=10; slow: n=9). 
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Adding gender as a cofactor to the between-visits analysis did not affect these results; 
the visit * phenotype effect remained significant (p=0.035) and an effect of gender was 
also observed (p=0.012), with females having a lower overall glucose response than 
males. Post hoc analysis was employed to determine the source of these differences. 
When genders were examined individually (one-way RM ANOVA) there was a trend 
for a visit * phenotype effect (p=0.067) for females only (panels C and D, Figure 
7.4.2.2-4), with no significant difference in males (p=0.419). Post hoc analysis, 
examining the phenotypes separately (one-way RM ANOVA) found a difference 
between visits (p=0.031) and an effect of gender (p=0.018) for the fast phenotype only 
(panels B and D, Figure 7.4.2.2-4), with no significant difference between visits 
(p=0.400) or genders (p=0.214) in the slow phenotype. 
 
 
  
Figure 7.4.2.2-4  Postprandial glucose response by visit, phenotype and gender, within the 
coffee group. 
Panel A: males with slow phenotype; Panel B: males with fast phenotype; Panel C: females with slow 
phenotype; Panel D: females with fast phenotype. The effect of coffee varied by phenotype (Two-way 
RM ANOVA, p=0.035) and there was an overall effect of gender (p=0.012). Error bars are SEM (fast 
females: n=3; fast males: n=7; slow females: n=6; slow males: n=3). 
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 Serum insulin 
Baseline data: all participants (n=27) 
When baseline data for the whole cohort were analysed there were no differences 
found between fast and slow phenotypes for fasted insulin (unpaired t test, p=0.803) 
or IAUC (unpaired t test, p=0.139), nor was there any phenotype * time effect (RM 
ANOVA, p=0.340), however there was a difference between fast and slow phenotypes 
at 90 min (unpaired t test, p=0.020). Adding gender as a cofactor did not significantly 
affect these results (data not shown). The 2 h postprandial insulin response for each 
phenotype is shown in Figure 7.4.2.3-1. 
 
 
Effect of phenotype in the coffee group (n=19) 
There was no difference in fasted serum insulin or IAUC between fast and slow 
phenotypes in the CC group either at baseline (unpaired t test, p>0.103) or between 
visits (RM ANOVA, p>0.353). There was a difference between fast and slow 
phenotypes at 90 min for the baseline visit (p=0.009), in line with that found for all 
participants.  
  
Figure 7.4.2.3-1  Baseline postprandial insulin response for all participants, by phenotype. 
There were no significant differences between phenotypes either for fasted insulin or IAUC (unpaired t 
test, p>0.138). Error bars are SEM (fast: n=13; slow: n=14). 
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Repeated measures ANOVA on time-point data found a visit * time effect (p=0.019), 
but no effect of phenotype, with both phenotypes having a delayed peak (60 min) at 
the second visit. Again, adding gender as a cofactor did not significantly affect these 
results (data not shown). The 2 h postprandial insulin response by visit for each 
phenotype in the CC group is shown in Figure 7.4.2.3-2. 
 
 
Figure 7.4.2.3-2  Postprandial insulin response by visit and phenotype, within the coffee group.  
Panel A: slow; Panel B: fast. A visit * time effect (RM ANOVA, p=0.019) was found, but no effect of 
phenotype, with both phenotypes having a delayed peak at visit 2 (60 min). Error bars are SEM (fast: 
n=10; slow: n=9). 
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 Measures of insulin sensitivity and beta cell function 
Baseline data: all participants (n=27) 
There were no differences at baseline between fast and slow phenotypes in the whole 
cohort for any measure (unpaired t test, p>0.146). When the analysis was repeated 
with phenotype and gender as cofactors (two-way ANOVA), there was a trend for an 
effect of phenotype on the Matsuda index (p=0.084), with the fast phenotype having a 
slightly higher Matsuda index (mean 6.62; SD 2.8) than the slow phenotype (mean 
5.25; SD 1.8) Baseline data for all participants, split by phenotype are reported in Table 
7.4.2.4-1. There was also an effect of gender on the Matsuda*AUCI/G product 
(p=0.044), with the females having a higher product (mean 442; SD 153) than the 
males (mean 349; SD 64). 
 
Effect of phenotype in coffee group (n=19) 
There was no effect of phenotype in the CC group either at baseline (unpaired t test 
p>0.133) or between visits (RM ANOVA, p>0.225) for any measure. Mean values by 
visit for each phenotype are reported in Table 7.4.2.4-2. 
 
HOMA: Homeostatic model of assessment; %S: sensitivity; %B: beta cell function; AUCI/G: ratio of insulin 
to glucose area under curve; Matsuda * AUGI/G : product of Matsuda index and AUCI/G ratio.  
Table 7.4.2.4-2  Insulin sensitivity measures by visit and phenotype, within the coffee group. 
Mean Mean
Mean SD Mean SD Change Mean SD Mean SD Change
HOMA-2 %S 77.77 31.51 74.54 32.13 -3.22 86.28 35.90 85.97 36.06 -0.31
HOMA-2 %B 136.57 18.07 137.76 29.21 1.19 146.64 55.56 123.85 35.35 -22.79
Matsuda 4.76 2.02 4.88 2.12 0.12 6.55 3.11 6.10 2.49 -0.45
AUCI/G 89.32 28.33 89.65 25.22 0.33 71.50 31.97 70.30 41.38 -1.20
Matsuda*AUCI/G 383.31 120.42 416.44 154.45 33.13 402.40 133.14 353.78 74.51 -48.62
Slow (n=9) Fast (n=10)
Visit 1 Visit 2 Visit 1 Visit 2
Mean SD Mean SD
HOMA-2 %S 83.02 29.95 86.65 31.10
HOMA-2 %B 131.04 20.93 144.99 48.69
Matsuda 5.25 1.78 6.62 2.76
AUCI/G 80.99 29.34 68.09 28.93
Matsuda*AUCI/G 388.93 128.81 398.17 121.44
Slow (n=14) Fast (n=13)
HOMA: Homeostatic model of assessment; %S: sensitivity; %B: beta cell function; AUCI/G: ratio of insulin 
to glucose area under curve; Matsuda * AUGI/G : product of Matsuda index and AUCI/G ratio.  
Table 7.4.2.4-1 Baseline insulin sensitivity measures, for all participants, by phenotype. 
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When the analysis of the baseline data in the CC group was repeated with phenotype 
and gender as cofactors (two-way ANOVA), there was a trend for an effect of 
phenotype on Matsuda index (p=0.085), with the fast phenotype displaying greater 
postprandial insulin sensitivity than the slow phenotype, and an effect of gender on the 
Matsuda*AUCI/G product (p=0.038), with females displaying greater postprandial beta 
cell function than males, as was previously observed when all participants from both 
groups were analysed together. 
When fasted beta cell function (HOMA2_%B) was compared between visits with 
phenotype and gender as cofactors (two-way RM ANOVA) there were trends for visit 
(p=0.053), visit * phenotype (p=0.052), visit * gender (p=0.071) and visit * phenotype * 
gender (p=0.088). Examination of the data reveals little change in male fast, male slow 
and female slow phenotypes between visits, with an apparent decrease in fasted beta 
cell function at visit 2 for females with the fast phenotype (Figure 7.4.2.4-1). 
 
  
Figure 7.4.2.4-1  HOMA2_%B by visit, phenotype and gender, within the coffee group.  
Two-way RM ANOVA revealed trends for an effect of visit, visit * phenotype, visit * gender and visit * 
phenotype * gender (p<0.089). Error bars are SEM (fast females: n=3; fast males: n=7; slow females: 
n=6; slow males: n=3). 
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 Triacylglycerol (TAG) 
 
Baseline data: all participants (n=27) 
When baseline data for the whole cohort were analysed by phenotype there were no 
significant differences found between fast and slow phenotypes for fasted TAG 
(unpaired t test, p=0.250) or IAUC (Mann-Whitney U, p=0.720), nor was there any 
phenotype * time interaction (RM ANOVA, p=0.472). The results did not change 
significantly when gender was added as a cofactor. The 2 h postprandial TAG 
response for each phenotype is shown in Figure 7.4.2.5-1. 
 
  
Figure 7.4.2.5-1 Baseline postprandial TAG response for all participants, by phenotype.  
There were no significant differences between phenotypes either for fasted TAG (unpaired t test, 
p=0.250) or IAUC (Mann-Whitney U, p=0.720). Error bars are SEM (fast: n=13; slow: n=14). 
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Effect of phenotype in coffee group (n=19) 
There was no effect of phenotype on TAG in the CC group at baseline, either for fasted 
TAG (unpaired t test, p=0.478), IAUC (Mann Whitney U, p=0.905) or 2 h postprandial 
response (RM ANOVA, p>0.641), nor were there any differences in fasted or 
postprandial TAG between the two phenotypes in their response to the CC intervention 
(RM ANOVA, p>0.303). The 2 h postprandial TAG response at each visit split by 
phenotype is shown in Figure 7.4.2.5-2. 
 
 
  
Figure 7.4.2.5-2  Postprandial TAG response by visit and phenotype, within the coffee group.  
Panel A: slow; Panel B: fast. There was no difference in the effect of coffee between phenotypes, either 
for fasted TAG or the 2 h postprandial response (p>0.303). Error bars are SEM (fast: n=10; slow: n=9). 
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When fasted TAG was compared between visits with phenotype and gender as 
cofactors (two-way RM ANOVA) there was an overall effect of gender (p=0.042), with 
males having higher fasted TAG than females across both visits (Figure 7.4.2.5-3).  
 
 
  
Figure 7.4.2.5-3  Fasted TAG by visit, gender and phenotype, within the coffee group. 
There was an overall effect of gender (two-way RM ANOVA, p=0.042). Error bars are SEM (fast 
females: n=3; fast males: n=7; slow females: n=6; slow males: n=3). 
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An overall effect of gender (p=0.045) was also found when the time-point data were 
analysed by two-way RM ANOVA, with phenotype and gender cofactors, with males 
having an overall higher postprandial TAG response than females across both visits 
(Figure 7.4.2.5-4). 
 
 
  
Figure 7.4.2.5-4  Postprandial TAG response by visit, phenotype and gender, within the coffee 
group. 
Panel A: males with slow phenotype; Panel B: males with fast phenotype; Panel C: females with slow 
phenotype; Panel D: females with fast phenotype. There was an overall effect of gender (two-way RM 
ANOVA, p=0.045). Error bars are SEM (fast females: n=3; fast males: n=7; slow females: n=6; slow 
males: n=3). 
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 Non-Esterified Fatty Acids (NEFA) 
Baseline data: all participants (n=27) 
When all baseline data were analysed by phenotype there were no differences found 
between fast and slow phenotypes for NEFA AUC (Mann Whitney U, p=0.169), nor 
was there any phenotype * time interaction (RM ANOVA, p=0.604), however there was 
a trend for a difference in fasted NEFA between the fast and slow groups (unpaired t 
test, p=0.062). The 2 h postprandial NEFA response for each phenotype is shown in 
Figure 7.4.2.6-1. 
 
 
 
 
When gender was added to the baseline analysis as a cofactor, the previously 
observed trend for a difference in fasted NEFA between phenotypes became 
significant (two-way ANOVA, p=0.036). When gender was added as a cofactor in the 
time-point analysis (two-way RM ANOVA), a time * gender effect (p=0.016) and a 
gender effect (p=0.028) were observed, as previously discussed in Chapter 6, along 
with a strong trend for an effect of phenotype (p=0.055). Post hoc analysis was 
employed to determine the source of these differences; one-way RM ANOVA was 
utilised to independently examine the effect of gender within phenotype and then to 
Figure 7.4.2.6-1 Baseline postprandial NEFA response for all participants, by phenotype.  
There was a trend for a difference between phenotypes in fasted NEFA (unpaired t test, p = 0.062), but 
no difference in the 2 h AUC (Mann-Whitney U, p=0.169). Error bars are SEM (fast: n=13; slow: n=14). 
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examine the effect of phenotype within gender. This post hoc analysis revealed a time 
* gender effect (p=0.030) and a trend for an effect of gender (p=0.062) in the slow 
phenotype only, with no significant differences between genders in the fast phenotype 
and no significant effects of phenotype for either males or females. This suggests that 
most of the gender differences occurred within the slow phenotype. Examination of the 
baseline response (Figure 7.4.2.6-2) reveals little or no NEFA suppression in the slow 
male subgroup in comparison with the slow females. 
 
Effect of phenotype in coffee group (n=19) 
Baseline NEFA values were different between the phenotypes in the CC group, with 
the fast phenotype exhibiting a lower fasted NEFA than the slow phenotype (unpaired 
t test, p=0.005) and a lower total AUC (Mann-Whitney U, p=0.010). There were also 
significant differences between fast and slow phenotypes at 15 and 30 min time-points 
(Mann-Whitney U, p<0.011).  
When gender was added as a cofactor in the baseline analysis (two-way ANOVA), 
there were significant effects of gender (p=0.006) and of phenotype (p<0.001) on 
fasted NEFA, with females having lower fasted NEFA than males and the slow 
phenotype having a higher fasted NEFA than the fast phenotype.  
  
Figure 7.4.2.6-2  Baseline postprandial NEFA response for all participants, by phenotype and 
gender. 
Two-way RM ANOVA revealed an effect of gender (p=0.028), a time * gender effect (p=0.016) and a 
trend for an effect of phenotype (p=0.055). Error bars are SEM (fast females: n=4; fast males: n=9; slow 
females: n=9; slow males: n=5). 
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When gender was added as cofactor in the baseline time-point analysis in the CC 
group (two-way RM ANOVA), significant effects of phenotype (p=0.001) and gender 
(p=0.006) were observed, along with trends for phenotype * gender (p=0.069), time * 
gender (p=0.055) and time * gender * phenotype (p=0.052). Post hoc analysis was 
employed to determine the source of these differences; one-way RM ANOVA was 
utilised to independently examine the effect of gender within phenotype and then to 
examine the effect of phenotype within gender. This post hoc analysis revealed a time 
* gender effect (p=0.07) and an effect of gender (p=0.024) in the slow phenotype only 
and an effect of phenotype in males (p=0.009) with a trend for an effect of phenotype 
in females (p=0.086). This suggests that most of the gender differences occur within 
the slow phenotype and that most of the effect of phenotype occurs within males. 
Examination of the baseline response (Figure 7.4.2.6-3) reveals little or no NEFA 
suppression in the slow male subgroup, with all other subgroups displaying a degree 
of NEFA suppression with some smaller differences between these subgroups.  
 
 
  
Figure 7.4.2.6-3  Baseline postprandial NEFA response by phenotype and gender, within the 
coffee group. 
Two-way RM ANOVA revealed a significant effect of phenotype (p=0.001) and gender (p=0.006). Error 
bars are SEM (fast females: n=3; fast males: n=7; slow females: n=6; slow males: n=3). 
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The difference between phenotypes was non-significant at visit 2 for both fasted NEFA 
and AUC values (Mann-Whitney U, p>0.112), however there was a difference between 
phenotypes at 60 min (Mann-Whitney U, p=0.028) and a trend for a difference at 120 
min (p=0.053) for visit 2. One-way RM ANOVA on the time-point data revealed a 
visit * time * phenotype interaction (p=0.044) and a trend for an effect of phenotype 
(p=0.056). The 2 h postprandial response by visit for each phenotype in the CC group 
is shown in Figure 7.4.2.6-4.  
 
  
Figure 7.4.2.6-4  Postprandial NEFA response by phenotype and visit, within the coffee group.  
There was a difference in fasted NEFA between phenotypes at visit 1 only (Mann-Whitney U, p=0.006). 
One-way RM ANOVA on time-point data found a visit * time * phenotype effect (p=0.044). Error bars are 
SEM (fast: n=10; slow: n=9). 
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When the change in fasted NEFA between visits was analysed by two-way RM ANOVA 
with phenotype and gender as cofactors, there was a significant effect of phenotype 
(p=0.005) and gender (p=0.022), along with phenotype * gender (p=0.027) and 
visit * phenotype * gender (p=0.036) interactions. The change in fasted NEFA 
response between visits, split by phenotype and gender is shown in Figure 7.4.2.6-5. 
 
Two-way RM ANOVA on the time-point data with phenotype and gender as cofactors 
revealed significant effects of phenotype (p=0.003) and gender (p=0.010), along with 
gender * phenotype (p=0.014), visit * time * phenotype (p=0.026), time * gender 
(p=0.016), and visit * time * gender * phenotype (p=0.020) interactions and a trend for 
a time * phenotype interaction (p=0.084). Post hoc analysis was employed to 
determine the source of these differences; one-way RM ANOVA was utilised to 
independently examine the effect of gender within phenotype and also to examine the 
effect of phenotype within gender. This post hoc analysis revealed a slight trend for a 
visit * gender effect (p=0.093) and visit * time * gender (p=0.089) for the fast phenotype 
(panels B and D, Figure 7.4.2.6-6), and a time * gender (p=0.049) and gender effect 
(p=0.025) in the slow phenotype (panels A and C). The analysis also found a visit * 
phenotype effect (p=0.020) and a visit * time * phenotype effect (p=0.019) for females 
only (panels C and D). There was no visit * phenotype effect (p=0.322) in males 
(panels A and B) but there was an overall effect of phenotype (p=0.007).  
Figure 7.4.2.6-5  Fasted NEFA by visit, phenotype and gender, within the coffee group. 
Two-way RM ANOVA found a significant effect of phenotype (p=0.005) and gender (p=0.022), along with 
phenotype * gender (p=0.027) and visit * phenotype * gender (p=0.036) interactions. Error bars are SEM 
(fast females: n=3; fast males: n=7; slow females: n=6; slow males: n=3). 
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This suggests that slow males and females had a different response to each other, but 
no difference in their response to the intervention, whereas there was a trend for a 
difference between the fast males and females between visits. Furthermore, although 
the fast and slow males had a different postprandial response to each other, there was 
no difference between them in their response to the intervention, whereas the fast and 
slow female phenotypes responded differently to the intervention.  Examination of the 
change between visits for each gender/phenotype subgroup (Figure 7.4.2.6-6) reveals 
the differences to be most apparent between fast and slow females over the first 60 
min, mainly as a result of differences in fasted NEFA at visit 2, with the fast females 
having higher fasted NEFA at the second visit. 
 
Figure 7.4.2.6-6  Postprandial NEFA response by visit, phenotype and gender, within the coffee 
group. 
Two-way RM ANOVA revealed significant effects of phenotype (p=0.003) and gender (p=0.010), along 
with gender * phenotype (p=0.014), visit * time * phenotype (p=0.026), time * gender (p=0.016), and visit 
* time * gender * phenotype (p=0.020) interactions. Error bars are SEM (fast females: n=3; fast males: 
n=7; slow females: n=6; slow males: n=3). 
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 Total cholesterol 
Baseline data: all participants (n=27) 
There were no differences between fast and slow phenotypes for baseline total 
cholesterol (unpaired t test, p=0.254). This did not change significantly when gender 
was added as a cofactor.  
Effect of phenotype in coffee group (n=19) 
When baseline data for the CC group were analysed, there were no differences 
between fast and slow phenotypes for total cholesterol (unpaired t test, p=0.298). This 
did not change significantly when gender was added as a cofactor.  
Total cholesterol in the CC group was compared between visits by one-way RM 
ANOVA with phenotype as cofactor. No effect of visit, phenotype or visit * phenotype 
effect was found (p>0.123), nor was there a difference between phenotypes at 
baseline (unpaired t test, p=0.298), however there was a trend for a difference between 
phenotypes at visit 2 (unpaired t test, p=0.080) with the fast phenotype exhibiting lower 
total cholesterol.  There were no significant changes when gender was added as a 
cofactor in the analysis. Fasted cholesterol by visit for each phenotype in the CC group 
is shown in Figure 7.4.2.7-1. 
  
Figure 7.4.2.7-1  Mean total cholesterol by visit and phenotype, within the coffee group.  
There was no difference between phenotypes at baseline (unpaired t test, p=0.298), however there was 
a trend for a difference at visit 2 (unpaired t test, p=0.080). Error bars are SEM (fast: n=10; slow: n=9). 
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 HDL cholesterol 
Baseline data: all participants (n=27) 
There were no differences between fast and slow phenotypes in both groups for 
baseline HDL cholesterol (unpaired t test, p=0.623). Adding gender as cofactor did not 
significantly change this result. 
Effect of phenotype in coffee group (n=19) 
One-way RM ANOVA was used to compare changes in HDL cholesterol between 
visits, by phenotype, in the CC group. No effect of visit, phenotype or visit * phenotype 
effect was found (p>0.232) nor was there any difference between phenotypes at 
baseline (unpaired t test, p=0.362) or visit 2 (unpaired t test, p=0.261). Adding gender 
as cofactor did not significantly change these results. HDL cholesterol by visit for each 
phenotype in the CC group is shown in Figure 7.4.2.8-1. 
 
  
Figure 7.4.2.8-1  Mean HDL cholesterol by visit and phenotype, within the coffee group.  
There was no difference between phenotypes at baseline (unpaired t test, p=0.362), nor were there any 
differences in change between visits between phenotypes (RM ANOVA, p>0.232). Error bars are SEM 
(fast: n=10; slow: n=9). 
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 Inflammatory markers, IL-6 and TNF-
 
Baseline data: all participants (n=27) 
There were no differences between fast and slow phenotypes for all participants at 
baseline for IL-6 (Mann Whitney U, p=0.583) or TNF- (unpaired t test, p=0.987). 
These results did not change when gender was added as cofactor. 
 
Effect of phenotype on IL-6 and TNF- in the coffee group (n=19) 
When baseline values in the CC group were compared, there was no difference 
between phenotypes for TNF- (unpaired t test, p=0.487), however there was a slight 
trend for a difference in IL-6 (Mann Whitney U, p=0.095), with the slow phenotype 
having higher IL-6 (Figure 7.4.2.9-1, panel A). This trend disappeared when gender 
was added as cofactor (p=0.100). 
TNF- was compared between visits by RM ANOVA with phenotype as cofactor. No 
effect of visit, phenotype or visit * phenotype effect was found (p>0.483). There was 
no difference between groups in the change between visits for IL-6 (Mann Whitney U, 
p=0.211). Adding gender as cofactor did not significantly affect any results. 
Mean IL-6 and TNF- by visit for each phenotype in the CC group is shown in Figure 
7.4.2.9-1. 
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Figure 7.4.2.9-1  Mean IL-6 and TNF- by visit and phenotype, within the coffee group.  
Panel A: IL-6; Panel B: TNF-. There were no differences between phenotypes, either at baseline or in 
their response to the intervention (p>0.094), Error bars are SEM (fast: n=10; slow: n=9). 
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7.4.3 Summary of results 
There were differences between the two phenotypes at baseline for several measures, 
both for the whole cohort as a group, and for those within the CC group; these are 
summarised in Table 7.4.3-1. When participant characteristics were examined, there 
was a trend for those with the slow phenotype to be older and to have lower SBP when 
all participants were analysed, but this trend disappeared when just the CC group were 
analysed. Males with the slow phenotype had a higher amount of body fat than those 
with the fast phenotype. Those participants with the slow phenotype had higher fasted 
and postprandial glucose at baseline and higher fasted and postprandial NEFA than 
those with the fast phenotype, although many of these differences only became 
apparent or reached significance after gender was included as a cofactor in the 
analysis. There was also a trend for higher Matsuda index in those with the fast 
phenotype after gender was added into the analysis.  
 
 
  
↗  : A trend for a higher result was observed in this phenotype (p<0.100);↑: A statistically higher result 
was observed in this phenotype (p< 0.050); +G: result was only observed after gender added as cofactor; 
-G: result disappeared after gender added as cofactor; BMI: body mass index; F: fast phenotype; FM: 
fast males; G: gender; NEFA: non-esterified fatty acids; P: phenotype; S: slow phenotype; SBP: systolic 
blood pressure; SM: slow males; T: time; V: visit.  
Table 7.4.3-1  Summary of baseline differences between fast and slow phenotypes. 
Measure Fast (n=13) Slow (n=14) Other results Fast (n=10) Slow (n=9) Other results
Age ↗ trend for SM > FM
SBP ↗
Body fat (%) SM > FM SM > FM
BMI trend for SM > FM
Weight trend for SM > FM
Fasted glucose ↑ +G ↗ +G
Postprandial glucose ↑ +G ↑ +G
Postprandial insulin S > F at 90 min
Matsuda index ↗ +G ↗ +G
Fasted NEFA ↑ +G ↑
Postprandial NEFA ↗ +G ↑ trend for P*G and T*P*G
IL-6 ↗ -G
All participants Coffee group
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The two phenotypes reacted differently to the CC intervention, as summarised in Table 
7.4.3-2.  Participants with the fast phenotype saw a worsening in their glucose 
response, and a reduction in HOMA2_%B, but greater NEFA suppression after the 
intervention, whereas those with the slow phenotype had an improvement in glucose 
response, but exhibited less NEFA suppression at visit 2. Both phenotypes showed a 
delayed peak in insulin response at the second visit, with no difference between fast 
and slow. Interactions between gender and phenotype were also observed for 
HOMA2_%B and postprandial NEFA. 
 
7.5 Discussion  
7.5.1 Baseline differences between phenotypes 
The differences between genotypes observed at baseline are somewhat surprising 
given that the increased enzyme activity associated with the fast metaboliser 
phenotype requires induction by, for example, regular caffeine use or smoking, and 
the participants reported to be non-smokers and non-coffee drinkers. They were, 
however, not caffeine-naïve, having a median weekly caffeine intake of 80 mg (range: 
0 - 410 mg). It has been suggested that “heavy” coffee consumption of at least 3 
cups/day is required to induce the fast phenotype (158). Three cups of coffee per day 
equates to a minimum weekly caffeine intake of over 1000 mg, so it seems unlikely 
that any of the participants had a sufficiently high caffeine intake to have had the 
increased enzyme activity characteristic of the fast phenotype. The data imply that 
there is some as yet uncharacterised effect of this genotype, independent from its 
effects on caffeine metabolism, which has resulted in the baseline differences. Giving 
Measure
Within-group 
change
Between-group 
change Details
Postprandial glucose ✓ V*P;     F:↑ at visit 2;     S: ↓ at visit 2
Postprandial insulin ✓ delayed insulin peak at visit 2 in both phenotypes
Insulin sensitivity ✓ HOMA-2 %B: trends for V*P,   V*G and  V*P*G
Fasted NEFA ✓ P*G;   V*P*G 
Postprandial NEFA ✓ V*T*P;  S:↑ at visit 2;   F: ↓ at visit 2;    V*T*P*G
Total cholesterol ✓ trend for F < S at visit 2
Table 7.4.3-2  Summary of changes between visits for fast and slow phenotypes in the coffee 
group. 
F: fast phenotype; G: gender; NEFA: non-esterified fatty acids; P: phenotype; S: slow phenotype; T: time; 
V: visit  
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weight to this argument is a recent study which examined associations between 
several SNPs and T2DM risk and found an association between carriers of the 
rs762551 C allele (conferring a slow phenotype) and increased T2DM risk irrespective 
of actual coffee consumption (159). They also found that being a carrier of the slow allele 
was not predictive of coffee intake, suggesting that it is not simply lower coffee 
consumption causing the increased risk in this group. Interestingly, they also observed 
a coffee consumption * gender interaction effect on T2DM risk, with their data 
suggesting a protective effect of high coffee consumption in women, but not in men. 
However, the protective effect in women was not statistically significant, leading the 
authors to conclude that they had insufficient power in their sample size. 
 An equally viable hypothesis is that there was some other, unaccounted for, factor 
common to participants in each phenotype group that caused the differences observed 
in the current study, with phenotype having no effect.  
7.5.2 Effects on glucose and insulin metabolism 
There was no difference between the two phenotypes at baseline for either fasted or 
postprandial glucose until gender was added into the analysis as a cofactor, although 
there was a difference at the 90 min time-point in the initial analysis, which is perhaps 
indicative of an overall effect. Given the known differences between men and women 
in glucose metabolism, and the differences observed between genders in both fasted 
glucose and postprandial glucose response, as discussed in Chapter 6, it is quite 
possible that gender was confounding the results until it was accounted for in the 
analysis. This is particularly likely when one considers the uneven, albeit non-
significant, distribution of genders observed between phenotypes (4 male: 9 female 
with the fast phenotype; 9 female: 5 male with the slow phenotype). Once gender was 
included in the analysis, a significant difference between phenotypes was observed at 
baseline for both fasted glucose and postprandial glycaemic response, with the slow 
phenotype displaying higher fasted and postprandial glucose. Females were also 
observed to have lower fasted and postprandial glucose than men, as previously 
discussed in Chapter 6.  
Whilst differences were anticipated between phenotypes in response to the CC 
intervention, the differences observed at baseline were unexpected. The fast 
phenotype displaying lower fasted glucose and a lower postprandial glucose response 
is however consistent with the epidemiology, previously discussed, which suggests 
that coffee drinking is associated with greater risk of IFG only in those with the slow 
phenotype. When the 2 h postprandial glucose response for each gender/phenotype 
Chapter 7. 
188 
 
combination is examined (Figure 7.4.2.2-2) the response in the fast female subgroup 
appears markedly different from the other subgroups, with these participants 
displaying very little postprandial increase in plasma glucose and indeed, post hoc 
analysis, examining the genders separately, revealed a difference between fast and 
slow phenotypes for women only. 
A difference was observed between the two phenotypes in their response to the CC 
intervention, with the visit * phenotype interaction indicating an increase in the 
postprandial glucose response in those with the fast phenotype and a reduction in 
those with the slow phenotype, however post hoc analysis suggests an effect in the 
fast phenotype only, with those in the fast female subgroup being most affected by the 
intervention. When the number of participants in each subgroup is considered, it is 
likely that the analysis lacked sufficient power to detect smaller differences in some 
subgroups. This apparent worsening of the glucose response in those with the fast 
phenotype is in contrast to the epidemiology which suggests that carriers of the slow 
allele are at greater risk of developing T2DM and IFG. However it should be considered 
that most of the observed effect was in the fast female subgroup which had better 
glycaemic control at baseline. This may simply be a case of regression to the mean, 
as female fast and slow phenotypes had a very similar postprandial glycaemic 
response at the second visit.  
There were no significant differences between fast and slow phenotypes at baseline 
for either fasted or postprandial insulin, although there was a slight trend for the slow 
phenotype to have higher insulin at the 90 min time-point, which may be indicative of 
a difference. There was also no difference in the effect of the CC intervention on either 
of these measures. 
There was a trend for greater postprandial insulin sensitivity, as measured by Matsuda 
index, in those with the fast phenotype at baseline. There was also an effect of gender 
on postprandial beta cell function, with women having a higher Matsuda * AUCI/G 
product at baseline and women with the fast phenotype exhibiting a decrease in 
postprandial beta cell function at visit 2. These differences, whilst contrary to the 
epidemiology previously discussed, are consistent with the observed differences in 
glucose metabolism between genders and phenotypes. 
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7.5.3 Effects on lipid metabolism 
There were no differences at baseline between phenotypes for total or HDL 
cholesterol, however there was a trend for the fast phenotype to have lower total 
cholesterol than the slow phenotype at visit 2. This suggests that having the fast 
phenotype may confer some benefit in terms of lipid profile. It should be noted, 
however, that both phenotypes had total cholesterol levels within the healthy range. 
There were also no significant differences between phenotypes for fasted or 
postprandial TAG at baseline or in their response to the CC intervention. However, as 
discussed in Chapter 6, postprandial TAG was only measured for 2 h; if measurements 
had continued for several hours, beyond the postprandial peak, it is possible 
differences would be observed. Furthermore, little increase in TAG was observed 
during that 2 h period, if the meal had provided a greater fat challenge a larger increase 
might have been observed. 
There were differences between phenotypes at baseline for both fasted and 
postprandial NEFA when gender was included in the model as a cofactor, with the slow 
phenotype having higher fasted NEFA and, consequently, higher overall postprandial 
NEFA, despite similar levels of NEFA suppression. Both slow and fast males displayed 
little postprandial NEFA suppression in comparison with the females, as previously 
discussed in Chapter 6. 
When baseline data in the CC group were analysed, a phenotype * gender effect was 
observed along with effects of phenotype and gender, with females having lower 
overall NEFA and greater NEFA suppression than males. This difference in response 
is consistent with the baseline differences observed between phenotypes for insulin 
sensitivity, where the fast phenotype was observed to have greater postprandial insulin 
sensitivity than the slow phenotype and females displayed greater postprandial beta 
cell function than males. Closer examination revealed the slow male subgroup to 
exhibit very little postprandial NEFA suppression in comparison to the other 
subgroups. It should be noted however, that there were only three participants in this 
subgroup, too small a number to draw any firm conclusions. Also, this subgroup were 
older and had a higher mean body fat percentage than the fast male subgroup. The 
known effects of age and body fat on insulin resistance may be contributing to the 
observed difference and may be confounding the results. 
The two phenotypes responded differently to the CC intervention, with the slow 
phenotype displaying less postprandial NEFA suppression at the second visit and the 
fast phenotype displaying greater postprandial suppression, despite an increase in 
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fasted NEFA. As the fast phenotype had a lower overall NEFA response than the slow 
phenotype at baseline, this has resulted in a greater difference between the two 
phenotypes after the intervention and is indicative of a potential detrimental effect of 
CC on those with a slow phenotype.  
When gender was included in the analysis and the various phenotype/gender 
subgroups examined, there was an apparent difference in the way the genders and 
phenotypes reacted to the intervention, with the main difference appearing to be 
between the fast and slow females. The fast females exhibited an increase in fasted 
NEFA, consistent with the observed decrease in fasted beta cell function previously 
discussed. Despite this increase, there was no difference between visits from the 60 
min time-point onwards. Again, care should be taken when drawing conclusions from 
the subgroup analysis due to the small numbers involved.  
 
7.5.4 Effects on inflammatory markers 
There were no apparent effects of phenotype on the inflammatory markers, IL-6 and 
TNF-, either at baseline or in response to the CC intervention. As discussed in 
Chapter 6, the participants displayed large inter-individual variation in these markers, 
which could be masking small differences between the phenotypes. 
 
7.5.5 Potential confounders 
A number of SNPs, other than rs762551, have been reported to be associated with 
glucose metabolism. A recent study found associations between 51 individual SNPs 
and various measures of CHO metabolism, including five SNPs associated with fasted 
glucose and six associated with fasted insulin (260), however they did not measure 
rs762551, or indeed any others on the CYP1A2 gene, so direct comparisons cannot 
be made. As none of these other SNPs were measured in the current study they are 
potential confounders to the results. Similarly, several other SNPs on the CYP1A2 
gene, for example rs2069514 and rs12720461, are associated with decreased enzyme 
activity and are therefore also potential confounders. The rs2069514 SNP in particular 
may be a confounder; a cross-sectional study in Japanese men found rs2069514 
modified the association between coffee drinking and prevalence of T2DM, although 
they found no effect of either rs2069514 or rs762551 on the association between 
coffee drinking and IFG/IGT (261). The A allele of the rs2069514 SNP, which confers 
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the slow metaboliser phenotype, is uncommon in Caucasians (8%), but is relatively 
common in Asians (28%); as 41% of the study group were Asian it is likely that some 
participants were carriers of this allele. 
 
7.5.6 Weaknesses 
Whilst the fast and slow phenotype groups were not statistically different in terms of 
gender, ethnicity, age and baseline anthropometrics, the gender split in particular was 
uneven and there were several baseline differences between males with the fast and 
slow phenotypes. It was not possible to recruit by genotype for financial reasons, 
however this would have ensured a more even balance of genders, age, and adiposity 
across groups. Also, although some potentially interesting gender/phenotype 
interactions were observed, the study was underpowered for this post hoc analysis. 
 
7.6 General discussion/conclusion 
At baseline, the slow phenotype was observed to have higher fasted and postprandial 
glucose, higher fasted NEFA and lower postprandial insulin sensitivity. Taken together, 
this suggests a less healthy overall physiological state in those with the slow 
phenotype, however it is not known whether this difference is a result of random 
chance, or whether it has been caused by this genotype, particularly as in theory the 
fast phenotype should not have been “activated” at this point. It is however consistent 
with the epidemiology observing an association between carriers of the slow C allele 
and T2DM risk irrespective of coffee consumption, as discussed previously. 
Following twelve weeks of CC consumption, an increase was observed in the 
postprandial glucose response in those with the fast phenotype. This was unexpected 
and suggests a potentially detrimental effect of habitual CC drinking on the glucose 
response in this phenotype, contrary to the epidemiology, although it should be noted 
that this increased glucose response was not abnormally high and glucose levels at 
the end of the test were no different from those measured at the first visit. In contrast, 
the coffee intervention resulted in greater NEFA suppression in the fast phenotype and 
less NEFA suppression in the slow phenotype. This apparent worsening in the 
postprandial NEFA response in the slow phenotype is particularly interesting when one 
considers that they exhibited poorer levels of NEFA suppression at baseline than the 
fast phenotype and is indicative of a potentially detrimental effect of CC in this 
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phenotype. It should however be noted that there were differences in adiposity 
between the subgroups, which might be confounding the results as higher amounts of 
adipose tissue are associated with greater insulin resistance and consequently higher 
circulating NEFA. 
The differences at the gender/phenotype subgroup level are potentially very 
interesting, particularly the apparently greater differences observed between the two 
female subgroups in their response to the intervention, however it should be 
remembered that numbers in these subgroups were very small. With such low 
numbers no conclusions can be drawn from these results, however it does serve to 
highlight this as a potentially interesting area for further study. 
In conclusion, this is the first study to our knowledge to compare the effects of habitual 
CC drinking on fast and slow caffeine metabolisers, as determined by the rs762551 
SNP. The observed baseline differences suggest that coffee-naïve individuals who are 
carriers of the slow C allele may exhibit a worse glucose and lipid profile than those 
homozygous for the fast A allele. Supporting the hypothesis that the two phenotypes 
would respond differently to the intervention, a potentially detrimental effect of CC was 
observed on glucose response in the fast phenotype and on lipid response in the slow 
phenotype. These differences between phenotypes make it inadvisable at this stage 
to recommend either coffee drinking or abstention to either group, particularly when 
the apparent gender differences are considered. More work is clearly required in order 
to investigate these differences further. 
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There is strong epidemiological evidence demonstrating an association between 
coffee drinking and reduced risk of T2DM, however epidemiology cannot demonstrate 
a causal relationship and results from interventional studies have been somewhat 
contradictory, with many acute studies demonstrating a detrimental effect of CC 
consumption on the postprandial glycaemic response.  
Studies examining the acute effects of coffee drinking have typically used a single 
large dose of coffee. Little was known about the acute effects of a more normal dose, 
such as a single serving of instant coffee, as is commonly consumed in the UK. 
Moreover, previous studies have examined the effects of coffee taken first thing in the 
morning when people are at their most insulin sensitive. It was not known whether 
people would respond differently to coffee consumed later in the day when glucose 
tolerance declines. A possible confounder to interpretation of previous studies is the 
lack of data on the composition of the individual coffees. Caffeine is known to increase 
the postprandial glycaemic response, whereas CGAs have been demonstrated to 
lower it. It is possible that different proportions of these coffee components may explain 
the varying results reported by previous studies, however the majority have failed to 
report their coffee composition. 
There have been few previous studies examining the longer-term effects of coffee 
drinking, with the majority of these having examined the effects in regular coffee 
drinkers. If there are beneficial effects of coffee drinking in the longer term then one 
would expect habitual coffee drinkers to have already adapted to these changes and 
so they are perhaps not the ideal candidates for a longer-term intervention. Another 
possible confounder to previous work is a particular SNP in the CYP1A2 gene which 
determines whether one is a fast or slow caffeine metaboliser. The slow phenotype of 
this SNP has been associated with increased risk of T2DM and with IFG in coffee 
drinkers; it is possible that it might also affect how people respond to coffee 
interventions, however to our knowledge, this has not previously been examined. 
The aims for this thesis were to address some of these gaps in the existing 
knowledgebase. A systematic review (Chapter 3) was carried out on all studies to date 
that had examined the acute effects of coffee on postprandial glucose metabolism, to 
investigate whether there were any patterns explaining the apparent inconsistency in 
results between studies. The first experimental study (Chapter 4) had three aims: firstly 
to investigate the acute effects of a single “normal” serving of instant CC on the 
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postprandial glycaemic response; secondly, to establish whether there was any dose-
response relationship; and thirdly, to investigate whether there was any dose-response 
effect of increasing the non-caffeine components of coffee when taken along with the 
amount of caffeine typically found in a single serving of instant CC. The second 
experimental study (Chapter 5) investigated the effects of a single serving of DC on 
the postprandial glucose and insulin response when taken at different times of day. It 
also examined whether there was any carry-over effect of morning DC on the lunchtime 
postprandial response and whether there were any effects of repeated dosing. The 
final experimental study (Chapters 6 and 7) was a longer-term intervention 
investigating the effects of regular CC drinking in coffee-naïve individuals, with further 
analysis examining whether there was any difference in the response to the CC 
intervention between fast and slow caffeine metabolisers.  
8.1 Overview of main findings 
Twenty studies were eligible for inclusion in the systematic review (Chapter 3). All 
investigated the acute effects of CC and/or DC on the postprandial glycaemic 
response. The methodologies employed by these studies were varied. Coffee doses 
ranged from a rounded teaspoon of instant coffee up to the equivalent of six teaspoons 
of instant coffee, taken as a single dose, with the majority utilising relatively high doses. 
Types of coffee varied and included instant, filter and espresso coffees; the timing of 
the coffee dose ranged from one hour before the test meal to concurrent dosing. Seven 
studies did not report the caffeine content of their coffees and only two studies reported 
total CQA or CGA content. The amount of CHO in the tests ranged from 24 – 75 g and 
was provided either in a mixed meal or as a glucose drink. A mix of capillary and 
venous blood sampling techniques were employed. The number of participants ranged 
from 8 to 33, with the majority recruiting young healthy adults. Despite the 
heterogeneity of the study designs, the majority of studies utilising CC reported an 
increased postprandial glucose response following CC consumption, although most of 
these only observed an increase at isolated time-points, with only five studies 
observing an effect on the overall glucose response. There was less evidence for a 
detrimental effect of CC on the postprandial insulin response. Furthermore the majority 
of studies observed no effect of DC on the acute postprandial glucose and insulin 
responses. A detailed examination of the differences in methodology provided no 
obvious explanation for the lack of uniformity in the reported results. However, as most 
of the studies did not report a detailed analysis of their coffee, and with several failing 
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to report the caffeine content, it was not possible to determine whether varying 
proportions of the different coffee components had determined the observed results. 
The first interventional study carried out for this thesis (Chapter 4) was split into two 
parts. The first part examined the effects of escalating doses of instant DC, with 
caffeine added in proportion to the DC dose, on the postprandial glucose and insulin 
response. The doses given to the participants were the equivalent of one, two and four 
servings of regular instant CC. Similarly to the majority of studies in the systematic 
review, an increase in the postprandial glucose response was observed following CC 
consumption, for both the one and two serving equivalents, with no effect on insulin. 
Interestingly no significant effect was observed following the highest dose, equivalent 
to four servings of CC, nor was there any dose-response effect. The second part of 
the study examined the effects of the same three doses of DC as used in Part A, but 
this time with a constant amount of caffeine added to each drink, including control. The 
amount of added caffeine was set to the lowest caffeine dose from Part A of the study. 
No differences were observed in the postprandial glucose and insulin response 
between any of the test drinks and the control in this part of the study. 
The second study (Chapter 5), investigated the acute effects of DC consumed at 
different times of day on the postprandial glucose and insulin response. Similarly to 
the studies in the systematic review, there were no observed effects of a single serving 
of DC taken in the morning on either measure. Nor was there any carry-over effect of 
DC consumed in the morning on the postprandial response to a later meal. There were 
however some interesting trends for an effect of DC consumed at lunchtime, with a 
single serving of DC at lunchtime resulting in a reduced glucose peak. Furthermore, a 
reduction in the lunchtime postprandial insulin response was observed when DC was 
consumed at breakfast and lunch. 
The final study was a longer-term parallel-arm intervention, examining the effects of 
twelve weeks of CC consumption on glucose and lipid metabolism in coffee-naïve 
individuals. In the primary analysis (Chapter 6), no effect of longer-term CC drinking 
on fasted or postprandial glucose response was observed, nor were there any 
observed effects on fasted and postprandial lipid metabolism. However, an effect on 
the postprandial insulin response was observed, with the participants in the CC group 
displaying a delayed insulin peak following the intervention. Differences between 
genders at baseline were observed, with females having lower fasted and postprandial 
glucose and TAG and greater postprandial NEFA suppression, however there were no 
differences between males and females in their responses to the intervention. 
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In the secondary analysis (Chapter 7), the baseline data for all participants was 
analysed to determine whether there were any innate differences between those with 
the fast and slow caffeine-metaboliser phenotypes. This revealed some interesting 
differences, with the slow phenotype exhibiting a less healthy profile, with higher fasted 
and postprandial glucose and NEFA. Analysis of the CC group was then performed to 
determine whether there were any differences between the two phenotypes in their 
response to the intervention. This revealed further differences, with participants with 
the fast phenotype displaying an increased postprandial glucose response and a 
reduction in HOMA2_%B but greater NEFA suppression after the intervention. In 
contrast, those with the slow phenotype displayed a reduction in postprandial glucose 
and less postprandial NEFA suppression. 
Finally, subgroup analysis was performed to determine whether there were any 
interactions between male and female, fast and slow phenotypes. It should however 
be noted that numbers in these subgroups were very low and these results are 
reported solely for purposes of hypothesis generation. This subgroup analysis 
suggests that the baseline difference in the postprandial glucose response between 
phenotypes was primarily due to a difference between fast and slow females, with little 
difference observed in the males. Furthermore when the response to the intervention 
was examined, the effect of phenotype on the postprandial glucose response was most 
apparent in women, with the greatest difference observed in the fast female subgroup, 
who displayed a noticeable increase in glucose response. Subgroup analysis of the 
baseline NEFA data revealed most of the gender/phenotype differences in NEFA 
suppression to be found in the slow phenotype, with slow males exhibiting minimal 
postprandial NEFA suppression in comparison with other subgroups. Interestingly, 
although the fast phenotype displayed increased NEFA suppression overall, when the 
subgroups were analysed the biggest effect was observed in the fast females who 
displayed an increased NEFA AUC following the intervention, as a result of an increase 
in fasted NEFA. 
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8.2 Study limitations 
Limitations of the individual studies were discussed in detail in their respective 
chapters; only the main limitations are summarised here. 
The participants in these studies were mainly young, healthy individuals. These results 
cannot be extrapolated to other populations, such as those with IFG/T2DM who may 
react differently to both acute and longer-term coffee ingestion. 
The acute studies, whilst using the recommended number of participants for GI testing, 
were likely underpowered to detect a dose-response effect. Similarly the longer-term 
study was underpowered to detect the unexpected differences observed between 
genders and phenotypes, although these were secondary endpoints. 
The CGA content in the coffees was relatively low, both in the DC used in the two 
acute studies and in the CC used in the longer-term intervention. It is possible that 
different effects may have been observed if different coffees had been used, however 
this is coffee on sale to the UK public and therefore is representative of typical 
consumption. 
The coffee doses were not tailored to match the participants’ body sizes. This may 
have confounded the results, however this approach was taken to reflect normal 
consumption patterns rather than artificial laboratory conditions. 
Retrospective genotyping and analysis was performed on the participants in the 
longer-term intervention, due to financial constraints. Recruitment by genotype would 
however have ensured a better balance between genders and genotypes which would 
have helped the interpretation of the subgroup analysis. 
8.3 Comparison of acute and longer-term studies 
The first two studies reported in this thesis examined the acute effects of coffee, both 
caffeinated (Chapter 4) and decaffeinated (Chapter 5) on the 2 h postprandial glucose 
and insulin response. Consistent with the majority of studies reported in the systematic 
review (Chapter 3), these acute studies reported an increased postprandial glycaemic 
response following a single dose of CC, with no effect of a single dose of DC. These 
results, along with studies examining the effects of caffeine in isolation, support the 
hypothesis that it is the caffeine component of coffee that produces the temporary 
worsening in glycaemic response following coffee consumption.  
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The same brand, batch and dose of DC was used in both acute studies, with the only 
difference in treatment being the addition of caffeine in the CC study. However, the CC 
study provided 50 g CHO in the form of glucose added to the coffee, whereas the DC 
study provided 75 g CHO as a mixed meal. Whilst the higher amount of CHO in the 
DC study would likely produce a larger overall glycaemic response, the rate of 
absorption would be attenuated by the presence of protein and fat in the mixed 
meal (262). This difference in CHO and macronutrient composition means that any 
comparison of the postprandial response between studies should be interpreted with 
caution.  
Furthermore, the participants recruited to each study were from different sample 
populations. The participants in the CC study were overweight males (mean BMI: 27.8 
kgm-2,), whereas the participants in the DC study were normal-weight females (mean 
BMI 21.6 kgm-2). As discussed in previous chapters, overweight people tend to be 
more insulin resistant than normal weight and males tend to have higher fasted 
glucose, but lower 2 h glucose following an oral glucose challenge. In support of the 
epidemiology, although not tested statistically, the males in the CC study appear to 
have a higher fasted glucose (mean: 5.2 mmol/L) than the females in the DC study 
(mean: 4.8 mmol/L). Furthermore plasma glucose concentrations for the males in the 
CC study had returned to baseline after 2 h, in contrast to the females in the DC study. 
When the postprandial glycaemic responses to the control drinks are compared, the 
responses from the two study populations appear different. Whilst not tested 
statistically, the mean peak glucose for the CC study (8.3 mmol/L) appears to be higher 
than that observed for the DC study (7.5 mmol/L), despite similar peak insulin 
concentrations (CC: 193 pmol/L; DC: 183 pmol/L). This suggests that the overweight 
men in the CC study may be more insulin resistant, particularly when one considers 
the smaller amount of CHO utilised in this study. The higher peak may also be a 
consequence of the liquid glucose being absorbed faster than the mixed meal. 
However, as the IAUCs were similar between treatments (CC: 172 mmol/L.120 min; 
DC: mean 160 mmol/L.120 min), despite the larger CHO load in the DC study, it 
appears likely that the overweight men were more insulin resistant.  
The longer-term study (Chapters 6 and 7) did not give an acute dose of CC on either 
study day as its aim was to examine the chronic effects of coffee drinking. It would be 
interesting to compare the baseline postprandial response from this study group with 
those from the control visits of the two acute studies, to examine whether there were 
any differences in response between coffee-naïve individuals (longer-term study) and 
regular coffee drinkers (acute studies). However, in addition to differences in sample 
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populations, as discussed in relation to the acute studies, there were differences 
between the acute and longer-term studies both in blood sampling and laboratory 
analysis methods, rendering this comparison inappropriate. 
The two acute studies utilised the capillary sampling methodology, whereas the longer-
term study employed venous sampling via cannula. Capillary sampling is widely 
regarded as the gold standard method for GI testing as capillary blood is primarily 
arterial blood and therefore provides a more accurate representation of glucose 
absorption. Conversely venous blood glucose concentrations tend to be lower as a 
result of glucose disposal into muscle and other tissues before reaching the veins. The 
results from the longer-term study appear to support this as mean baseline fasted and 
peak glucose concentrations ((4.6 and 6.3 mmol/L respectively) were lower than those 
observed in both acute studies, despite this group exhibiting a higher mean BMI (23.2 
kgm-2) than that observed in the DC study. However, these differences are relatively 
small, particularly for fasted glucose concentrations, and may be confounded by a 
difference in glucose analysis methodology. Samples from both acute studies were 
analysed on the YSI 2300 Stat Plus analyser, whereas samples from the longer-term 
study were analysed on the ILab 650. Whilst both analysers utilise the glucose oxidase 
reaction, there are nevertheless likely to be small differences in the absolute values 
reported. 
As discussed previously, blood from capillary samples tends to have lower insulin 
concentrations than venous samples. This is apparent when the insulin responses for 
each study are examined, with mean insulin concentrations for the longer-term study 
(fasted: 64 pmol/L; peak: 660 pmol/L) almost threefold that of the acute studies (fasted: 
23 and 27 pmol/L; peak: 183 and 193 pmol/L). As with the glucose analysis, different 
methodologies were employed for the insulin analysis. A comparison of 11 different 
human insulin assays reported that RIA returned higher insulin concentrations than 
ELISA and further that serum samples resulted in higher insulin concentrations than 
plasma (263). As the acute studies analysed plasma insulin by ELISA whereas the 
longer-term study analysed serum samples by RIA this difference in methodology is 
likely to have contributed, along with the different sampling methodologies, to the large 
differences observed in insulin concentrations between the acute and longer-term 
studies. 
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8.4 Overall conclusions 
From the results of the systematic review, it can fairly confidently be stated that acute 
consumption of CC results in a temporary disruption to postprandial glucose 
metabolism. Furthermore, the results of the first study demonstrate that large doses of 
CC are not required and that this temporary disruption can be observed following a 
single serving of instant CC, such as is typically consumed in the UK. However, it is 
not known whether this effect is physiologically relevant as the magnitude of the effect 
is relatively small, with plasma glucose quickly returning to normal fasted levels in 
healthy individuals. There has been little research into the acute effects of CC in other 
groups, such as those with IFG and T2DM, where effects may be larger and clinically 
relevant. Furthermore, these studies have been carried out early in the morning after 
an overnight fast, when insulin sensitivity is high; these results cannot be extrapolated 
to later in the day when glucose tolerance declines. Outside of the laboratory setting, 
habitual coffee drinkers are likely to consume several cups of coffee throughout the 
day and will therefore have some caffeine in their system for most of the day. The 
effects of this habitual coffee consumption on the postprandial response to meals 
taken throughout the day is not known and should be investigated further. 
There were no observed beneficial effects of increasing amounts of non-caffeine 
components on the postprandial response when consumed with 100 mg caffeine, 
suggesting that the amount of caffeine in a single serving of CC is sufficient to 
attenuate any beneficial effects of these other components. However, as discussed 
previously, 100 mg caffeine is towards the high end of the normal range, whereas the 
DC in this study contained relatively low amounts of the other components. 
Furthermore, it is probable that the study was underpowered to detect such a dose-
response effect. Before drawing any conclusions from this data it would be advisable 
to repeat the study with a greater number of participants and a lower caffeine:CGA 
ratio. 
In line with the systematic review, the second study found no effects of a single serving 
of DC, consumed in the morning, on the postprandial glucose and insulin response. 
This is in contrast to the literature observing a beneficial effect of CGAs when 
consumed in isolation, however it should be noted that the amount of CGAs consumed 
in these studies is much higher than that naturally found in a single serving of DC. 
Some interesting, albeit small, effects of DC consumed at lunchtime were observed, 
which may support the epidemiology reporting a reduction in T2DM risk associated 
with lunchtime coffee drinking. However, as this appears to be the first time this has 
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been investigated, and as the observed effects were small, further research is clearly 
required. 
In the final study, there was little observed effect, beneficial or detrimental, of longer-
term CC consumption in a group of coffee-naïve individuals, when the group was 
analysed as a whole. This is in contrast to Ohnaka et al. who observed some 
improvement in the postprandial glucose response following a similar intervention. 
However, their participants were older, with IFG; it is possible that the current study 
may have observed a similar effect in a less insulin-sensitive group. In the secondary 
analysis baseline differences were observed between participants with fast and slow 
caffeine-metaboliser phenotypes, with results suggesting that carriers of the slow allele 
may naturally have a less healthy overall metabolic profile. Furthermore, differences 
were observed between the two phenotypes in their response to the intervention, with 
both fast and slow phenotypes displaying some beneficial and some detrimental 
effects.  
In conclusion, no strong evidence was found from either the acute studies or the 
longer-term study to support a preventative effect of coffee drinking on T2DM risk, as 
suggested by the epidemiology. There were however some interesting and conflicting 
effects in specific participant subgroups which warrant further investigation. It may be 
that coffee drinking is beneficial for some groups of people and not for others, however 
with little research to date in this area, it is clearly inadvisable to make any 
recommendations at this present time. It should also be remembered that the 
epidemiology only reports an association between coffee drinking and reduced 
incidence of T2DM. It cannot demonstrate a causal link. It is quite plausible that there 
is some other factor, unassociated with coffee drinking, and not corrected for within 
the statistics, that confers a reduced risk in this group. 
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8.5 Future work 
Whilst producing some interesting results, these studies have also exposed further 
gaps in the literature which warrant study. Given sufficient time and funding the 
following additional investigations are suggested. 
 
A repeat of Part B of the initial study, with the following modifications: 
 Selection of instant DC based on its CGA content to ensure a higher total 
amount of CGA and/or addition of GCE to further enhance CGA content whilst 
maintaining a palatable drink. 
 Addition of a reduced amount of caffeine, such as 40 mg, to further reduce the 
caffeine:CGA ratio and increase the possibility of observing a beneficial effect 
of the coffee, if one exists. 
 Recruitment of a larger number of participants to increase the power to detect 
a dose-response effect. 
 Repetition of study days to minimise intra-individual variation and increase the 
power of the study. 
 Recruitment by genotype to establish whether fast and slow caffeine 
metaboliser phenotypes react differently to acute coffee consumption. 
 
A crossover study investigating the acute effects of coffee consumption throughout the 
day in habitual coffee drinkers: 
 One study day where the participants do not consume any coffee. 
 A second study day where all meals and snacks are accompanied by a normal 
dose of instant CC. 
 The study would be carried out under laboratory conditions, with timing and 
content of all meals carefully controlled. 
 Postprandial glucose, insulin and lipid responses would be measured for all 
meals. 
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A repeat of the longer-term study with several modifications is advised: 
 Recruitment by genotype and gender, with participants matched for bodyweight 
and body fat percentage to ensure an even balance between groups and 
reduce confounding. 
 Recruitment of a larger number of participants to ensure subgroup analysis has 
sufficient power to detect any differences. 
 Further analysis examining other SNPs known to be associated with caffeine 
metabolism as discussed in Chapter 7. 
 Addition of two further study days to examine the acute effects of coffee in this 
group, both before and after the intervention. 
 
A longer-term study investigating the effects of total coffee abstinence in habitual 
coffee drinkers may be of interest: 
 Whilst it is not known how long it may take for any potential beneficial effects 
of regular coffee drinking to accumulate, it is also not known how long these 
potential benefits may take to disappear.  
 Examining the effects of coffee abstinence may be a simpler way to investigate 
the longer-term effects of coffee drinking.  
 It may also be easier to recruit coffee drinkers prepared to give up coffee for 
several weeks than it is to find non-coffee drinkers who are prepared to start 
drinking coffee regularly. 
 
Finally, repetition of any/all of the above studies in people with IFG/T2DM would be of 
particular interest as little research has been carried out in these patient groups. 
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Study name 
 
 I the undersigned voluntarily agree to take part in the above named study.                                 
 
 I have read and understood the Information Sheet provided.   I have been given a 
full explanation by the investigators of the nature, purpose, location and likely 
duration of the study, and of what I will be expected to do.   I have been advised 
about any discomfort and possible ill-effects on my health and well-being which 
may result.   I have been given the opportunity to ask questions on all aspects of 
the study and have understood the advice and information given as a result.                                   
 
 I expect to be able to comply with the requirements of the study as already 
outlined to me and to co-operate fully with the investigators.   I shall inform them 
immediately if I suffer any deterioration of any kind in my health or well-being, or 
experience any unexpected or unusual symptoms.                                                                               
 
 I consent to my personal data, as outlined in the accompanying information sheet, 
being used for this study and other research.  I understand that all personal data 
relating to volunteers is held and processed in the strictest confidence, and in 
accordance with the Data Protection Act (1998). 
 
 I understand that I am free to withdraw from the study at any time without needing 
to justify my decision and without prejudice. 
 
 I acknowledge that in consideration for completing the study I shall receive the 
sum of £150. I recognise that the sum would be less, and at the discretion of the 
Principal Investigator, if I withdraw before completion of the study. 
 
 I understand that in the event of my suffering a significant and enduring injury 
(including illness or disease) as a direct result of my participation in the study, 
compensation will be paid to me by the University (or sponsor where a clinical trial 
is sponsored by a pharmaceutical company), subject to certain provisos and 
limitations.  The amount of compensation will be appropriate to the nature, severity 
and persistence of the injury and will, in general terms, be consistent with the 
amount of damages commonly awarded for similar injury by an English court in 
cases where the liability has been admitted 
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 I confirm that I have read and understood the above and freely consent to 
participating in this study.  I have been given adequate time to consider my 
participation and agree to comply with the instructions and restrictions of the study. 
 
Name of volunteer (BLOCK CAPITALS)       ........................................................  
 
Signed   ........................................................  
 
Date       ......................................  
 
Name of witness (where appropriate) (BLOCK CAPITALS) ............................................  
 
Signed   ........................................................  
 
Date       ...................................... 
 
Name of researcher/person taking consent (BLOCK CAPITALS)  ..................................  
 
Signed    ........................................................  
 
Date        ......................................  
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Self-Certificate Medical Questionnaire 
 
Name: ………………………………   Date of Birth: ………………………………….. 
Address: ……………………………………………………………………………………….. 
………………………………………………………………………………………………….. 
Contact Telephone Number: ………………………………...……………………………… 
 
Please tick all/any of the following that apply: 
 I have no prior/present history of Coronary Heart Disease, Angina or Stroke 
 I have no prior/present history of Type 1 or Type 2 diabetes 
 I have no prior/present history of anaemia 
 I have no prior/current history of gastrointestinal diseases (for example Crohn’s 
disease, Coeliac disease, Irritable Bowel Syndrome) 
 I have no prior/present history of liver disease 
 I have no prior/present history of endocrine disorders 
 I have no prior/present history of, nor am I currently being treated for, clinical 
depression and/or other psychological disorders 
 I have no prior/present history of eating disorders, including anorexia or bulimia 
nervosa 
 I have no prior/present history of drug or alcohol abuse within the last 2 years 
 I am not currently taking or have taken any regular medication (including oral 
contraceptives) prescribed by my GP in the last 6 months (if you are please state 
what you are taking) 
    I am not currently pregnant or breast-feeding 
Have you been involved in a clinical trial in the last 3 months?  YES / NO 
Are you currently on a weight-reducing diet or other dietary restriction? YES / NO 
If yes, please provide details. 
Are you allergic or intolerant to any foods?     YES / NO 
If yes, please state what foods you are allergic to. 
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Do you have any religious dietary requirements?    YES / NO 
If yes, please provide details.  
 
Do you smoke?        YES / NO 
If yes, how many per day? 
Do you drink alcohol?        YES / NO 
If yes, how many units per week? (See below) 
 
 
Signed_________________________________________            Date___/___/____ 
 
 
This study has received a favourable ethical opinion from the University of Surrey Ethics 
Committee. 
 
……………………………………………………………………………………………… 
 
 
Researchers use: 
 
Fasted blood glucose:         
 
Fasted haemoglobin:          
 
  
Alcohol Measure Unit 
Ordinary strength lager (4%) e.g. Carling, Fosters Pint 2.3 
Strong lager (5.2%) e.g. Stella Artois, Kronenburg Pint 3 
Strong lager e.g. Stella Artois, Carlsberg Export, Grolsch 440ml can 2.2 
Beer/ordinary strength Ale e.g. John Smith’s, Guinness Pint 2.3 
Red/White Wine Std 175ml 2 
Red/White Wine Lg. 250ml 3 
Spirits Std 25ml 1 
Spirits Lg. 35ml 1.4 
Alcopop e.g. Smirnoff Ice, Bacardi Breezer, Reef 275ml 1.5 
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Caffeine Questionnaire 
 
Participant Number ______________ Date: ________________ 
 
 
Please answer the following questions as accurately as possible. 
 
 
On average, how many of each of the following types of drink do you drink per week: 
 
 
 Number 
per week 
 
Size 
 
With milk? With 
sugar? 
With 
sweetener? 
Instant coffee 
(caffeinated) 
  
YES/NO YES/NO YES/NO 
Instant coffee 
(decaffeinated) 
  
YES/NO YES/NO YES/NO 
Filter coffee   YES/NO YES/NO YES/NO 
Espresso-type 
coffee 
(includes 
espresso, 
cappuccino, 
latte etc) 
  
YES/NO YES/NO YES/NO 
Tea 
  
YES/NO YES/NO YES/NO 
Caffeinated 
cold drinks (eg 
cola, Red Bull) 
  
N/A N/A N/A 
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Carbohydrate (% w/w)
Amount per 
portion (mg)
Manitol (Free)
0.00 0
Fucose (Free)
0.00 0
Arabinose (Free)
0.98 20
Galactose (Free)
0.62 12
Glucose (Free)
0.29 6
Sucrose (Free)
0.00 0
Xylose (Free)
0.00 0
Mannose (Free)
1.93 39
Fructose (Free)
0.67 13
Manitol (Total)
0.00 0
Fucose (Total)
0.00 0
Arabinose (Total)
3.30 66
Galactose (Total)
16.20 324
Glucose (Total)
1.39 28
Sucrose (Total)
0.00 0
Xylose (Total)
0.09 2
Mannose (Total)
21.54 431
Fructose (Total)
0.08 2
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Study on the Effects of Different Coffees on Blood Glucose and Insulin 
 
Participant No: ______________   Product: ________      Date: __________ 
 
Please circle the appropriate score 
1) On a scale of 1-5 how would you rate the overall palatability of the drink? 
1  2  3  4  5  
          1 = unacceptable                 5 = very acceptable 
 
2) On a scale of 1-5 how would you rate the taste of the drink?  
 
1  2  3  4  5 
             1 = unpleasant         5 = very pleasant 
 
3) On a scale of 1-5 how would you rate the smell of the drink?  
 
1  2  3  4  5 
            1 = unpleasant          5 = very pleasant 
 
4) On a scale of 1-5 how would you rate the strength of the drink?  
 
1  2  3  4  5 
                 1 = weak              5 = very strong 
 
This study has received a favourable ethical opinion from the University of Surrey Ethics Committee. 
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Data courtesy of Professor Alan Crozier and Dr Iziar Amaia Ludwig Sanz Orrio at the 
University of Glasgow. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data expressed as mean value ± standard deviation (n=4) of 5-CQA equivalents. CQA: caffeoylquinic 
acids; CoQA: p-coumaroylquinic acids; FQA: feruloylquinic acids; diCQA: dicaffeoylquinic acids; CQL; 
caffeoylquinides/caffeoylquinic lactones; FQL:feruloylquinides/feruloylquinic lactones; diCQL: 
dicaffeoylquinides/dicaffeoylquinic lactones 
Rt Compound mg/g  
7.64 CQA 0.29 ± 0.01  
8.93 CQA 0.46 ± 0.01  
9.55 3-CQA 5.87 ± 0.24  
11.46 CQA 0.65 ± 0.04  
12.00 CQA 1.25 ± 0.08  
13.94 5-CQA 8.67 ± 0.28  
14.70 4-CQA 6.28 ± 0.35  
15.98 CQL1 0.36 ± 0.04  
16.72 3-FQA 1.20 ± 0.05  
20.79 CQL3 0.42 ± 0.03  
22.26 CQL2? 0.32 ± 0.03  
22.99 CQL4 1.46 ± 0.09  
24.34 CQL5 0.76 ±0.03  
25.59 5-FQA/4-FQA 3.00 ± 0.04 co-elute 
30.83 CQL6 0.06 ± 0.01  
34.03 FQL1 0.08 ± 0.01  
36.77 FQL2/FQL3 0.37 ± 0.04 co-elute 
38.08 FQL4 0.16 ± 0.03  
44.20 3,4-diCQA 0.65 ± 0.05  
44.85 3,5-diCQA 0.23 ± 0.02  
50.51 4,5-diCQA 0.49 ± 0.02  
65.00 diCQL1 0.02 ± 0.00  
70.88 diCQL2 0.03 ± 0.00  
71.93 p-Coumaroyl-tryptophan 0.08 ± 0.01  
    
 Total CQA 23.47 ± 0.97  
 Total FQA 4.21 ± 0.02  
 Total diCQA 1.38 ± 0.09  
    
 Total CQL 3.38 ± 0.04  
 Total FQL 0.70 ± 0.01  
 Total diCQL 0.05 ± 0.00  
